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Abstract
Note: Parts of these abstract have been previously published in the journal Nature Scientific Reports,
Russell et al. 2017 Nov 10, in the journal BBA – Molecular Basis of Disease, Lemma, et al. 2017 Sep 1, in
Oncotarget, Pompo, et al. 2017 Apr 13, in Cancer Research, Ibrahim-Hashim, et al. 2017 Mar 1, journal Nature
Scientific Reports, Russell et al. 2017 Nov 10, in the journal Cancer Research, Pilon-Thomas, et al. 2015 Dec
30,and on BioRxiv, Wu, et al. 2019 Jul 2 and have been reproduced in this manuscript under the Creative
Commons Attribution 4.0 International License and permission from the publishers.

Cancer is a complex and heterogeneous disease. Not only is there considerable variability
between different cancer types, but there is enormous variability between and within patients
who have the same type of cancer. Within tumors, there are multiple cell types, including cancer
cells, stromal cells, and immune cells. The tumor microenvironment often induces the healthy
cells to become pro-tumorigenic. Cell metabolism is exquisitely sensitive to changes in the tumor
microenvironment and can be measured to infer the aggressiveness of cancer and predict
response to therapy. In this dissertation, we aim to understand how the microenvironment,
specifically low pH, affects the phenotype, metabolism, and function of cell types within tumors
and ultimately, how this relates to metastasis and therapeutic outcome.
Chapter 2: Unfortunately, measuring metabolism is challenging as metabolism is dynamic and
can change depending on the types of models we use. Current studies utilize 2D models of
cancer, i.e., cancer cell lines grown in flat, plastic flasks or dishes. 2D cultures are exposed to
higher concentrations of nutrients, drugs, and have a reduced cell surface area to volume due to
adhering to the plastic; this also causes altered expression of adhesion proteins. The 2D models
do not accurately reflect the tumor in vivo, and this can result in discrepancies between in vitro
xiv

and in vivo results. Growing cancer cell lines in 3D better recapitulates what occurs in vivo. We
developed an in vitro live-cell tooling and methodology to metabolically profile 3D cell cultures
and directly compare them to 2D cell cultures. Using this, we observed differences in the basal
metabolism of 2D and 3D cell cultures in response to metabolic inhibitors and
chemotherapeutics. We further expanded this methodology to profile 3D microtissues generated
from mouse organs and tumors. The metabolic profiles of microtissues derived from normal
organs (heart, kidney) were consistent when comparing microtissues derived from the same
organ. Treatment of heart and kidney microtissues with cardio- or nephrotoxins had early and
marked effects on tissue metabolism.
In contrast, microtissues derived from different regions of the same tumors exhibited
significant metabolic heterogeneity, which correlated to histology. Hence, metabolic profiling of
complex microtissues is necessary to understand the effects of morphology and structure on
metabolism. This method has the potential to be used as a reproducible, early and sensitive
measure of drug toxicity and a potential drug screening methodology. Moreover, this
methodology provides an important stepping stone to improve experimental design between in
vitro 2D studies and in vivo animal studies.
Chapter 3, 4, 5: Development of novel methodologies and tooling development can drive
progress in scientific research. Our method highlights the metabolic heterogeneity within the
tumor which is often missed by other means. One under-explored component of tumor
heterogeneity is the substantial distinction between the edge and the core. Ongoing intratumoral
evolution is apparent in molecular variations among cancer cells from different regions of the
same tumor. However, genetic data alone provide little insight into environmental selection
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forces and cellular phenotypic adaptations that govern the underlying Darwinian dynamics. We
have observed in three spontaneous murine cancers (prostate cancers in TRAMP and PTEN
mice, pancreatic cancer in KPC mice), that there are two subpopulations with distinct nicheconstruction adaptive strategies that remained stable in culture. One population is what we call a
“pioneer” phenotype, which is found at the invasive edge of tumors. Pioneers are invasive cells
that produce an acidic environment through upregulated aerobic glycolysis and upregulation of
proton exporting machinery, such as carbonic anhydrase -9 (CA-IX).

The other metabolic

population observed is what we call an “engineer” phenotype. Engineers are found at the core of
tumors; they are non-invasive and have upregulated angiogenesis. These engineer cells are
metabolically near-normal with an increased reliance on oxidative metabolism. Intratumoral
evolution occurs generating cells with different fitness advantages in different regions of the
tumors. These cells may purposefully migrate to their preferred area i.e. edge vs core, or end up
there serendipitously, and once there, their phenotype may change with exposure to changing
microenvironmental conditions or may be fixed. In our cases, these cells were cultured for many
generations and their metabolic profiles were steady, indicating that the selected phenotypes
were fixed.
Darwinian interactions of these subpopulations were investigated in TRAMP prostate
cancers. Computer simulations predicted and experiments confirmed that invasive, acidproducing, proliferative (C2) “pioneer” cells maintained a fitness advantage over non-invasive,
angiogenic, quiescent (C3) “engineer” cells. This is most likely managed by promoting invasion
and hampering the immune response. Immunohistochemical analysis of untreated tumors
confirmed that C2 cells invariably outgrew and were more abundant than C3 cells in TRAMP
prostate tumors. However, the C2 adaptive strategy phenotype incurs a high cost due to
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inefficient energy production (i.e., aerobic glycolysis). Mathematical model simulations
predicted that small perturbations of the microenvironmental extracellular pH (pHe) could invert
the cost/benefit ratio of the C2 strategy and select for C3 cells. Altering pH using buffer therapy,
NaHCO3, increased pH in a TRAMP mouse model, and promoted the growth of C3 engineer
cells over C2, enabling the tumor to remain low grade and reducing metastasis when treating
established tumors. Mathematical models of the intratumoral Darwinian interactions of
environmental selection forces and cancer cell adaptive strategies indicated that the tumor
trajectory was steered into a less invasive pathway through the application of small but selective
biological forces, such as altering pH.
Pioneer cells found at the invasive edges of tumors, tend to have a high glycolytic
metabolism and generate an acidic microenvironment. These cells are necessary for local
invasion and cancer progression. Therefore, we were interested to see the impact of this acidic
microenvironment on other components of the tumor. We studied how glycolytic metabolism
and low pH affects three components of the tumor: the stroma, the immune compartment, and
the cancer cells themselves.
Glycolytic metabolism of cancer co-opts vital nutrients needed for normal cell growth
and this forces the surrounding cell types to use other metabolites for fuel. One area where this
occurs is in bone metastases. We have identified that the metabolic interplay between bone
stroma and cancer cells enhances metastases. In our study, we demonstrated that highly
glycolytic triple-negative MDA-MB-231 cancer cells, compared to non-metastatic MCF7 cells,
release more lactate and form osteolytic bone metastasis in vivo. In vitro, lactate generated by
cancer cells was shown to be consumed by osteoclasts as a fuel for oxidative metabolism,
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ultimately enhancing Type I collagen resorption in the bone. The transport of lactate into
osteoclasts was mediated by MCT1, as shown by the significantly upregulated expression during
osteoclast differentiation, and using an MCT-1 inhibitor, 7-(N-benzyl-N-methylamino)-2-oxo2H-chromene-3-carboxylic acid, which impaired Type I collagen resorption in the osteoclasts.
Together, these data indicate that lactate released by glycolytic breast carcinoma cells in the bone
microenvironment promotes the formation of osteolytic lesions and provide the rationale for
using MCT1 inhibitors as a novel therapeutic approach in patients with bone metastases.
Additionally, one common symptom of bone metastasis in patients is pain (cancerinduced bone pain -CIBP). We have shown bone metastatic cancer cells are highly glycolytic,
which generates high lactate levels and an acidic microenvironment. We postulated the acid in
the tumor microenvironment may be a cause of CIBP which warranted further investigation. We
found breast carcinoma cells that prefer bone as a metastatic site have very high extracellular
proton efflux and express pumps/ion transporters associated with acid-base balance (MCT4,
CA9, and V-ATPase). Acidosis can stimulate and sensitize the nociceptors in bone and result in
hyperalgesia. Exposing cancer-associated fibroblasts, mesenchymal stem cells, and osteoblasts to
acidic pH promoted the expression of inflammatory and nociceptive mediators (NGF, BDNF,
IL6, IL8, IL1b, and CCL5). Further, the impairment of intratumoral acidification via V-ATPase
targeting in bone metastases models significantly reduced CIBP. Current treatments for patients
with CIBP are often ineffective, but our in vivo results correlate with patients clinically providing
a potential new treatment avenue. Pain in patients, as measured by a questionnaire, correlated
with higher levels of inflammatory and nociceptive mediators’ production, e.g. IL6 and IL8 by
the stromal cells, suggesting tumor microenvironments generate pro-tumor stroma. Notably, a
clinical trial (NCT01350583) treated 9 patients in a phase I trial of Na-bicarbonate (to raise pH)
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as an adjuvant to reduce bone pain. While the study failed to escalate, there was a significant
reduction in patient reported CIBP. In summary, intratumoral acidification in the bone marrow
may activate the tumor-associated stroma promoting CIBP and this finding offers a new target
for palliative treatments in advanced cancer.
Chapter 6: Immune cells are another component of the tumor that are exposed to the stressful
microenvironmental conditions generated by tumor cells. In our studies, we have focused on
effector T cells of the immune system; i.e. CD8+ lymphocytes that have the potential to kill
tumor cells through release of granzyme B. CD8+ T cells are regulated under normal conditions
through expression of checkpoint inhibitor proteins that reduce effective lifetime or prevent T
cell activity.

Immunotherapy, such as checkpoint blockade inhibitors, increases T cell

persistence, and has induced durable responses in many patients. However, many tumor types
and many patients have shown minimal or no response, and it is unknown why. As we have
discussed, aggressive tumors are often acidic, and we have seen effects of low pH on both cancer
cells and the stroma. However, the impact of acid on T cells is unclear. Therefore, we aimed to
understand the effect of acidity on T cell function. We found that activated murine T cells
primarily rely on glycolytic metabolism, have reduced effector function and reduced glycolysis
in low pH conditions. Specifically, acid inhibits glycolysis by preventing lactate transport out of
the cell, which increases intracellular lactate and reduces intracellular pH resulting in
downregulation of glycolysis. Altering the pH of solid tumors using buffer therapy improved the
efficacy of immunotherapies. These findings have shown that acidity in solid tumors inhibits T
cell effector function, which is vital for response to immunotherapy. By reducing intratumoral
acidosis, we may be able to improve immunotherapy response in tumors and patients which have
so far seen little benefit.
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Chapter 7: In our studies, we assume low pH is generated by the highly glycolytic metabolism of
cancer cells. However, expression of proteins involved in cellular acid export, such as carbonic
anhydrase IX, are often concurrently expressed in cells which exhibit high levels of glycolysis
such as in pioneer cells at the invasive edges. What if acid export drove the uptake and
metabolism of glucose? Prior work strongly correlates tumor acidity with increased invasion and
metastasis, and that neutralization of tumor acidity can prevent the formation of metastases in
many systems. However, correlation is not causation. We tested the hypothesis that acidosis can
systemically cause metastasis by induction of acid production through the expression of plasma
membrane proton exporters. We designed two “gain-of-function” systems to generate acid
production independent of metabolic acid production. We engineered acid-producing cells by
overexpressing a yeast proton pump, H-ATPase (PMA1), or a proton-exporting exofacial human
carbonic anhydrase 9 (CA-IX). In vitro studies showed expression of either proton exporter into
non-metastatic human cancer cell lines enhanced aerobic glycolysis, migration, and invasion. In
vivo, the acid-producing cells formed higher-grade tumors, which were associated with increased
spontaneous and experimental metastases. Neutralizing acidity with buffer therapy reduced
metastasis. Therefore, increased rates of H+ export can drive increased aerobic glycolysis (the
Warburg Effect) and convert non-metastatic cells into those that form extensive metastasis. Thus,
we propose that variables associated with metastasis may be activated and enhanced by increased
acid production, and thus acidosis is systemically causal of metastasis.
Overall, we have been able to understand the impact of low pH on multiple different cell
types in tumors, how this impacts their function and the resultant implications for cancer
aggressiveness and response to therapy.
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Figure 1: Graphical abstract of understanding the influence of the cancer microenvironment on
metabolism and metastasis. Created with biorender.com
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Chapter 1: Background
Note: Parts of this chapter have been previously published in the book “Ecology and Evolution. Chapter 4
Pseudohypoxia: Life at the Edge” Russell et al. 2017 and has been reproduced in this manuscript under the
Creative Commons Attribution 4.0 International License.

In this dissertation, we aimed to understand the influence of the tumor microenvironment
on both the metabolism and the metastasis of tumors. These studies encompassed developing
new technology to measure the metabolic heterogeneity in 3D models, understanding the spatial
organization of tumors, and understanding the impact of acidity on cancer cells and stromal cells
such as fibroblasts and T cells. In Chapter 1, we review literature pertaining to each of these
aforementioned topics.

Technologies to measure metabolism
One of the hallmarks of cancer is altered cellular metabolismpampaloni1, and an
increasing number of studies are including or focusing on aberrant metabolism in order to better
understand how to treat cancer and improve response to therapy. There are multiple tools and
techniques utilized to measure the different metabolic pathways such as glycolysis, pentose
phosphate pathway, fatty acid, and amino acid metabolism. However, many of these tools use 2D
cell cultures, which are limited in recapitulating the heterogeneity observed in vivo. In our
studies, we have generated a new tool and methodology to measure the metabolism of spheroids
and tumor-derived microtissues in real-time which fills a gap in the metabolic technologies pool
(Chapter 2). Here we will discuss other tools to measure metabolism in cancer.
1

In vitro 2D studies
Many of the 2D based metabolism studies are kit based. These require growth of cells in
varying sizes of plates or dishes, often 96 well plate format and then the media is collected, cells
are lysed to collect contents or cells are incubated with the reagents to be taken up and measured.
These kits are often colorimetric, fluorescence or luminescence based. These assays can be used
to detect metabolites such as glucose, lactate, and glutamate or energy in the form of ATP using
CellTitre-Glo (Promega). CellTitre-Glo is often used to determine the viability of cells; it uses a
luciferin-based agent which is catalyzed in the presence of ATP and luciferase, resulting in
luminescence. It can be used to compare ATP levels across cell lines. CellTitre-Glo is one of the
only assays which has a 3D counterpart to measure the viability of 3D spheroids. The research
industry realizes the need for these types of tests, and this reiterates why we resolved to develop
a 3D based methodology to interrogate metabolism, as these tests are currently lacking. Many
kit-based assays measure the activity of metabolic enzymes rather than the metabolite itself, for
example, to measure glucose uptake, the Glucose Uptake-Glo assay (Promega) is often used. It is
also a luciferase-based method, which uses the production of NADPH from the catabolism of 2deoxyglucose-6-phosphate to measure glucose uptake. NADPH is used by reductase to convert
proluciferin into luciferin, which is then catalyzed by luciferase to generate luminescence.
Although this bioluminescent method does measure parts of glycolysis, it does not directly
measure metabolite levels.
One technology that measures specific metabolites is the YSI multi-analyte Biochemistry
analyzer 2950D, which can measure up to 6 metabolites in a single sample. This technology is
not used explicitly for cancer cell research; it can be used for many applications including
biofuel production, food and beverage processing, and biological research. The YSI analyzer can
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measure a range of metabolites such as glucose, lactate, glutamine, glutamate, sucrose, and
choline. The YSI extracts a sample from a cell culture plate, conical, or micro- centrifuge tube
and adds it to a chamber containing coupled metabolic enzymes embedded in permeable
membranes. In the case of glucose, the membrane contains glucose oxidase producing hydrogen
peroxide, which is measured in the module to calculate the glucose concentration in the media.
The machine only uses 10ul per reading and has a sizeable detection range 0.05-25g/L enabling a
wide variety of samples to be measured.
Alternative plate-based assays include kits to measure oxidative stress, nucleotides,
cofactors, and fatty acid oxidation assays. As mentioned, aberrant metabolism is a hallmark of
cancer, and a prominent phenotype is the Warburg effect or elevated fermentation of glucose in
well oxygenated conditions. Although once considered to be due to defects in mitochondria, it is
now appreciated that many cancers preferentially utilize aerobic glycolysis, irrespective of
mitochondrial health. Even so, measuring mitochondrial metabolism is of great interest in cancer
research. Often plate-based or imaging assays can be used to characterize mitochondrial health or
behavior. Analysis of mitochondrial function can include membrane polarity, reactive oxygen
species (ROS), membrane potential, specific enzyme activity in electron transport chain
complexes and the overall biogenesis, mass, and viability of mitochondria2. The Clark Electrode
has been historically used to measure O2 consumption to infer mitochondrial activity3. An
interesting feature of cancer cells is they appear to produce and withstand higher levels of
oxidative stress compared to non-cancerous cells, although this is not canonical thought4. ROS
cause oxidative stress and plate-based assays can measure ROS, for example, superoxide and
hydrogen peroxide.

3

One technology which is now utilized heavily to measure metabolism, including
mitochondrial metabolism, is the Seahorse Extracellular Flux Analyzer. Many of the previous
assays mentioned utilized time point metabolism studies, whereas the Seahorse is a live cell
metabolic flux analyzer. It uses the extracellular acidification rate (ECAR) and the oxygen
consumption rate (OCR) to probe different parts of metabolism, including glycolysis,
mitochondrial metabolism, fatty acid fuel oxidation, fuel dependency, and overall energetic
phenotype of the cells. Previously, Seahorse Technology was strictly a 2D plate-based assay, but
we have been able to expand this technology into the 3D spheroid and microtissue metabolism
realm (Chapter 2).

Seahorse extracellular flux analyzer
One of the most widely used tests of the Seahorse is the glycolytic stress test, and we will
use this as an example of a Seahorse assay5. To start the assay, cells are plated in a Seahorse 6,
24, or 96 well plates at 85-95% confluence. The surface area of a Seahorse plate is smaller than a
regular 96 well plate well and it is designed to form a transient microchamber during the assay;
thus, it is essential to optimize the seeding density for each cell line used. Cells are seeded the
day before to allow time for attachment. Non-adherent cells, for example, T cells, are adhered
the same day of the assay using an adhesive polymer such as Cell-Tak (Corning). Drugs are
loaded in a specific sequence into up to four individual drug ports on the Seahorse drug plate.
The glycolytic stress test drugs are: 1) glucose (to stimulate glycolysis), 2) oligomycin (an
electron transport chain complex 5 inhibitor to shut down mitochondrial ATP metabolism and
maximize glycolytic flux); and 3) 2-deoxyglucose ( an analog of glucose that cannot be
metabolized further than conversion to 2-Deoxyglucose-6-phosphate by hexokinase). These
4

drugs are injected in sequence into the cell chamber. Measurements of ECAR and OCR are taken
simultaneously before, and after, each injection for a specified number of measurements. The
Seahorse technology uses solid-state sensor probes with polymer embedded fluorophores to
measure OCR and ECAR. During each measurement, the transient microchamber is formed to
increase sensitivity. The solution in the chamber is mixed between measurements to redistribute
the nutrients and gases to maintain accurate measurements of ECAR and OCR. Assay results are
normalized to cell number, protein concentration, or the number of nuclei6. Here is a typical
glycolytic stress test assay.
Depending on the metabolic inhibitors used and the sequence of injections, these types of
live cell assays can provide valuable insight into the metabolic phenotype of cells. Other
available tests include mitochondrial stress test, mitochondrial fuel test, glycolytic rate assay,
ATP rate assay, exogenous and endogenous fatty acid oxidation assay, and cell energy
phenotype assay.

Metabolomics
One of the newest -omics technologies is metabolomics. With a reinvigorated drive to
better understand the dynamic metabolic state of cells, it is fast becoming a popular method for
probing cellular metabolism. In cells, metabolites can be measured by untargeted metabolomics,
taking a global view of metabolites, or by targeted metabolomics, such as only measuring the
glycolytic metabolites, wherein a narrower, more detailed approach is taken. The most common
techniques used are gas or liquid chromatography coupled to mass spectrometry (GC- or LCMS)7 or nuclear magnetic resonance. In MS, metabolites are separated by their mass to charge
ratio and retention times8. Primary carbon metabolism is the most comprehensively defined in
5

terms of metabolites. The detection and identification of unknown metabolites is a challenge in
metabolomics, but many labs are working to improve this area. To better understand cellular
physiology, metabolic pathway flux analysis has been implemented in the metabolomics field.
Stable isotopes such as

13

C or

15

N can be used to quantify metabolic flux and provide further

insight into cellular metabolism. As the labeled substrate is metabolized through metabolic
pathways, specific labeling patterns (isotopomers) are observed within the metabolites. Both
uptake and secretion rates of metabolites are required to enable quantitation of flux and provide
the constraints needed for each pathway. These rates are used to inform metabolic models, and
various software packages such as INCA or Metran can be applied to quantitate flux9. Flux
analysis is a powerful tool and an improvement to the metabolomics field, but tracers can be
expensive, and it is difficult to get a broader picture of the metabolome as pathways will only
metabolize labeled substrates specific to them. Significant improvements are needed to identify
compartment-specific metabolic flux such as in the mitochondria, but overall this technique and
analysis can improve understanding of cancer metabolism and may identify critical metabolic
pathways or vulnerabilities that have heretofore been unknown.

Metabolic flux analysis using imaging
Another approach to measuring metabolic flux is through substrate removal and
monitoring changes in, for example, intracellular pH6. Monitoring efflux can be used to see if
various inhibitors, oxygen concentrations, and extracellular pH conditions can change the uptake
or efflux of specific metabolites. Lactate efflux can be measured via this method. Lactate efflux
is correlated to changes in intracellular pH by the efflux of lactate as lactic acid: the higher the
flux, the more basic the intracellular pH becomes due to loss of H+. This method can help
6

delineate active from passive flux by measuring efflux of membrane-permeable molecules such
as ammonia and acetic acid (Chapter 6). These molecules passively diffuse through the
membrane, unlike lactate which is usually actively transported by monocarboxylate transporters
MCT’s6. MCT inhibitors can also be utilized to measure active versus passive flux.

3D metabolism studies
Currently, 3D metabolic studies are lacking. That is not due to a lack of available models,
but more due to a lack of robust tools. One of the only plate-based assays for 3D metabolism is
the CellTitre-Glo which measures ATP but does not delineate the mechanism of ATP generation
or the maximum energy capacity of spheroids. Spheroids can be formed utilizing gravity by
suspending cells in media from the lid of a cell culture dish or in specialized anti-gravity 96 well
plates. Standardized plate formats generate spheroids with minimal variation. Not every cell line
can form spheroids, but some cell lines can be coaxed to form spheroids with a media containing
a low percentage of scaffold material such as Matrigel. The matrix helps to recapitulate the
structural heterogeneity and the nutrient and gaseous gradients that form in tumors. Other 3D
models use a completely engineered matrix environment, where cells are fully embedded in
Matrigel to form spheroids, again this is dependent on the cell line and the type of matrix chosen
for the cells10 and these tend to form more heterogeneous spheroids. Some microtissues can be
generated from ex vivo organs or tumors, as well as the production of organoids grown from
tissue stem cell populations11.

7

Importance of 2D vs. 3D models
There are considerable expression differences, microenvironments, and heterogeneity that
will only occur in a 3D cell culture model, and this necessitates the use of both 2D and 3D
models. When cells have cell:cell contact in 3D, it alters their gene and protein expression12,
resulting in phenotypic changes, altered nutrient preferences, and variable response to therapy.
One of the earliest demonstrations of this was a study in 1977, which showed murine mammary
epithelial cells when cultured in a 3D fashion using floating collagen membranes responded to
hormones and produced casein as occurs in vivo. The mammary cells cultured in 2D on plastic
had no response to hormones and did not produce casein13. Cell cultures are commonly grown in
plastic dishes or flasks in 2D; these dishes are of supraphysiological stiffness and alter the cell
surface to volume ratio of a cell which can change penetrance of drugs, and nutrient and gaseous
gradients in 2D culture. The lack of gradients can alter the zones of proliferation observed in 3D,
cells in 2D usually proliferate at the same rate whereas because of the varying gradients in
spheroids some regions will proliferate faster than others14. Often the outer edges of the
spheroids are more proliferative whereas the cores are more hypoxic, quiescent, and/or necrotic.
These variations induced by cell:cell contact and the altered microenvironment generated,
compared to 2D cultures, highlights the need to incorporate 3D models.

In vivo and patient studies to measure metabolism
Many of the metabolic techniques that we use on in vivo animal models can be similarly
used in patient studies. These can be non-invasive, minimally invasive, or invasive requiring
surgery. Blood tests are a minimally invasive way to measure metabolites in patients and animal
models such as mice. These can include, for example, a comprehensive metabolic panel which
8

measures glucose, calcium, albumin, total protein, creatinine, chloride, and liver function. These
tests can be repeated over time to monitor metabolic changes in response to drugs, or to monitor
for organ toxicity. In liver tests, high levels of bilirubin, AST, and ALT, or low levels of
albumin can be a sign of liver problems. As previously mentioned, metabolomics is used more
and more frequently, and patient serum, tumor, and normal tissue samples can be used for
metabolomics analysis. We observe different metabolite abundance when comparing normal to
tumor tissue in several cancer types such as bladder, breast, kidney, and pancreas15. These
metabolite changes could be associated with tumor initiation or more aggressive cancer
phenotypes and therefore warrants further study. One study16, utilized U-13C labelled glucose and
lactate infusions in non-small cell lung cancer patients and found that the tumors were
consuming lactate as a fuel to feed the TCA cycle. Those tumors which had high lactate
consumption similarly had high fluorodeoxyglucose (FDG) uptake which is associated with poor
survival.

Imaging modalities
There are numerous imaging modalities used to determine the metabolism of tumors,
which are minimally invasive with few side effects for patients. Both MRI and PET are
commonly used to image tumor metabolic phenotypes. Radiotracers such as
probe glycolysis17, or magnetic resonance spectroscopy isotopes such as 1H,

18
31

F-FDG PET to

P for measuring

mitochondrial function, and 13C to measure glucose and lactate metabolism18.However, MRI has
low sensitivity for isotopes, such as

13

C and one way to circumvent this is through

hyperpolarization. Hyperpolarization creates a non-equilibrium state of the nuclei resulting
greater signal to noise ratio and a faster acquisition time. This method has been used to measure
9

metabolism such as glycolysis, krebs cycle, and glutaminolysis19. Additionally, hyperpolarized
MRI has been expanded to measure pH in , for example, breast xenograft tumors and rat kidneys
using 13C labelled zymonic acid20.
The technologies to decipher cancer cell metabolism in situ need much improvement. We
are still failing to treat patients, and cancer numbers may increase as our global population
increases in both number and age. Metabolic studies provide a method for personalized patient
care and could prevent chemotherapy failure and organ toxicity. These tests are often noninvasive or minimally invasive. We need better in vitro, in vivo, and patient studies because there
is a lack of translation which is hindering treatment progress.

Tumor heterogeneity
Over time and with clonal expansion driven by localized selective pressures, tumors
commonly become irregular in shape and contain multiple clones and microenvironemnts21.
Heterogeneity within tumors is relevant to patient outcome and may be a proximal cause of
therapy resistance. 3D models better re-capitulate this heterogeneity over 2D models. Further,
tumor heterogeneity explicitly dictates that single biopsies may not accurately reflect the
complexity of a tumor as a whole22. Nevertheless, although this inter-tumor heterogeneity is
vitally important, the difference between the edge and the core of the tumor is an undervalued
piece of data currently not being utilized to its full potential. We see the importance of this in our
studies in Chapter 5 on adaptive sub-populations within tumors. The differences between the
edge and core are likely due to different microenvironments, leading to various evolutionary
selection forces.
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Tumor edge
Often tumors have variable cellular compositions at their edges. Some tumor edges are
smooth and round while others are irregular and jagged. Within a tumor, cell density varies as a
result of necrosis, proliferation, and nutrient and gaseous gradients throughout the tumor. We
know that larger tumors can become necrotic in the center due to inadequate nutrient supply, a
hypoxic environment, and an inability to remove waste, and hence, these larger tumors become
more metabolically heterogeneous.
Within the tumor edge itself is heterogeneity as not every region of the tumor is exposed
to the same microenvironmental stresses, and each region will evolve according to their fitness
within the surrounding environmental pressure. This variability allows for different regions of
the tumor to expand until conditions are favorable for other sections of the same tumor. These
irregularities equate to different cellular adaptations resulting in observation of an irregular edge
in MR and CT images. Using defined features extracted from CT images, lung tumors could be
quantitatively described using two features: tumor shape complexity and intratumor density
variation

23,24

. These independent studies observed that non-small cell lung (NSCLC) tumors

with a more irregular shape and a large tumor shape complexity feature score had a poorer
prognosis. They identified through this study: features at different lung cancer stages were
significantly different from each other; tumor cores with high entropy were likely due to necrosis
and heterogeneity; tumor edges with relatively higher heterogeneity (entropy) resulted in
decreased patient survival. CT imaging is a modality which can be used to describe habitats and
tumor heterogeneity through specific features. Analyzing imaging features in CT has shown that
the edge of a tumor is not only variable, but features can be extracted to predict prognosis, with
higher variability (for example, entropy) at the edge showing poorer prognosis23. These simple
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quantitative imaging biomarkers comparing the edge and the edge versus core of the tumor could
be used in the clinic as additional diagnostic and prognostic tools.
Although CT scans can show an irregular tumor edge, histology is needed to definitively
define stage and sub-type of a tumor, in addition to genetic screening for targeted therapies. The
ability to dissect images for prognosis is not meant to be a tool to replace clinicians but a tool to
aid with patient prognosis and diagnosis. It has the potential to be implemented for nonresponsive patients; non-responders may have different physiological features that play a role in
drugs being ineffective or in developing drug resistance. This is an intriguing prospect that needs
to be pursued.
Other studies have investigated solitary pulmonary nodules and could distinguish using
CT textural features which nodules would most likely be malignant based on the edge-to-core
heterogeneity24. A study in 1991 of uterine leiomyomas, T2 weighted MR images showed higher
signal intensity at the border was related to a more blood vessel, lymphatic system rich region
around the tumor edge 25. This study proposed tumors with a high-intensity tumor edge are more
likely to be aggressive and progress. Ultrasound has even been used to distinguish malignant vs.
benign breast tumors where a rough edge suggests malignant and a smooth edge suggests benign
26

.
Tumors are not altering the edge without benefit. There is an evolutionary benefit to

these cells to be different from the core. It allows the tumor to survive and thrive under different
conditions. If we take a look at examples in nature, we can see that they parallel extremely well
with tumors. The invasive delicate skink was introduced to Lord Howe Island in the 1980s, and
subsequently, over time, seven distinct haplotypes were observed. These haplotypes were usually
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found in specific regions of the island, likely due to the genetic fitness advantage gained in the
surrounding environment27. Evolutionary pressure selects for cells with genotypes and
phenotypes that provide a fitness advantage. These phenotypes are suited to the surrounding
microenvironment because if the cells did not evolve, they would die.
Although there are differences between primary tumors, metastases from the same
primary tumor and inter- and intra-tumor heterogeneity; the edge is often a unique feature in all
of these presentations. The edge of the tumor is derived under different selective pressures
compared to the core. This results in phenotypically different attributes compared to the core,
which impacts the surrounding stromal and immune components of the microenvironment. The
"acid-mediated invasion hypothesis" states that expression of glycolytic proteins at the edge
creates an acidic microenvironment, which untransformed stromal cells are not equipped to
withstand, inducing apoptosis and this results in the creation of space which tumor cells can
proliferate into28. This acidic pressure drives selection for a phenotype that favors migration and
invasion, allowing the edge to grow faster and invade into the stroma and surrounding tissue.
Cane toads (native to Central and South America) were introduced to Australia over 70 years ago
29

. They subsequently thrived due to a lack of natural predators or disease susceptibilities. The

cane toad is toxic, and, similarly, tumors keep their predators, i.e., the immune system, at bay by
secreting toxins. One of the "toxins" secreted by tumors is lactic acidic, which hampers T cell
effector function by inhibiting T cell glycolytic metabolism

30

. One way in which tumor cells

create this acidic environment is through the Warburg effect, and then this acidity is enhanced by
increased CA-IX expression

31,32

. The edge will employ protective strategies by up-regulating

sodium hydrogen exchangers (NHE) to maintain a neutral internal pH; as even cancer cells
cannot have an internal pH which strays far from neutral 33,34.
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Tumor core
The core, unlike the edge, is a more stable region of a tumor, it does not appear to evolve
at a fast-enough rate to withstand pressures such as hypoxia which will often induce cell death.
The core is more oxidative, so protection from acidosis is not as vital. Core cells are not exposed
to very acidic pH conditions and are unlikely to expend as much energy on production of
proteins such as NHE’s to maintain a neutral intracellular pH, which edge cells must do. Often
invasive species will induce genetic and phenotypic changes in the surrounding species, for
example, on small islands in The Bahamas, introduction of an invasive rat species caused loss of
genetic diversity within the endemic brown anole lizard population, over a single generation 35.
This loss of differentiation is mimicked in cancer with the acidic environment stimulating rapid
adaptation in fibroblasts which can result in metabolic co-operation between cancer cells and
cancer-associated fibroblasts 36.
The edge consumes large amounts of glucose and produces acid, out-competing other
cells in the vicinity. Although tumors produce highly acidic environments, even they have a limit
as to how much acid they can withstand before the cost is too high. Environmental pressures are
known to induce species to adapt and evolve in much a similar way that microenvironmental
pressures cause cancer to evolve. The peppered moth is one such example, in England during the
1950's coal factories produced a large amount of black smoke that caused the habitats of a
predominantly white species of moth to become blackened. This change in habitat resulted in
predators having an increased chance of being successful in hunting the moths. However, a black
melanic form of the same moth was then selected for as it would blend into the background of
the blackened trees. The pressures from the environment selected for this color as it provided a
fitness advantage 37. Selection is observed at the edge of tumors as a glycolytic, acid-producing
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phenotype is selected for over an oxidative one, with multiple benefits including, but not limited
to, suppression of immune attack.

Pseudohypoxic tumor phenotype
The edge of tumors is well oxygenated, yet they commonly exhibit a phenotype as if they
are exposed to hypoxic conditions, which is termed pseudohypoxia. Pseudohypoxia is a
relatively uninvestigated phenomenon wherein cells and tissues express hypoxia-related proteins,
HRPs, in the presence of oxygen. We propose that pseudohypoxia provides an evolutionary
advantage allowing tumor cells at the edge to achieve fitness maxima in stressful, often transient,
microenvironments. Pseudohypoxia is energetically costly because it is associated with a reliance
on fermentative glucose metabolism, yet cells appear to be willing to expend this cost, which
presumably increases their fitness maximum and survival in hostile environments.
Pseudohypoxia was a term first coined to describe effects of hyperglycemia in diabetes,
used to define the complications occurring in diabetes due to metabolites acting on the blood
vessels, causing them to behave as if starved of oxygen. Pseudohypoxia is also occasionally
used to refer to the generation of hypoxic conditions using a chemical substrate, for example,
cobalt chloride38 which increases HIF-1α. In the current work, we use pseudohypoxia to describe
a cellular phenotype that results from evolutionary selection and hence, must confer a selective
advantage.

In this chapter, pseudohypoxia refers to a state in which cells or tissues express

hypoxia-related genes and proteins, even when there is ample oxygen present.
The clinical relevance and physiological impact that a pseudohypoxic edge has on tumor
behavior can be profound. One possible benefit could be that, during invasion, periods of
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hypoxia may be encountered during tissue remodeling that is inherent in invasion.
Pseudohypoxic cells may be more likely to survive in hypoxia as they are already functioning as
if exposed to a lower oxygen concentration. Pseudohypoxic phenotypes are unlikely to change
during hypoxic conditions, meaning cellular resources need not be expended to alter responses
under times of fluctuating oxygen concentration in the microenvironment.
The initiation or mechanism behind the induction of a pseudohypoxic phenotype does not
appear to be due to one specific event in every tumor. We have previously observed that
intermittent (but not chronic) hypoxia selected for a pseudohypoxic phenotype where cells are
more proliferative, more invasive, and more resistant to chemotherapies39.The pseudohypoxic
phenotype was fixed even after cells were cultured for multiple passages in normoxic conditions.
Intermittent hypoxia is likely to occur in tumors naturally while they are growing, and blood
vessels are forming and collapsing40. Pseudohypoxic cells may already be present in a mixed
tumor population and grow out via clonal selection, or induction of random mutations by
fluctuating hypoxia may generate, and select for, a pseudohypoxic phenotype. Pseudohypoxic
phenotypes can occur through specific mutations which upregulate HIF-1α expression or prevent
its degradation. In glioma, isocitrate dehydrogenase (IDH) mutants result in the reduction of
alpha-ketoglutarate, which is involved in the degradation of HIF-1α and as a result, forms a more
pseudohypoxic, invasive phenotype41. Other mutations linked to up-regulation of HIF-1α in
normoxia include, among other things: phosphatase and tensin homolog (PTEN), von HippelLindau protein (pVHL), p53, epidermal growth factor (EGF) and mutant Ras and src42. It has
been suggested that metabolite balance within the cell can induce a pseudohypoxic phenotype.
For example, increased succinate and fumarate in succinate dehydrogenase and fumarate
dehydrogenase deficient cells have been shown to activate HIF-1α

41,43

. Imbalances in NAD+
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levels trigger HIF-1α and downstream metabolic reprogramming, and this occurs during aging,
but this is also possible in tumors44. All these different mechanisms result in HIF-1α upregulation
or stabilization. However, it must be remembered that although stabilization of HIF can be a
proximal cause of pseudohypoxia, other factors come into play between this activation and the
resulting phenotype of increased aerobic glycolysis.
Among other phenotypic characteristics of pseudohypoxia, a predominant pathway is that
of the Warburg effect, wherein cells preferentially use glucose as a substrate to feed into
glycolysis, producing lactic acid even in the presence of oxygen. Studies have shown that cells at
the tumor edge that produce acid are much more likely to invade compared to non-acid
producing cells at the core

45

. These core and edge cell types have been broadly termed

“pioneers” and "engineers". Pioneers are more invasive, aggressive, proliferative, and at a higher
risk of cell death, whereas engineers are more quiescent, induce angiogenesis, and have limited
resources. The pioneers are more glycolytic, and this produces a more acidic microenvironment
at the tumor edge

45

. Pioneers at the edge and engineers at the core express different proteins

likely suited to their microenvironment. These will be covered briefly.

Proteins of the tumor edge
Carbonic anhydrase IX (CA-IX)

CA-IX is a zinc metalloenzyme that catalyzes the reversible hydration of CO2 into H+ and
HCO3- 46. CA-IX is up-regulated and a negative prognostic factor in several cancers; including
ovarian, pancreatic, medullary thyroid, breast, lung, glioblastoma, and multiple other cancer
types

46-54

. CA-IX is often found at the tumor edge and can generate and maintain an acidified
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microenvironment in concert with GLUT-1 overexpression

45

. Not only does CA-IX stimulate

extracellular acid production, but it has been suggested that the bicarbonate ions produced can be
shuttled back into the cell to neutralize the intracellular pH 55.
CA-IX is commonly used as a hypoxia marker, as it is a HIF client protein. However,
both published and unpublished data have shown that CA-IX is not invariably associated with
hypoxia and hence, can be differentially classified as a marker of hypoxia or pseudohypoxia,
depending on its location

56

. CA-IX will be further described in the background sub-section

Acidic microenvironment: Proton producing and exporting proteins.
Glucose transporter 1 (GLUT-1)

The acidic environment is, in large part, the result of lactic acid excretion from the tumor
generated by glycolysis. Cells need to increase their glucose uptake by up-regulating the
expression of glucose transporter 1 (GLUT-1) to up-regulate glycolysis. Tumor growth at the
leading edge of tumors requires not only sufficient energy but the macromolecules to build and
move forward. Glycolysis provides both of these at a high rate compared to oxidative
phosphorylation

57

. Indeed, a study by Young et al. in 2011

58

showed that decreased GLUT-1

transporter expression did not affect cellular ATP levels, but significantly affected lipid synthesis
and growth on plastic, suggesting a role of glycolysis in providing building blocks for
macromolecular synthesis 58.
GLUT-1 is a HIF client gene product that is observed in both hypoxic and oxygenated
conditions making it a relevant marker for hypoxia/pseudohypoxia depending on its location. As
mentioned, cancer cells often metabolize glucose at high rates, even in the presence of sufficient
oxygen; known as aerobic glycolysis or the Warburg effect. A critical regulatory component of
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glycolytic flux is upregulation of glucose transporters so that membrane transport will not
become rate-limiting in times of high demand. GLUT-1 is the most commonly observed glucose
transporter isoform found to be highly expressed at the edge of tumors in both models and by
immunohistochemistry (IHC) 45,59. GLUT-1 expression is higher at the leading edge of the tumor
and localizes to invasive regions of the tumor periphery

45,60

. Further, GLUT-1 expression is

often found adjacent to the stromal areas with high CD31 staining, a blood vessel marker,
suggesting these regions are not hypoxic and yet the pseudohypoxic phenotype is observed.
The elevated expression of GLUT-1 is attributed to at least five different intrinsic
pathways, including, HIF, Myc, src, p53/TIGAR, and mitochondrial defects

61

. Activation of

PI3K and MAPK pathways also can lead to HIF-1α stabilization, resulting in elevated GLUT-1
expression

62

. GLUT-1 is often observed in more aggressive tumors

17

, where it is associated

with poor prognosis. However, other glucose transporter family members, notably GLUT-3, can
facilitate glucose uptake and promote a pseudohypoxic phenotype, as GLUT-1 is not seen in all
types of cancer

59

. GLUT-1 can be extrinsically regulated by several hormones, including

epidermal growth factor (EGF), estrogen

63

, insulin

64

, insulin-like growth factor and follicle-

stimulating hormone (FSH), which could be stimulated or coopted by the tumor to stimulate
GLUT-1 upregulation 63-65.
Clinically, GLUT-1 expression correlates highly with increased 18-FDG uptake in
tumors by PET imaging 66. Elevated uptake of FDG and upregulation of GLUT 1 are observed in
several cancers including bladder, prostate, breast, and pancreatic and are associated with poorer
prognosis

67-70

. Therefore, through multiple mechanisms, GLUT-1 is already seen to be a
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clinically relevant target and could be one of the essential features in a pseudohypoxic phenotype
by generating an acidic microenvironment.
Ki-67

Ki-67 is a commonly used stain for cellular proliferation and is often seen elevated at the
edge of invasive tumors by IHC

45,71-73

. Increased Ki-67 expression has been linked to worse

prognosis and increased the likelihood of metastasis in prostate cancer

74

. In breast cancer, the

expression of Ki-67 in the primary tumor has been suggested as a significant independent factor
for reduced overall survival 75. Hence, a tumor edge with high Ki-67 staining may be more likely
to be invasive, metastatic, and chemo-resistant. Thus, there are many, possible interrelated
components expressed at the edge of invasive tumors, making it an attractive target to overcome
resistance and sensitize to immune responses. Targeting one or multiple parts of this unique
microenvironment could reduce the fitness of cells at the leading edge, driving the tumor into an
evolutionary corner.

Proteins of the tumor core
In parallel to the tumor edge, the core exhibits a very different phenotype; one which
does not appear to have the ability to be fit in more adverse environments. Indeed, the core can
be characterized by areas that are well perfused, adjacent to areas with poor perfusion and high
necrosis. The interface between these two populations may impact high evolutionary selection
for cells with edge-like characteristics.
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Carbonic anhydrase XII (CA-XII)

Carbonic anhydrase XII (CA-XII) is in the same family as CA-IX and catalyzes the same
reversible reaction CO2 into H+ and HCO3-. CA-XII is more active at neutral pH as it does not
have a proteoglycan (PG)-like domain to shield its active site, which CA-IX does. It is known to
form homodimers in cellular membranes and appears to be ubiquitously expressed throughout
tumors, including the core 45,76. Unlike CA-IX, CA-XII is a positive prognostic factor in certain
types of cancer, including breast and lung77,78. However, this is not universal, as CA-XII can
also be a negative prognostic factor in, for example, gliomas and oral squamous cell carcinomas
78-81

. It may be the prognostic value for CA-XII depends on it intratumoral location, which has

not been adequately explored, i.e., its spatial relationship in conjunction with other
pseudohypoxic phenotypes such as increased glycolysis, acidification, and up-regulation of Ki67 at the tumor edge.
Caspase 3 (CC3)

Proteolytic cleavage, and hence, activation of the protease, caspase-3 (CC3), occurs
during programmed cell death (apoptosis) and is often seen in tumors under microenvironmental
or genotoxic stress, often in areas adjacent to "necrotic" cores. Necrosis and CC3 are linked to
increased aggressiveness and poor prognosis in, for example, endometrial cancer 82.

Other cell types that contribute to tumor heterogeneity
Immune cells

Immune cells make up a significant component of the tumor and contribute to the
observed heterogeneity. Both the innate and adaptive immune system play a role in cancer.
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Innate immunity is antigen-independent, broadly specific, involved in inflammation and is the
immediate response to infection. Adaptive immunity is antigen-dependent, antigen-specific, and
can result in the generation of memory phenotype immune cells. There is a lag between the
initial exposure to a pathogen and response by the adaptive immune system. Within the tumor T
cells, B cells, dendritic cells, natural killer cells, macrophages, and myeloid-derived suppressors
cells (MDSC's) have been found, and they can play both anti-tumorigenic and pro-tumorigenic
roles. Which role these cells play is temporally and spatially dependent as during a tumor’s
lifetime, different microenvironments are generated, placing different stressors and cytokines on
the immune cells resulting in differential responses.
B cells are part of the adaptive immune system and in some cases, can make up around 25% of
the cells in the tumor83. B cells produce antibodies against tumor neo-antigens to mount a
humoral immune response, although some have argued that B cell infiltration can promote tumor
growth84. B cells can up-regulate T cell response by producing chemokines, or through antigen
presentation and costimulatory molecule expression85. B cells can also suppress T cell
immunity86. Within the tumor, B cells respond to the microenvironmental conditions. Tumors
can secrete factors which attract B cells into the tumor and promote their differentiation into B
regulatory cells87. These cells, which are CD25+, CD19+, and CD220+, can facilitate cancer
progression and metastasis through the conversion of T cells into T regulatory cells88. Hypoxia, a
common microenvironmental stressor has been shown to induce abnormal B cell development
through activation of HIF1, and both HIF1 and HIF2 activation in T cells enhances cell death
and reduces cellular proliferation89,90. Low pH is another common microenvironmental stressor,
but few studies have looked at the impact on B cell function. Low pH is known to enhance
degradation of antibodies which may prevent anti-tumor roles of B cells91.
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Dendritic cells can be both pro and anti-tumorigenic. Dendritic cells present tumor antigens to T
cells and can release cytotoxic cytokines to kill tumor cells; they have been shown to suppress T
cell function, which can promote the progression of tumors. Dendritic cells have increased
activity in hypoxic microenvironments due to HIF1 activity which increases survival,
differentiation, and antigen presentation92,93. Acidic pH can decrease differentiation of
monocytes into DC’s94.
Natural killer cells appear to be mainly anti-tumorigenic and release cytotoxic cytokines to kill
cancer cells. Under hypoxic conditions, HIF stabilization reduces cytotoxic functions of NK cells
and could enhance tumorigenesis. Under acidic conditions, granzyme and perforin release from
NK cells is reduced as well as TNF-alpha and IFN-U production inhibiting NK function within
the tumor.
Myeloid-derived suppressor cells (MDSC's) are very pro-tumorigenic and suppress infiltrating T
cell function and can recruit immunosuppressive cells intratumorally. Hypoxia, found in the
TME, reduces STAT3 activity in MDSC’s converting them to tumor associated macrophages95.
MDSC's are classified into two major groups granulocytic and monocytic MDSC's. These
subtypes are enhanced depending on the microenvironmental conditions and hypoxia, and low
pH may inhibit granulocytic MDSC's as monocytic MDSC's are preferred in the tumor
microenvironment, this may also be a result of chemokines produced by the tumor cells96.
Macrophages can present antigens to T cells and release cytotoxic cytokines to induce tumor cell
killing. Macrophages are often portrayed as one of two subtypes, but it is likely to be a spectrum
of phenotypes. M1 macrophages are pro-inflammatory, anti-tumorigenic, present antigens and
kill intracellular pathogens. M2 macrophages are anti-inflammatory, immunoregulatory,
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involved in matrix formation in the tumor and are pro-tumorigenic. Acidosis has been shown to
select macrophages towards an M2 phenotype97 and activation of HIF-1a by hypoxia increases
tumor-associated macrophages.
T cells are the second most common immune cell in the tumor. The recent re-invigoration of the
immune-oncology therapy field has been predominantly focused on T cells. Tumor-infiltrating
lymphocyte therapy (TIL) and checkpoint blockade therapy have shown some robust responses
in patients. T cells are part of the adaptive immune response98. Naïve T cells are primed by
antigen-presenting cells in the draining lymph node and can migrate to the tumor to kill tumor
cells. Unfortunately, T cells are matured in the thymus wherein any auto-reactive T cells are
programmed to die. As tumor cells are self, unless they express tumor neo-antigens, they often
go undetected by T cells99.
Additionally, cancer cells express inhibitory ligands, for example, PD-L1 which can
interact with T cell receptors PD-1 inducing T cell anergy, reducing activation time of T cells in
the tumor. The tumor microenvironment, i.e., acidosis and hypoxia, negatively impact T cells. T
cells have reduced activation, cytokine production, and cytotoxicity in acidic pH100. Acidic pH
also negatively impacts T cell metabolism, and we identify the mechanism in Chapter 6.
Hypoxia promotes TH17 and T reg differentiation101 and induces metabolic reprogramming as
well as increased expression of coinhibitory molecules.
Fibroblasts

Fibroblasts are found in normal tissues in the interstitial space as single cells which do
not attach to the basement membrane. Fibroblasts help to maintain connective tissue and are
involved in wound healing102. These cells are usually quiescent until activated for their normal
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function103. Cancers are considered “wounds that do not heal”104, and it has been observed that
cancer cells can co-opt the fibroblasts, converting them into pro-tumorigenic cancer-associated
fibroblasts (CAF's). Fibroblasts exposed to acidic stress become undifferentiated exhibiting a
stem cell-like phenotype including expression of stem cell marker, OCT-4

105

. Other CAF

markers include fibroblast activation protein alpha (FAP), platelet derived growth factor receptor
(PDGFR), and caveolin 1. Fibroblasts experience cell:cell contact with tumor cells as well as
exposure to tumor chemokines such as TGF-ß and PDGF's. These can induce fibroblasts to
produce tumor-promoting growth factors, cytokines and to remodel the extracellular matrix
(ECM). ECM remodeling by CAF’s is driven by ROCK pathway signaling, JAK1, and STAT3
expression which promotes matrix stiffness and aids tumor cell invasion. Additionally, cancer
cells can express wnt7a, il-1b, leukemia inhibitory factor (LIF), and release exosomes which
activate CAF’s. CAF's can include fibroblasts and myofibroblasts which are alpha SMA positive,
a marker of an activated fibroblast106. Alpha SMA negative myofibroblasts can still be protumorigenic102. CAF's influence immune cells within the tumor by secreting inflammatory
cytokines, IL-4, IL-6, and CXCL8, which polarize macrophages into a pro-tumorigenic M2
phenotype. The tumor microenvironment impacts fibroblast function too. Hypoxia, reduced
nutrients, acidosis107, and oxidative stress can activate heat shock factor 1(HSF1)108 in CAF’s,
which positively impacts the tumor by enhancing angiogenesis, ECM organization, and
migration. CAF's may secrete growth factors, such as bone morphogenic proteins (BMP’s), to
aid in niche colonization of distant organs. Secretion of growth factors may help tumor cells
metastasize more successfully as the organs are primed for metastasis. Additionally, CAF’s can
promote a mesenchymal to epithelial transition in tumor cells to aid in colonization of distant
organs. Clinically, increased CAF’s in the tumor can result in poorer patient outcome.
25

We observed in our studies in Chapter 3 & 4 that fibroblasts and osteoblasts, part of the bone
stroma, are altered and are involved in cancer metastasis and patient symptoms.
Bone osteoclasts & osteoblasts

One of the most commonly observed metastatic sites is the bone. Bone is composed of
specialized stromal cells, including osteoblasts and osteoclasts.

Osteoblasts, derived from

mesenchymal stem cells, synthesize and mineralize bone to enable remodeling. Their
counterparts are osteoclasts which are derived from hematopoietic stem cells. Osteoclasts can
break down and resorb bone to maintain normal bone remodeling. Both cell types are implicated
in metastasis. It has been shown that osteoclasts contribute to the acidic bone microenvironment
in metastatic lesions, which upregulates ASIC expression resulting in hyperalgesia109. ASIC's are
acid-sensing ion channels which are activated in an acidic microenvironment110. In Chapter 3,
we observed that tumor cells produce lactate which can be consumed by osteoclasts, stimulating
their ability to resorb bone by enhancing type 1 collagen resorption111. Subsequently, we
identified acid-induced bone stroma, including CAF's, mesenchymal stem cell, and osteoblasts
can enhance nociceptor sensitivity and contribute to hyperalgesia. When treating at low pH,
these cells increase expression of both nociceptive and inflammatory mediators. Inhibiting
acidosis with V-ATPase inhibitors showed a reduction in cancer-induced bone pain

112

. One of

the components within the bone microenvironment thought to exacerbate113 this process are
matrix metalloproteinases (MMP’s). Expression and activity of some MMP’s, such as MMP9114,
MMP14115, and MMP3116 are increased in acidic pH environments.
All the cell types discussed above contribute to the heterogeneity of the tumor. More
heterogeneous tumors are challenging to treat as the sub-clones within the tumor could each
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respond differently to therapy. These cells can also contribute to the ability of cancer cells to
metastasize. In Chapter 7, we explore the effect of acidosis produced by proton exporters as a
driver of metastasis. Acidosis is often observed in the tumor microenvironment and has been
associated with metastasis.

Cancer metastasis
There is a great deal of heterogeneity within tumors, and yet it is only a small subset of
cells which can leave the primary tumor site. Even smaller still are the number of cells which
leave the primary tumor and can successfully colonize other organs. Often those characteristics
which provide a fitness advantage within the primary tumor may negatively impact the cells that
metastasize and therefore, cells in the primary tumor do not always match those found in
metastases. Metastasis is a heavily studied area of cancer research as metastasis causes the
highest number of cancer deaths.

Steps in the metastatic cascade
The steps of metastasis are numerous and are covered in detail in many recent reviews117119

, so here we will only discuss the steps briefly. Before metastasis, a primary tumor must form.

Step 1: Tumor formation induces both angiogenesis and lymphangiogenesis through secretion of
angiogenic factors by the cancer cells and also by other cell types found within the tumor, for
example, tumor-associated macrophages and cancer-associated fibroblasts120. As the tumor
grows, often the vasculature becomes leaky as there is an imbalance between pro and antiangiogenic factors. Cell types needed for functional blood vessel formation, such as pericytes in
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tumors are often too few to sustain functionality. Pericytes wrap around the endothelial cells of
blood vessels preventing leakage of blood and thus maintain functionality.
Step 2: Tumor cells are then thought to go under an epithelial to mesenchymal transition(EMT),
although some argue that this is not a necessary step for metastasis121. Cells which undergo EMT
change from an epithelial round cell type with strong adhesion between cells to an elongated
spindle shape with adhesion loss. We characterize EMT cells by expression of different markers
and transcription factors, for example, SNAI1, TWIST, and Zeb and increased vimentin and Ncadherin expression. Phenotypically, EMT cells are more invasive and stem-like, which are both
linked to increased metastasis122. The heterogeneity within the tumor microenvironment can
facilitate EMT transition. For example, in breast cancer, an increased extracellular matrix has
been linked with EMT phenotype123-125
Other phenotypes within the heterogeneous tumor that upregulate EMT include hypoxia
and acidosis. Tumors often generate hypoxic environments due to their lack of functional blood
vessels leading to insufficient oxygen transport to the tumor. Hypoxia activates EMT through
stabilization of HIF-1 and increased transcription of SNAIL, an EMT marker126. Glycolysis,
aerobic or anaerobic, are both found in the tumor. Hypoxia induces a switch to glycolytic
metabolism as oxygen is necessary for oxidative phosphorylation (OXPHOS); therefore, to
maintain ATP generation, cells switch to glycolysis which does not require oxygen.
Alternatively, tumor cells often exhibit the Warburg effect127, a preferential reliance on aerobic
glycolysis over OXPHOS even when oxygen is present. Glycolysis increases EMT, for example,
through hexokinase two upregulation which is a hypoxia-inducible gene known to upregulate
SNAIl and SLUG EMT markers128.
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Step 3: Cells detach from the tumor, and studies have shown, metastasis can form from both
single cells and clumps of cells that break off from the tumor129.
Step 4: The cells degrade the extracellular matrix and basement membrane to enable
intravasation into surrounding blood and lymphatic vessels. Cancer cells will secrete, or induce
other cells, to secrete MMP's and proteases, which can degrade the ECM. These MMP's enhance
invasion into the surrounding tissues; cells will use their invadopodia to push the ECM
components like collagen and laminin aside to enable invasion into the blood or lymphatic
system.
Step 5: Tumors cells will squeeze in between cells to intravasate the blood vessels. Once the
cells are in circulation, they need to survive to enable colonization of distant sites. Survival
requires resisting immune cells, preventing anoikis, and withstanding the sheer mechanical stress
of moving through the vasculature130.
Step 6: Often, cells will arrest in the narrow capillary beds of organs. This narrowing of the
capillaries enables attachment of the tumor cells to the blood vessel wall through adhesion and
receptor expression. The tumor cells also secrete factors to increase expression of tight and
adherens junctions to facilitate attachment to the vessel wall. Once cells are arrested, they
extravasate into the metastatic site.
Step 7: Organ Colonization. Tumor cells migrate through the transendothelium or between two
endothelial cells, called paracellular migration, which involves rearranging cells and disrupting
cell:cell junction. Cells which extravasate into these sites then transition back to an epithelial
phenotype, known as mesenchymal to epithelial transition (MET)131. Some have proposed the
increased oxygen concentration in the metastatic site compared to the primary tumor site,
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activates the MET switch132. Once in the new site, cells can undergo cell cycle arrest and reduced
cell proliferation becoming more quiescent. Quiescent cells may go undetected by immune cells
or quiescence may be necessary until the microenvironmental conditions are optimal for cell
growth. Tumor cells can remain dormant for many years before metastatic lesions grow. Some
even argue that before cells leave the primary tumor, they prime the metastatic niche through
exosomes and cytokine release to prepare the site for cells to seed there, the "seed and soil “
hypothesis133.

Hallmarks of metastasis
The hallmarks of cancer have been well established, but the hallmarks of metastasis have
been less well established134. The lack of robust hallmarks contributes to the difficulty in treating
metastasis. There are a few traits that metastatic cells commonly exhibit. Metastatic cells are
more stem cell-like and are more plastic. They have higher motility, including both increased
invasion and migration. Metastatic cells can colonize other sites, and sometimes they exhibit
genetic heterogeneity from the primary tumor135. Metastatic cells can modulate the
microenvironment. These cells are often found at the leading, invasive edge of tumors where
they produce acid to degrade the ECM. Acid production by metastatic cells can suppress the
immune system. Cells which metastasize often secrete MMP’s and proteases to degrade the
ECM. Metastatic cells exhibit altered metabolism compared to normal cells. Some studies have
suggested reliance on fatty acid metabolism for colonization at the metastatic site136, and others
have suggested that different metastatic sites dictate which metabolism is utilized137.
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Time and location of metastasis
Tumor cells can metastasize exceptionally early on in primary tumor formation138,139, or
they can be

released throughout the lifetime of the primary tumor.

Except in extremely

aggressive cancers, cells that metastasize will colonize a distant organ and lie dormant until
conditions are right for growth. The presence of dormant cells means that even when primary
tumors appear to be treated successfully, patients will often recur with distant disease. In women
with breast cancer, up to 30% form distant metastases following surgery for treatment of their
primary tumor, at which time there was no evidence of disseminated disease140. Latency tends to
be cancer type dependent; lung cancer often exhibits metastasis a few months after diagnosis,
whereas breast can be many years141. We, therefore, need to understand how to treat patients
chronically to prevent "waking" cells from dormancy in those distant metastatic sites. There are
so few cells in those dormant metastatic sites that their growth cannot be monitored by imaging.
Understanding what influences metastasis could be used to prevent dormant cells from growing.
Although there are common sites that regularly present with metastasis, the type of
primary tumor seems to determine the preferred location of a metastatic lesion. The vascularity
or tumor microenvironment may influence the metastatic location. Another common site of
metastasis is the lymph node; tumor cells migrate from the primary tumor through the lymphatic
system and form regional lymph node metastasis142. In breast cancer biopsies, lymph nodes are
often resected concurrently to see if the cancer has spread. Breast cancer, for example, tends to
metastasize to liver, lung, brain, and bone, whereas ovarian cancer metastasizes to lung,
peritoneum, and liver143.
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Detecting metastasis
Metastasis causes around 90% of cancer deaths by preventing normal organ function.
Metastases are often therapeutically resistant as well which contributes to this statistic. One
problem is metastases are difficult to detect until they are very large or numerous. Metastasis is
generally detected by blood and urine tests that lack specificity and sensitivity, as well as
imaging, which has high specificity, but low sensitivity. Because of obvious advantages, many
studies are focusing on blood-based biomarkers (cell free DNA, miRNA, macrophages) to detect
tumor burden and metastasis. One blood biomarker in breast cancer is circulating tumor cells
(CTCs), the TREAT CTC trial identified that CTC positive patients were more likely to
relapse144. Additionally, in breast cancer, clinicians look for osteoblast-like cells in the primary
tumor and correlated higher osteoblast like cells with propensity for metastasizing. Another
marker used in breast cancer is ERBB2, which is as a marker for bone metastasis and
prognosis145 146.
Imaging is another technique used clinically to detect metastasis along with theranostic
and imaging agents to improve visualization and treatment. CT, PET, and MRI are some of the
imaging modalities commonly used to look for metastasis in patients. Often this occurs when
patients start experiencing worsening, or new symptoms or when blood tests detect an increase in
cancer or metastasis markers, such as PSA in prostate cancer or CA19-9 in other cancers.
Metastatic bone lesions are challenging to detect but are very common in multiple cancer types.
Bone lesions are often asymptomatic, but when they are severe, they can cause cancer-induced
bone pain. Bone scans are commonly performed with SPECT imaging of

99m

Tc-MDP, which is

readily incorporated into remodeling bone. However, its uptake is not specific for metastases.
MRI is suitable for detecting lesions in the bone marrow, and X-rays can detect osteolytic
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fractures which can be a sign of osteolytic lesions. CT is most useful for early detection as it can
pick up small lesions. Although detection is necessary, metastasis treatments are still limited.

Treating metastasis
Metastatic disease is late stage, with numerous lesions and thus limiting treatment to
systemic therapies. These therapies include monoclonal antibodies, bisphosphonates,
chemotherapy and targeted therapy. Unfortunately, metastatic disease can often be therapy
resistant, which results in palliative treatment of patients. Palliative pain medication includes
NSAID's, opioids, anti-depressants, and corticosteroids which are used to mitigate or minimize
pain and improve patient comfort. In some cases where few or large lesions are operable, surgery
or radiosurgery may be undertaken. Oligometastasis, where only a few metastatic tumors are
present, can be targeted using external beam radiation, such as proton beam therapy147. Many
people are looking into ways to target metastasis, but as mentioned metastasis can occur very
early on in primary tumor growth. We postulate that the acidic tumor microenvironment may
drive metastasis in cancer and could be targeted to reduce metastasis. We have tested this
hypothesis in Chapter 7.

Acidic microenvironment
Although cancer research has often focused on genetics, there has been a realization that
the tumor microenvironment also significantly impacts the tumor. The tumor microenvironment
includes temporal and spatial heterogeneity of hypoxia, altered nutrient concentrations, and
acidosis. Acidosis is commonly thought to be produced because of the favored metabolism of
many different types of cancer, aerobic glycolysis. Warburg was first to identify that cancer cells
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preferred glycolysis even when there is sufficient oxygen present for cells to use oxidative
metabolism. Glycolysis catabolizes glucose generating lactic acid, which is commonly thought to
be the primary producer of the acidic tumor microenvironment. Glycolysis is not the only
mechanism by which tumors generate an acidic pH. We will now discuss how acid can be
produced in the tumor, how acid affects cells in the tumor microenvironment and why this is
relevant clinically. Our studies on the influence of acidosis can be found in Chapters 3, 4, 5, 6
and 7.
Mechanism of acid production in the tumor
Aberrant vasculature

There are three main mechanisms of acid production within the tumor. These are aberrant
vasculature, metabolism, and expression of acidifying proteins. Fast tumor growth is associated
with aberrant vasculature148. Even though tumors often exhibit high concentrations of blood
vessels, due to their rushed formation, these vessels are usually inefficient. The vessels generated
are leaky, which prevents sufficient oxygen from getting to the tumor and consequently, prevents
sufficient waste removal. Many metabolic processes of the tumor generate waste, such as carbon
dioxide, lactic acid, and protons. Tumor cells are often unable to stimulate functioning blood
vessels because the surrounding microenvironmental conditions, such as hypoxia, can hinder
blood flow and oxygenation149. The improper generation of blood vessels results in
heterogeneous blood flow throughout the tumor and variable regions of acidity. Cancer cells
individually compete within the tumor for both nutrients, oxygen, and space. This competition
forces individual cells to produce angiogenic factors to promote blood vessel sprouting and
formation. Unfortunately, cancer cells often do not generate required factors needed for vessel
maturation and so only immature vessels are produced150. This lack of functional blood vessels
can benefit the tumor by creating an acidic environment which is immunosuppressive, but
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clinically it can hinder the penetrance of chemotherapeutics into the tumor and thus inhibit the
response to therapy151.
Metabolism of cancer

Since Warburg’s Seminal paper in 1926127, it has been known that many different tumor
types, even in the presence of oxygen, will preferentially use glycolysis. Warburg postulated that
cancer cells favored aerobic glycolysis because of impaired mitochondrial function. In some
specific cancer types, such as papillary renal cell cancer152 mutations in fumarate hydratase
force cells to use aerobic glycolysis, but this is the exception. Some postulate that cancer cells
are addicted to glucose to rapidly produce ATP, regardless of oxidative phosphorylation being
more efficient, others suggest it is to generate the proteins, lipid, and DNA153,154 to sustain the
high proliferation rate of cells. Alternatively, the generation of heterogeneous stressful
microenvironments by cancer cells requires rapid response through activation of membrane
transporters, which often require ATP, in order to maintain membrane gradients and cellular
homeostasis155. Finally, glycolytic metabolism results in the generation of the waste product
lactic acid. It is now appreciated that lactic acid and the low pH environment generated are very
beneficial for cancer cells, termed “acid-mediated invasion hypothesis”156 and we have shown
some further benefits of glycolytic metabolism and acid production in Chapters 3, 4, 5, 6 and 7
of this dissertation. Lactate produced can be used by other cell types157 as a primary fuel source
and often makes them pro-tumorigenic, and the low pH environment has been shown to induce
cancer-associated fibroblasts158 and hamper normal immune cell function97. Tumor cells have
been described as chronic wounds, and stressful conditions, such as hypoxia, acidosis, and
nutrient stress, are known to induce glycolytic metabolism159. We hypothesized that acid
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production by proton exporting proteins could induce glycolytic metabolism (See Chapter 7).
These proteins are often not considered due to concomitant occurrence of glycolysis, making it
hard to delineate the source of acidosis. We will now discuss which proton exporting proteins are
expressed by the tumor and how they play a role in acidifying the tumor microenvironment.
Proton producing and exporting proteins

We previously discussed that acid could be produced by glycolytic metabolism, whereby
cells will export lactic acid. Lactic acid is exported using monocarboxylate transporters, such as
MCT1 and 4, but these transporters can also import lactate into the cells in instances where cells
consume lactate for fuel. However, there are other proteins and transporters that cells express
independent of acid export by glycolysis, these include Sodium hydrogen exchangers (NHE1)160,
gastric hydrogen potassium ATPase or H+/K+ ATPase161,162 and indirectly bicarbonate
transporters. Bicarbonate transporters take up bicarbonate intracellularly, reducing the buffering
capacity of the extracellular media and increasing the intracellular pH. A study has shown that
tumors utilize connexins to prevent the build-up of waste in the hypoxic core of the tumor by
enabling transport of bicarbonate163.
One large family of proton producing proteins are the carbonic anhydrases. There are
carbonic anhydrases throughout the animal kingdom, but we know of 15 in humans, 3 are nonfunctional and are termed CARP's (CA related proteins), and 12 are functional and catalytically
active164. Most carbonic anhydrases are specific to certain tissues or are found in particular
regions of a cell. Carbonic anhydrases can be intracellular, transmembrane or mitochondrial.
These enzymes hydrate CO2 into H+ and HCO3- and are some of the fastest mammalian enzymes
known. Although CO2 can dissociate naturally, carbonic anhydrases increase this dramatically,
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preventing waste buildup and enabling easier removal of CO2 gas. Carbonic anhydrases have
conserved active sites which makes targeting individual members challenging. This chapter will
not go into detail about the inhibitors, but inhibitor reviews are referenced165-168. Although
carbonic anhydrases are essential for life, one isoform, in particular, seems to be providing a
significant fitness advantage to cancer, accounted for by its expression in numerous subtypes of
cancer with mostly poor prognosis. We will focus on this clinically relevant isoform, carbonic
anhydrase IX (CA-IX). We utilized CA-IX expression for our studies on acid production
independent of metabolic acid production and its subsequent impact on metabolism and
metastasis in Chapter 7.
Carbonic anhydrase IX
CA-IX is an exofacial, zinc metalloenzyme that catalyzes the reversible hydration of CO2
into H+ and HCO3-46. Intracellular pH changes from CO2 production decrease with CA-IX
knockdown169. CA-IX is typically expressed in the stomach and helps to maintain the pH
homeostasis and function of gastric cells; mice that are CA-IX deficient develop hyperplasia of
the stomach. CA-IX is different from other family members as it has a proteoglycan domain
which extends out and is thought to protect its active site from pH extremes. The maintenance of
activity in acidic conditions may be why it is so heavily favored by cancer. There are many
residues in the CA-IX active site and PG domain which can bind protons, potentially maintaining
catalytic function and preventing buildup of protons at the cell surface, which would impair
MCT transporter function.
One of the most novel papers to come out described how CA-IX can act as pH-stat. CAIX can not only maintain tumors at a more acidic extracellular pH but it can prevent tumors from
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over-acidifying which would still be detrimental to them170. Compared to CA-IX null tumors, the
pH of cell media was more acidic ~6.71 and could not go higher than pH 6.93. CA-IX is vital to
prevent excessive acid loading by accelerating cells ability to hydrate CO2. This fits with other
studies which have shown CA-IX activity is maximal at pH6.8171. Enzymatic activity increases
with decreasing pH, and others have stated that the favorable reaction below pH 6.5 is the
generation of CO2. CA-IX expression in cells generates a reverse pH gradient at the leading edge
which is necessary for remodeling and degradation of ECM to enable invasion.
CA-IX is often used as a hypoxia marker, as it is a HIF client protein. However, both
published and unpublished data have shown that CA-IX is not invariably associated with
hypoxia and hence, can be differentially classified as a marker of hypoxia or pseudohypoxia,
depending on its location

56

. Multiple mechanisms, most prominently HIF-1A, can up-regulate

CA-IX. HIF-1a can also be stabilized in the absence of hypoxia, such as in conditions of αKG
depletion described above. CA-IX is observed in both the hypoxic periluminal region as well as
the non-hypoxic basement membrane-adjacent regions of DCIS, which are thus pseudohypoxic
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. CA-IX can be up-regulated by PI3K and MAPK pathways, irrespective of hypoxia status 47.

Studies in ovarian cancer, where PI3K is often amplified, showed CA-IX overexpression in
endometroid and mucinous ovarian cancer subtypes. This increased CA-IX expression was
associated with decreased overall survival

47

. ERK specifically is involved in CA-IX promoter

activation and induction of transcription at the hypoxia response element (HRE) and
pathogenesis-related (PR1) gene promoter regions 172.
CA-IX has additionally been shown to be regulated by microrchidia-2 (MORC-2) by
decreasing acetylation of histone H3 at the CA-IX promoter which, overall, decreases mRNA
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and protein expression. Therefore, any mutations in MORC-2 have the potential to up-regulate
CA-IX expression 173. Within medullary thyroid cancer, Ret proto-oncogene (RET) is frequently
up-regulated or amplified, and RET is linked to HIF-1a activation and downstream increased
CA-IX expression. Moreover, c-Src proto-oncogene(Src) has been linked to the regulation of
CA-IX 174; both Src and CA-IX have both been associated with a more metastatic phenotype 175.
Finally, CA-IX is known to be up-regulated when cells are exposed to acidic conditions in
glioblastoma
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. Thus, at the tumor edge where cells are glycolytic and producing acid, the

decreased pH could result in a phenotypic switch inducing CA-IX expression.
Importantly, CA-IX is associated with more aggressive and invasive phenotypes. Studies
have linked CA-IX to migration at the leading edge of invading tumors, and a decreased pHe can
influence the focal contacts of the tumor, increasing invasiveness
proliferation is reduced leading to decreased tumor growth
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. When CA-IX is inhibited

. CA-IX is indicative of a pioneer

phenotype. One of the reasons our group believes that CA-IX is a relevant target is due to studies
using buffer therapy to control and inhibit tumor growth. For example, a study in transgenic
prostate cancer (TRAMP) mice showed that bicarbonate containing water, systemic “buffer
therapy”, could neutralize tumor acidity and inhibit both tumor growth and metastasis, with the
forethought being that CA-IX is a specifically targeted drug that could potentially have the same
effect as buffer therapy

178

. Clinical trials with sodium bicarbonate buffer therapy have been

unsuccessful due to poor patient compliance; targeted therapy is likely to have more success.
Multiple CA-IX targeting compounds have been produced with promising results51,179-186.
CA-IX is often up-regulated and a negative prognostic factor in a number of cancers;
including ovarian, pancreatic, medullary thyroid, breast, lung, glioblastoma, and multiple other
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cancer types

46-54

. In pancreatic cancer, shRNA targeted towards CA-IX blocks tumor

proliferation and initiation, making CA-IX a desirable clinical target, not only in pancreatic but
the aforementioned cancer types as well 48. Recently CA-IX, through modeling and histological
analysis, has been observed at the edge of tumors, adding to the pseudohypoxic phenotype. CAIX expression can generate and maintain an acidified tumor microenvironment in concert with
GLUT-1 overexpression 45. Not only does CA-IX stimulate extracellular acid production, but it
has been suggested that the bicarbonate ions produced can be shuttled back into the cell to
neutralize the intracellular pH 55. A role for CA-IX in protein folding has been seen, similar to
the function of heat shock proteins which help to fold and traffic proteins, and it's postulated that
CA-IX can interact with immune cells such as DC's to prevent cross-presentation187.
An interesting study by Ledaki et al. 2015188 lends itself towards the pseudohypoxic
phenotype as they found that hypoxia promotes epigenetic regulation of CA-IX, resulting in the
formation of both inducible and non-inducible expressing CA-IX populations. This noninducible, constitutive form is linked to the pseudohypoxic phenotype, likely brought on by
intermittent hypoxia exposure, as we have observed previously 39 . Cells with constitutive CA-IX
exhibited stem-cell like markers with an increased self-renewal capacity and may be related to
increased survival at the tumor edge more readily than the inducible CA-IX expressing
populations 188.
Interestingly, we argue that CA-IX at the tumor edge promotes a more aggressive
phenotype and that the resulting acidosis can affect neighboring stromal populations and repel an
immune attack.

Expression of CA-IX is associated with G-CSF mobilization through up-

regulation of the NF-kappa B pathway and results in mobilization of myeloid-derived suppressor
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cells to metastatic lung niches, priming them for tumor formation

52

. Interestingly, CA-IX

expression is higher in metastatic tumors compared to primary and this may be associated with
CA-IX priming metastatic sites and exhibiting a more invasive, aggressive phenotype compared
to the core of the tumor

189

. A recent meta-analysis has shown that high CA-IX expression over

multiple cancer types resulted in worse treatment outcome, worse overall survival, decreased
disease-free survival, decreased metastasis and progression-free survival, and an increase in the
likelihood of a locoregional occurrence

190

. One potential use for CA-IX clinically is in blood

tests of patients as the ectodomain can be shed from the tumor and measured in the serum or
plasma of patients to help with their cancer diagnosis. The domain is shed when apoptosis occurs
so can be used as a marker of chemotherapy efficacy. This occurred specifically through
disintegrin and adam17, a matrix metalloproteinase interaction, which caused cleavage and
shedding191.

Effect of acidosis on the tumor
Tumor growth causes both temporal and spatial heterogeneity of tumor pH192, often
resulting in acidic stress being placed onto the tumor. Acidic microenvironments may select for
subpopulations of cells within the tumor which are pro-metastatic. This acidic microenvironment
can generate an imbalance between the cellular pHi and pHe, whereby pHe is acidic, and pHi is
more neutral, and this supports many of the early events necessary for metastasis193. There are
repercussions, benefits, and trade-offs associated with having an acidic microenvironment
surrounding the tumor. An acidic microenvironment affects the tumor cells themselves, the
immune system and the stroma, including fibroblasts.
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Cancer cells

The acidic tumor microenvironment appears to provide many benefits to cancer. Acidosis
has been associated with increased metastasis, and utilizing buffer therapy, which reduces
acidosis, subsequently reduces metastasis194,195. In vivo, using dorsal window chamber imaging,
Estrella et al. showed that areas in the tumor with the most acidic pH correlated with the highest
levels of invasion196. Increased tumor invasion correlates well with increased metastasis197.
Cancer cells can withstand this stressful microenvironment, unlike normal cells. Normal cells,
when exposed to chronic acidity often undergo apoptosis or necrosis. Acidic pH disrupts the
normal homeostasis of acid-base flux across the membrane in normal cells156. To counteract
this, cancer cells up-regulate proteins to maintain membrane homeostasis including CA-IX,
NHE’s and NBC’s. Spatial acidosis is important for enhancing migration, NHE1, a sodium
hydrogen exchanger, enhances migration through proton extrusion at the leading edge of
tumors198.
Stroma

The stroma is composed of cells such as fibroblasts and immune cells as well
encompassing the ECM. The ECM is vital for structural and biochemical support for the tumor
through the generation of the 3D network of extracellular molecules199. Low pH can negatively
impact the ECM, to favor tumor growth, invasion, and metastasis. Acidosis can enhance the
enzymatic activity of digestive enzymes within the ECM, such as MMP's and cathepsins200,201.
MMP's help to degrade the ECM to maintain normal tissue turnover and growth. Cathepsins are
proteases which appear to be more active in acidic environments. Acidic environments change
the protonation state of proteins which affects charge distribution, altering the tertiary structure
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and subsequent function of the protein. One component of the ECM is actin filaments and actinbinding proteins, such as cofilin, are essential for ensuring stability but are pH-dependent202.
Fibroblasts

In normal fibroblasts, their ability to migrate is dependent on pHi

203

. A higher pHi

resulted in enhanced migration through increased focal adhesion turnover. Acidic pH from
cancer cells has been shown to induce cancer associated fibroblasts by enhancing OCT-4
expression which is a marker of de-differentiation105.
T cells

T cells can be anti-tumorigenic but the acidosis in the tumor microenvironment inhibits their
effector function (Chapter 6).

Influence of acid on metabolism
Acidic microenvironments influence cellular metabolism. As acid is considered a
stressor, cells try to maintain energy reserves for protection. One suggested way of doing this is
through intracellular lipid droplet formation, which is postulated to occur, so there is an energy
reserve for cells to catabolize if needed quickly. Acid adapted cells show increased uptake in the
free fatty acid palmitate to fuel mitochondrial metabolism204. Acidic environments, such as those
generated in hypoxic conditions, enhance lipid droplet formation in cells. In a lung cancer model,
cells with increased lipid droplets have a higher metastatic potential, and this was similarly
observed in a prostate cancer model205. When the esterification of cholesterol was reduced in the
prostate cancer model, metastasis was reduced. Acidosis is thought to indirectly activate the
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sterol regulatory element binding proteins (SREBP) pathway, which is responsible for
controlling lipid metabolism, including cholesterol biosynthesis. Conversely, in a triple-negative
breast cancer model increased intracellular lipid droplets decreased metastasis in vivo, and lung
metastasis from this model had lower lipid droplet number when compared with the primary
tumor

206

. In acid adapted cells, it was found that the histone acetylation pattern of HIF

responsive genes was altered207. Hypoxic environments can concurrently be acidic, which may
be why the HIF genes are affected. These changes culminated in the cells favoring glutamine as
a fuel source. Our studies in Chapter 7 probed the impact of acidosis on glycolysis.

Role of acid in metastasis
An acidic pHe and disrupted pHe/pHi dynamics have been linked with tumor malignancy
and metastasis. Acidic pH can alter the expression of angiogenic factors, lysosomal enzymes,
and ECM enzymes. In a melanoma study, cells in pH6.8 media had increased invasive and
migratory potential208. One protein involved in the pHi/pHe homeostasis is sodium hydrogen
exchanger (NHE1). NHE1 can acidify the microenvironment and is pH sensitive. In acidic pH,
NHE1 re-distributes to the leading edge of the cell in pseudopodia to help enable invasion,
partially through stimulation of protease secretion209. This re-distribution to the invasive edge is
similarly observed in CA-IX expression in tumors45,115.
Tumors disrupt the normal tissue vasculature and induce leaky, non-functional blood
vessels which are associated with increased tumor growth, invasion, metastasis, and worse
prognosis. The up-regulation of many angiogenic factors occurs in acidic pH210. In melanoma
studies, acidic pH increased pro-angiogenic factors VEGF and IL-8 resulting in increased
metastasis200. Acidic pH increased VEGF promoter activity resulting in increased VEGF
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expression in glioma cell lines211. In ovarian cancer, acidic pH increased IL-8 expression and
enhanced collagenase secretion, which is linked to invasion212. Platelet-derived growth factor
(PDGF), is associated with vascular remodeling and vessel formation and in low pH, PDGF
expression is increased in breast cancer cells MDA MB 231213.
Tumors which exhibit low pH tend to be more invasive, and this is partly due to the
effects on the ECM. In cancer, the cells disrupt adherens junctions to facilitate their motility and
invasion required for metastasis. Acidic pH induces disassembly of adherens junctions in a liver
cancer cell line, through inhibiting E-Cadherin associations with other proteins214. As mentioned
previously, protonation state of proteins can affect their tertiary structure and thus their activity
and ability to bind to other proteins. Acidic pH activates proteases215 and MMP’s, both involved
in ECM maintenance, to the benefit of the tumor. In a murine melanoma study, acidic pH
increased MMP-9 expression216. Lysosomal enzymes can be secreted by tumors to facilitate
basement membrane degradation and subsequent metastasis. Acidic pH increases the activity of
heparanase217, a lysosomal enzyme, which could enhance basement membrane degradation in
tumors.
Any extreme of pH seems to favor cancer over normal tissue. A study in an ER silenced
breast cancer cell line showed alkaline pH, pH8.3, also increased metastasis218. However, such
alkaline pH is not seen clinically, whereas acidosis is commonly observed in tumors making it
more relevant to study. It does highlight that when trying to treat acidosis, as we will go on to
discuss, we will need to be careful of not tipping the pH too far in the opposite direction as it
may also be detrimental to the patient.
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Targeting acidosis
To target acidosis, we need to improve our imaging modalities to accurately map the pH
of patient tumors219. Current techniques for in vivo imaging include magnetic resonance
spectroscopy (MRS) utilizing NMR active nuclei such as

31

P, 1H, and

19

F. pH, using MRS, is

calculated using the difference in chemical shift of the pH-dependent resonance peak compared
to a pHi independent reference peak. However, these techniques are not commonly used in the
clinic for pH mapping. Acidosis is linked to chemoresistance as reverse pH gradients across the
membrane can hamper the uptake of chemotherapy drugs220. Measuring pHi and pHe is crucial
because pH can change the ionization state of chemotherapeutics, which can alter the kinetic
uptake into cells and potentially reduce their efficacy221. MRI chemical exchange saturation
transfer imaging (CEST)222 is being more commonly used to measure intratumoral pH, and
although it has limited sensitivity, it has excellent spatial resolution, important for pH mapping
of tumors and observing different habitats within the tumor.
Even though acidosis seems beneficial to a tumor, it is energetically unfavorable.
Maintaining homeostasis requires a lot of energy as many of the ion pumps and transporters are
ATP dependent. Cancer will upregulate NBCn1, a sodium bicarbonate co-transporter, which
results in overall net acid extrusion from the cell223. Targeting such transporters may enable
inhibition of increased pHi in cancer cells rendering them less aggressive. NHE's are sodium
hydrogen exchangers and together with NBC's help to maintain pHi of cells. In breast cancer
primary and metastatic tumors, compared to normal breast tissue, NBC transporter expression
was increased, resulting in increased pHi

224

. With so many variables seemingly negatively

impacted by acidosis, and many tumors exhibiting acidic pHe, it proves an attractive target.
Studies have also suggested acidosis, and other stressors such as low glucose and hypoxia, could
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negatively impact radiation-induced apoptosis. Treating patients prior to radiotherapy, with
inhibitors to alleviate these stressors, such as acidosis, may improve outcomes225. One potential
avenue is nano-theranostics which are specifically targeted to a low pH environment and would
only be released in areas such as an acidic tumor226.
Directly targeting acidosis is challenging, studies are looking at targeting proton pumps,
but these are expressed in normal cells. One of the simplest ways is utilizing oral buffer therapy
which does not change systemic pH but does increase intratumoral pH. However, although
tolerated in mouse models, in three clinical trials the amount required to be consumed by the
patients never reached the dose targets because patients did not like the taste and there were
some moderate, severe adverse events227. Other techniques to target acidosis include drugs which
can generate bicarbonate and buffer the pH such as L-DOS47228. L-DOS47 is targeted towards
the CEACAM6 antigen, expressed in many cancers. Although L-DOS47 could, in theory, be
targeted to any cancer antigen of choice. They use an antibody conjugated to jack bean urease,
and the urease can convert urea in the area into 2 NH4+ and 1 HCO3− which increases
intratumoral pH and has been used in an ongoing Phase 2 study in NSCLC

229

. Finally, other

disease types such as those with chronic kidney disease experience abnormally acidic pH,
metabolic acidosis, and have been treated with TRC101 which is a micron-sized buffer particle
given orally, Phase III trials are still recruiting, but this may be another avenue for treating
patients with cancer230.
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Figure 1: Seahorse analyzer glycolytic stress test

48

Chapter 2: Metabolic profiling of healthy and cancerous tissues in 2D and 3D
Note: This chapter has been previously published in the journal Nature Scientific Reports,
Russell et al. 2017 Nov 10, and has been reproduced in this manuscript under the Creative
Commons Attribution 4.0 International License. My contributions to this paper include method
design, performing and deciding the experimental plan, analysis and interpretation of data,
preparation of data for publication, preparation of figures and manuscript, and revision of the
manuscripts.
Introduction
From the time of Cori and Cori

231

, it has been understood that some cells generate

metabolic “waste”, sometimes at a distance, which is subsequently consumed by other cells.
Tissues commonly exhibit inter- and intra-organ metabolic co-operation. For example, during
periods of starvation: the liver produces ketone bodies to fuel the brain

232

; skeletal muscle

produces lactate which the liver converts into glucose 233; glia cells in the central nervous system
produce lactate, consumed by neurons234.
It has been recently appreciated that tumors have evolved metabolic cooperation wherein
fermentative cells consume glucose to produce lactate, and oxidative cells consume lactate for
respiration 235,236. Tumor survival is based on its ability to adapt to dynamic changes, such as, pH
237

, reactive oxygen species (ROS) 238, nutrient supplies 239 and hypoxia62, all of which can exert

evolutionary selective pressure. Adaptations to these factors generate phenotypic and genotypic
heterogeneity, which is a proximal cause of therapy resistance 240. Successful targeting of cancer
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is therefore a daunting task due to metabolic, genomic and physiological heterogeneity. We
contend that assessment of metabolic responses in complex tissues provides a drug testing
paradigm that accounts for such complexity and, perhaps, can improve the success rates in
screening of new drug candidates, especially emerging therapies targeted to metabolic disruption
241,242

.

2D monolayers fail to recapitulate the 3D interactions harbored within a tumor, including the
effect of cell: cell interaction 243, nutrient gradients and the role of microenvironmental stress in
3D, as opposed to 2D, models244.This may have bearing on the failure of agents to succeed in
vivo after showing promise in 2D monolayer culture. In recent years, the technology to produce
3D cell culture models has improved

245,246

, enabling semi high-throughput, reliable production

of 3D spheroids from multiple different cell types

247

. As a counterpoint to drug efficacy, off-

target toxicity is a major hurdle for the clinic and is a primary endpoint in phase I clinical trials.
Cardiac and nephro- toxicities are common limitations and are often not observed until
completion of rigorous toxicity testing or, in some cases, during expanded cohorts in phase II or
phase III clinical trials248.
In cancer, therapeutics commonly affect tumor and stroma cellular metabolism, either
directly or indirectly
metabolic plasticity

249
250

.The Warburg effect and “reverse Warburg effect”32 are examples of
that are observed frequently in cancer, enabling a constant fitness

advantage regardless of the environmental constraints. High throughput metabolic profiling
using, e.g. the Seahorse Bioscience extracellular flux (XF) analyzer has enabled observation of
differences between normal and cancerous cell lines, effects of microenvironmental stress and
the ability of drugs to alter the metabolic phenotypes of a 2D cell culture monolayer

251-253

.
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Further, cytotoxic perturbations in metabolism are often observed prior to cell death

189

and

hence, metabolic profiling can be a key data set in drug development. However, until now, there
has been no high-throughput, reliable method for studying metabolism of 3D culture or complex
microtissues in comparison to 2D monolayer cultures.
In this study, we developed a micro-chamber system designed to enable metabolic
profiling 3D spheroid cultures and microtissues from normal organs and tumors. These data
were compared to metabolic profiles obtained from 2D monolayers. Subsequently, this method
was able to be utilized in multiple cell lines, tumors and organ types in a moderately high
throughput manner and differential effects of chemotherapeutics on 2D 3D cell cultures and
microtissues were observed. This technique can be used to further basic science and
understanding of differences in 2D and 3D models and utilized as a key step for efficacy and
toxicity testing prior to in vivo studies or clinical trials.

Materials and methods
Spheroid production
HCT116 (colon cancer) or A549 (NSCLC) cells were cultured in DMEM F12 or
RPMI1640, respectively, supplemented with 5% FBS and 1% PenStrep. Cells were rinsed in
PBS once confluent and detached with 1ml of 0.05% trypsin and placed in a 37oC incubator until
detached. Once detached, 3mL of normal growth media was added and cells were centrifuged at
900rpm for 3mins in a 15mL falcon tube. Cell pellet was re-suspended in 5mL of complete
growth media and cells counted on an Invitrogen Countess following manufacturer’s protocol.
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Spheroids were formed in Perfecta3D Hanging Drop 96-well Plates (3D Biomatrix).
HCT116 cells were seeded at 5K in 40µL per handing drop in complete growth media and A549
cells at 5.5K in 40µL per hanging drop in complete growth media with 0.015% Phenol red free
Matrigel matrix (Corning) using a multi-channel pipette. Upper and lower troughs of the hanging
drop plate were filled with deionized water to reduce droplet evaporation. Plates were kept at
37oC until spheroid formation, HCT116 spheroids form in 5-7 days and A549 spheroids form in
8-10 days. During that time water was replenished in the troughs and media in the wells (10µL)
as required. Once spheroids formed the upper plate containing spheroids was placed over a 96
well ultra-low attachment round -bottomed plate containing 150µL of complete growth media in
each well. Plates were centrifuged up to 300rpm and allowed to stop with no brake. Plates
containing spheroids were then placed at 37oC for 2 days before any drug treatment or metabolic
analysis.

Microtissue production
Generation of microtissues was performed on both organs and tumors from mice. The
relative specimen was harvested from the mouse and placed directly in a falcon tube containing
ice cold KHB buffer (12 mM D-Glucose, 2 mM L-Glutamine, 1 mM Sodium Pyruvate, 2 mM
Sodium Citrate, 25mM PIPES, 25mM HEPES pH7.4) on ice. The specimen was then blotted dry
and attached using cyanoacrylate to the base plate of a Leica VT1200 semiautomatic VT1200
vibrating blade microtome equipped with a sapphire knife (Ted Pella Cat# 121-18). Once fixed
to the base plate, the specimen was covered in ice cold KHB buffer and ice packed into the
surrounding reservoir. Settings used to cut slices were Thickness – 500µm, Amplitude – 3mm,
Speed – 0.07mm/s. Slices were then placed into a petri dish on ice containing KHB buffer.
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Microtissues were then generated by punching out sections of each slice with a 1mm Hariss UniCore Punch and placing the resulting 1mm diameter disks directly into a Seahorse XFe96
Spheroid Microplate containing either Seahorse media or growth media, depending on the
experiment. Metabolic analysis and tests were then carried out using an Agilent Seahorse XFe96
Analyzer (Agilent Technologies).

Spheroid and microtissue imaging
Spheroids and microtissues were imaged using Cytation 3 Imaging Reader (Biotek®)
using Brightfield 4X and saved as “.tiff” files. These files were then imported into Definiens
Developer Software and pixel count within the spheroids quantified using a designed program
which detects spheroid border. Variance between spheroid sizes was not statistically significant
when untreated.

Metabolic profiling
Metabolic profiling of microtissues and spheroids was undertaken using a Seahorse
XFe96 Extracellular Flux Analyzer (Seahorse Bioscience) in XFe96 Spheroids Microplates.
Microtissues were placed directly into a microplate containing 160µL per well of media (8.3g/L
DMEM Powder and 31mM Na Chloride) supplemented with 12mM D-Glucose, 2mM LGlutamine and 1mM Na Pyruvate at pH 7.35. The plate was then placed in CO2 free incubator at
37oC

for

1

hour

prior

to

metabolic

analysis.

Spheroids were washed in complete growth media twice and then pipetted directly into XFe96
Spheroid Microplates containing 160uL of Seahorse XF Assay Medium supplemented with
6mM D-Glucose and 1mM L-Glutamine at pH 7.35 using the 8 well spheroid transfer system
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(Agilent Technologies) and a multi-channel pipette. Spheroids were then incubated in CO2 free
incubator for 1hr.
Spheroids and microtissues were centered into the micro-chamber inserts using a p200
pipette if not already naturally in the center of the well. Basal oxygen consumption rates (OCR)
and extracellular acidification rates/proton production rates (ECAR/PPR) were calculated using
2mins mix and 4mins measure cycles for up to 12 hours. Seahorse XF Cell Mito Stress Tests
were carried out using sequential injections of Oligomycin (1µM), FCCP (1µM), and Rotenone
plus Antimycin A (1µM), with 6 cycles for Oligomycin as penetration within the spheroid or
microtissue to allow an observed effect.

Toxicity studies
Mouse and heart microtissues were produced as described above and basal metabolic
measurements taken in Seahorse Extracellular Flux Analyzer prior to drug exposure for 1 hour.
Any microtissues not metabolically active were removed from the experiment before drug
treatment. Media within the flux plate was replaced with Seahorse XF Assay Medium
supplemented with 12mM D-Glucose, 2mM L-Glutamine and 1mM Na Pyruvate for kidney
microtissues or M-199 media supplemented with 5mM creatine, 2mM l-carnitine, 5mM taurine,
12mM glucose, 2mM glutamine and 1mM sodium pyruvate for the heart microtissues. Drugs
were added to media prior to 24hr incubation and post control basal metabolic measurements:
BDM

30mM,

Sorafenib

50µM,

Zoledronic

Acid

1mM,

Oligomycin

1µM

and

Rotenone/Antimycin A (1µM).Tissues were incubated in the corresponding media for 24 hours
at 370C and then washed three times in Seahorse media containing 12mM D-Glucose, 2mM LGlutamine and 1mM Na Pyruvate. Microtissues were then placed back in Seahorse Extracellular
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Flux machine for post-drug exposure basal metabolic measurements for 10 hours. Seahorse
Wave software, Microsoft Excel 2010, and GraphPad were used to analyze metabolic data
generated.

Microtissue pathology
Following metabolic analysis assay media was removed from the Spheroid Microplate
leaving microtissue or spheroid undisturbed. 200µL of fresh 10% formalin was added and left to
fix for 24 hours at room temperature. Formalin was then removed and 200µL of 70%
isopropanol added until processing. Prior to processing the specimen was transferred into a
1.5mL microcentrifuge tube. Specimen was then dehydrated in 70% ethanol 30 mins, 95%
ethanol 30 mins and 100% ethanol 30 mins three times. Clearing was done with Xylene for
30mins three times. Specimens were then embedded in paraffin wax after removal of xylene.
Paraffin wax was melted at 60°C, added to microcentrifuge tube and placed in a 60°C water bath
for 60 mins, repeated and then left in a water bath in the paraffin wax overnight. Once embedded
and cooled, the microcentrifuge tube was cut to access spheroid and transferred into a disposable
histology mold. Paraffin wax was then added to the mold attached to a histology cassette and
place at 4°C for 60 min. The embedded spheroid can then be sliced to generate slides for
histological analysis. Hematoxylin and Eosin staining was carried out on the embedded
spheroids and microtissues.
Data analysis
Unpaired T- Test with Welch’s correction was performed using GraphPad Prism (version
6.00 for Windows, GraphPad Software, and La Jolla, California, USA). p values of 0.05 were
deemed statistically significant. Values shown are mean ± SEM.
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Animal studies
All experiments on live vertebrates were carried out in accordance with the guidelines
and regulations set by University of South Florida (USF), Moffitt Cancer Center and the
Institutional Animal Care and Use Committee (IACUC). The experimental protocols used were
approved by USF and IACUC under protocol R IS00000736.

Results
Metabolic profiling of a 3D culture
To directly compare metabolic phenotype between 2D and 3D cultures, we developed a
tool allowing 3D profiling in the same technology used for 2D monolayer cultures- the Agilent
Seahorse XFe96 Flux Analyzer, in a 96-well plate format. The tooling design (Fig.1A) enables a
spheroid or microtissue to sit within an indent in a single well of the 96-well plates (Fig.1B),
preventing movement and allowing the production of a micro-chamber to measure both oxygen
consumption rate (OCR) and extracellular acidification rate (ECAR). This micro-chamber
formation254 mimics the conditions a monolayer undergoes when being metabolically
phenotyped.
We generated HCT116 spheroids using the hanging droplet method
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. Across a

population of HCT116 spheroids, there was a minimal dispersion in the oxygen consumption rate
(OCR) (Fig.1C). When we grouped the spheroids, we observed minimal variation, suggesting
that there was a low level of inter-spheroid metabolic heterogeneity (Fig.1D). Statistical analysis
determined that the coefficient of variance (CoV) was < 10% (Fig. 1G), which allows group
analysis and comparison to 2D monolayers.

This assay also showed the designed tooling
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(Fig.1A) was able to centralize the spheroid with minimal movement as can be seen by the
steady OCR/ECAR values (Fig.1C). Notably, movement of a spheroid within the tooling can
occur as the plunger goes up and down but is detectable by a transient increase or decrease in
OCR, e.g., Fig.1C at 100 and 110 minutes.
After verifying that the tooling was able to be utilized for metabolic profiling of the 3D
spheroid cultures, we performed an Agilent Seahorse XF Cell Mitochondrial Stress Test (MST)
to determine if there were differences metabolically between 2D and 3D cultures in both basal
metabolism and response to metabolic inhibitors.

The MST assay consists of sequential

additions of oligomycin to inhibit the ATP synthase
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, FCCP, an uncoupler that induces

maximal OCR, and a combination of Rotenone/Antimycin A to block the electron transport
chain revealing the extent of non-mitochondrial oxygen consumption. Figures 1E and F show a
direct comparison of mitochondrial respiration from multiple wells containing 2D (Fig. 1E) and
3D (Fig. 1F) cultures of HCT116 colon cancer cells. Notably, in both systems, the inter-sample
variability was low, as evidenced by the error bars (S.E.M.). In the 3D model, we observed
delayed effects upon addition of oligomycin, but not with FCCP or R/A. We initially attributed
this to the molecular weight of oligomycin (~791, logP=5.88) and an associated retarded
penetration into the core of the spheroid compared to a 2D monolayer. However, use of similar
ATP synthase inhibitor, N, N-dicyclohexylcarbodiimide (DCCD) with a lower molecular weight
and similar polarity (~206, logP=5.54) induced the same delayed inhibition of oxygen
consumption (data not shown); suggesting that penetration alone was not responsible for the
delayed effect. Therefore, reduced sensitivity to the ATP synthase may be an intrinsic
characteristic of the 3D culture. This particular difference in response to a common metabolic
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inhibitor leads us to believe that there would be observable differences in the metabolic profile of
2D and 3D cultures in response to different chemotherapeutics.

Metabolic profiling of tumor derived microtissues
We investigated the generation of microtissues from human cell line tumor xenografts in
a high-throughput manner similar to spheroids. First, we had to determine if it was possible to
produce microtissues from excised tumors in a reproducible manner. This procedure required
minimal damage occurring to the microtissue to enable it to be maintained alive ex vivo for a
period sufficient to carry out metabolic profiling.

Microtissues were generated from 0.5 mm

slices from MiaPaca2 tumors (Fig. 2A). In the case presented, three different slices were
generated and, from these, 1 mm diameter microtissues were obtained from these slices using a
Harris trochar punch (Fig. 2B). The sizes of these tissues were measured physically by mass and
computationally by imaging. Nine individual microtissues (generated from three different slices)
were weighed individually and showed no statistically significant differences in mass (Fig. 2E).
An alternative method to determine the size of the microtissue was quantifying the number of
pixels within the computationally identified border of the spheroid or microtissue (Figs. 2C and
D). This method produced a coefficient of variation of 7.5% (Fig. 2F).
Therefore, the two methods of measuring mass showed the microtissues could be
produced reliably with negligible size variation. MiaPaCa-2 microtissues were profiled for over
24hours before seeing a metabolic decline (Fig. S2A &B). On the other hand, Lewis lung
carcinoma (LL2) microtissues exhibited no metabolic decline up to 30 hours ex vivo (Fig.
S2C&D), suggesting genetic and phenotypic diversity can influence microtissue survival and
suggests there may also be disparities in response to a chemotherapeutic challenge.
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We examined the metabolic profile of microtissues generated from MiaPaca2 and HCT
116 tumors. Measuring both the basal OCR and glucose induced ECAR of each microtissue
demonstrated a large amount of heterogeneity between different microtissues captured from the
same tumors, despite similarities in microtissue and tumor size. Figures 2G and 2H show
representative heterogeneity of OCR and ECAR from 26 different microtissues from a single
MiaPaCa2 tumor. This heterogeneity is expected as there are multiple regions (habitats) within
tumors that contain different sub-populations of cells, including metabolically different cancer
cells and contributions from stromal fibroblasts, endothelial cells, smooth muscle cells, immune
cells and necrosis 257,258. Despite the heterogeneity apparent in Figures 2G and 2H, plotting the
OCR vs. ECAR for each microtissue (Fig. 2I) showed a positive correlation (R2= 0.642), which
suggests similar metabolic profiles across the tumor and that increased values corresponded to
increases in metabolically active tissue. Although there was a high correlation, there were some
apparent “outliers” exhibiting abnormally high or low OCR/ECAR ratios (Fig. 2I circles). The
cause and identity of these outliers have yet to be determined. Nonetheless, such variations
underscore the complexity of tissue architecture and why tumor targeting can be such a
challenge. Tumor heterogeneity increases with increasing tumor size and, to see if we also
observed this metabolically, we generated microtissues from different MiaPaCa-2 tumors of ca.
400mm3 and 2000mm3 in volume. Supplemental Figures 12A and 12B show the OCR for each
microtissue as a function of time and indicated a higher amount of dispersion in OCR and a
much lower metabolic output from the microtissues obtained from the larger, compared to the
smaller, tumors.

Such an observation would be consistent with increased volumes of necrosis

and avasculature within larger tumors, resulting in reduced metabolic output.
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To investigate whether metabolic output correlated with tumor architecture, we compared
metabolic profiles with histopathology from the same samples.

We chose six different

microtissues from the same MiaPaCa-2 tumor with a range of OCR and ECAR values. Figs. 3A
and 3B show representative values from 3 such microtissues. Following profiling, the tissues
were fixed, paraffin embedded, and the sections were stained with Hematoxylin and Eosin
(H&E), shown in Figures 3C-E, and for HCT116 microtissues shown in Supplemental Figures
S1 A-F.
Necrotic areas were automatically scored, as in Fig. 3F, as unstained areas and the
remaining stained areas, were quantified as percent viability of the microtissue. We correlated
percent viability values to the OCR and, as expected, those microtissues with a reduced OCR had
a reduced percent viability, for example, E06 (Fig. 3E, G). Conversely, microtissues with higher
OCR had an increased percent viability, for example, B03 (Fig. 3C, G). Based on these
observations, we believe that, not only can these microtissues be metabolically profiled but also
that the metabolic value can be related phenotypically and genotypically to specific microtissues,
formulating a more informed profile of metabolic heterogeneity and the habitats within each
tumor.

Chemotherapeutics on 2D vs. 3D cell culture models
In drug development, attrition rates increase when transitioning from in vitro to in vivo
models259. Hence, we studied whether we could observe any differences between 2D and 3D
metabolic phenotypes when exposed to the same chemotherapeutic agents. 5-Fluorouracil (5-FU)
260

, a standard chemotherapeutic, was chosen and its effect on metabolism was profiled over 96

hours in both 2D and 3D models at 2 and 20mM concentrations. In all cases, at both doses, 5-FU
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eventually resulted in complete metabolic inhibition, with disruption to metabolic phenotype
between monolayer and spheroid (Fig. S5).
Notably, 3D spheroids exhibited a lower basal level of PPR compared to the monolayer
(Fig. 4B), and 5-FU had a delayed effect on OCR in 3D culture compared to 2D monolayer
culture (Fig. 4A, Fig. S4A&B). The monolayer was much more oxidative than glycolytic at
earlier time-points (Fig. 4D), and this started to revert after the 48-hour time point, suggesting
2D becomes metabolically stressed and energy stifled resulting in a switch to glycolysis to try
and maintain energy production. Spheroids showed a more linear response to 5FU compared to
the monolayer (Fig S5G).5-FU disrupted the outer layer of the spheroids over time (Fig. S3A)
and reduced spheroid density seen by H & E staining (Fig. S3B&C), but the removal of 5-FU
did not revert the cellular edge disruption (data not shown).
Monolayer cultures all exhibited a spike of increased glycolytic activity at 48 hr. (Fig.
4B), which was reproducible, and we suspect due to the increased energy and macromolecular
synthesis requirements needed to survive chemotherapeutic exposure. In 3D culture, the PPR
declined monotonically throughout the entire exposure period. OCR decreased more rapidly in
the monolayer (Fig. 4A) as compared to the 3D spheroids under the same conditions in a parallel
experiment, and this decrease is mirrored in cell viability of the monolayer (Fig. 4E).
Notably, even at the end of the exposure period, spheroids remained metabolically viable
throughout the 96-hour time course, determined with metabolic profiling and Cell Titer Glo,
whereas the monolayers were dead by 96-hours, showing monolayers are more sensitive to 5FU
(Fig. S4C&D). Other chemotherapeutics (rapamycin (Fig. S6), foretanib (Fig. S7), cisplatin
(Fig. S10) and pemetrexed (Fig. S8, S9, S11)) were also tested and we observed variations in
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metabolism between the 2D and 3D models. Pemetrexed, in particular, has had disappointing
efficacy in clinical trials

261,262

. In our studies, pemetrexed was effective in perturbing A549

monolayer metabolic output but not that of spheroids (Fig. S8 A, C, D). We hypothesized that
this insensitivity might be due to penetration of the drug into the spheroid, as its hydrated mass is
ca. 1000 and its logP is ca. -1.5 263. To investigate spheroid penetration, we employed paclitaxel,
a microtubule-disrupting drug as an agent to disrupt cell: cell adhesions and theoretically
promote penetration. We incubated spheroids in the presence of cascade blue dextran (MW~10
000; logP < -3) in the presence or absence of paclitaxel to see if we could improve penetration
into the spheroid. Without paclitaxel, we observed no dextran in the spheroid (Fig. 4F), but in
the presence of paclitaxel, dextran could penetrate all the way to the core (Fig. 4G). This
observation suggested that penetration of hydrophilic kilo Dalton-sized agents into spheroids is
hampered and can be promoted by paclitaxel. However, when metabolically profiled, the use of
low concentration of paclitaxel to improve penetration, along with pemetrexed did not alter the
metabolic phenotype (Fig. S9). Collectively, this suggests there are additional mechanisms that
also play a role in altered drug efficacy 264 of 3D cultures, for example, upregulation of pumps to
export drugs such as Pgp, which is often exhibited in multicellular resistance, or downregulation
of transporters to prevent drug uptake 265.

Organ microtissue metabolic profiling
Finally, a major concern in drug development is toxicity to organs, such as cardio-
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or

nephron-toxicity267. If drug toxicity is too high in patients, it can cause drugs to fail in clinical
trials that have cost millions, if not billions, to get to that stage. Although this is something that is
supposed to be seen in in vivo models and Phase 1 trials, we feel there should be additional steps
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taken to try and circumvent this potential toxicity in organs. To examine toxicity ex vivo, we
generated organ microtissues in the same manner as tumor microtissues and profiled their
metabolism. Individual heart microtissues were generated from the left and right ventricle and
showed high variance in OCR (Fig. 5A), which may be due to differential cardiac myocyte
populations within the ventricles. Furthermore, it has been shown previously that calcium flux
can vary between adjacent cells in the heart268. Fig. 5B shows that the PPR of heart microtissues
is less varied than OCR. In contrast to heart microtissues, those derived from kidneys were
primarily from the cortex and exhibited a low amount of inter-tissue variability (Fig. 5C & D).
Fig. 5E shows that overall the kidney is more metabolically active than heart tissues ex vivo and
this may relate to the inability of the cardiac tissue to contract once excised as microtissues.
Overall, the ability to profile organs, as well as tumor microtissues, could ensure not only
efficacy but detection of toxic off-target effects. However, especially for heart tissues, for each
measurement to be meaningful, each tissue must serve as its pre-treatment control. Hence, we
took metabolic readings pre and post treatment with a drug.
To identify whether organ toxicity could be observed through changes in metabolic
profile, we investigated the effects of cardiotoxins (sorafenib, cyclophosphamide and 2,3Butane-dione monoxime (BDM)), nephrotoxins (zoledronic acid)
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and metabolic toxins

(oligomycin, 2-deoxyglucose(2-DG) or rotenone and antimycin A combined), on organ
microtissues. Heart and kidney microtissues were exposed to drugs for 24 hours, with pre- and
post-treatment metabolic measurements- a pre-treatment basal metabolic profile, followed by a
wash with media, and 24 hr. incubation in the presence of a drug, then a post-treatment profile.
Figures 6 A&B show that OCR and PPR are significantly reduced post-drug exposure with
sorafenib, suggesting cardiotoxicity. Sorafenib is known to induce apoptosis in myocytes,, and
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this can induce destruction of electron transport chain, resulting in a decrease in both glycolysis
and oxidative phosphorylation. Cyclophosphamide also has a significant effect on OCR, whereas
PPR appears unaffected. However, PPR appearing the same as the control may be glycolytic
burst before cell death. Heart microtissues treated with BDM, a known inhibitor of cardiac
muscle contraction, became metabolically inhibited (Fig. 6C&D). Kidney microtissues exhibited
reduced PPR and OCR in the presence of metabolic inhibitors oligomycin and
rotenone/antimycin a (Fig. 6E&F) but zoledronic acid, a known nephrotoxin, although trended
towards negatively effecting metabolism it was not significant. These data suggest drugs, which
specifically damage the organ tissue or mechanism of function, could show metabolic defects
through this type of assay before in vivo experiments or clinical trials. The increased knowledge
of toxicity at an early stage could lead to optimization or alteration of compounds to limit this
toxicity and further improve the likelihood of success in the clinic.

Discussion
Utilizing this novel method, we demonstrate the ability to metabolically profile and
observe subtle or substantial differences in the metabolic readout of 3D cell culture models,
tumor and organ microtissues, and metabolic perturbations upon exposure to various drugs.
Comparing the metabolic profile of 2D vs. 3D models, we observe differences in response to
mitochondrial stress test drugs suggesting we should consider 3D models as a gold standard
within research and pharmaceutical industries and may explain why some drugs fail in an in vivo
model.
The 3D microtissues exhibited a delayed response to oligomycin which did not appear to
be size mediated, as a substitution for a similar drug with a lower MW had the same delayed
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effect on OCR. We identify differences in metabolic phenotype when treating 2D and 3D
cultures with common chemotherapeutics, such as 5-FU. 2D models are more sensitive than 3D,
and often we observe the metabolic perturbation before viability decreases within these models.
We saw what appear to be protective rings of dead or dying cells around the spheroids,
while the core remains intact even after prolonged exposure to a drug. Although this could not be
rescued in vitro, it may give clues as to why, within in vivo models, drugs that have extremely
high effectiveness in monolayer could be failing in vivo, as residual surviving cells remain. By
profiling, we observe the densely packed nature of the spheroids is not the only protection used
upon drug exposure, as we saw no improvement in the effect of therapy when using a
microtubule-targeted drug that increased the penetrability of the spheroid. The different drug
response demonstrates there are differences in the metabolism between 2D and 3D cell models
and hence the effect of drugs on these. We attribute these differences to many reasons including
altered cell: cell contact
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, regional genotypic and phenotypic changes258 and diffusion

gradients.
The ability to profile complex tissues such as organs and tumors can be revolutionary in
delineating disease state, general metabolic health and the effect of pharmacological agents or
microenvironmental pressures. We, coupled with physiological understanding, observe
differences in microtissue metabolism and attribute this to cellular make-up. We have exhibited
greater variance within the heart microtissues and would anticipate that separation of kidney
cortex, and medulla microtissues would also have a more distinct metabolic phenotype. Greater
understanding enables our ability to comprehend metabolic crosstalk which is becoming
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increasingly apparent in biological research including cancer, for example, stromal fibroblasts
and tumor cells.
High-throughput metabolic analysis is more common practice and used to analyze many
different diseases such as Alzheimer’s 271, Friedrich’s Ataxia 272 and cancer 251. We showed with
the production of our tool that metabolic flux analysis instruments can be redesigned and
repurposed to metabolically profile 3D structures in a high-throughput manner with minimal
variance and difficulty.
The number of products available to enable the production of 3D spheroid models and the
utilization of these products has proven that it is a necessity, not an option, that we include 3D
models in our studies

245

. Mathematical modeling
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and in vitro studies
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have shown that a

3D model recapitulates the microenvironmental, regional, gradient and cellular interactions
better than a 2D model and much more akin to that observed in the tumor microenvironment,
albeit an avascular tumor.
This robust assay combines 3D morphology with metabolic profiling to give reproducible
and valuable information of cellular metabolic health, drug effects and organ metabolism and
toxicity. Weinberg introduced metabolism as a key hallmark of cancer 1, and yet the ability to
profile it in the lab tends to be limited to 2 dimensions. Therefore, metabolic profiling of
complex tissues can be utilized for numerous clinical and research aspects across multiple
disease types and as proven, with comparable normal tissue analysis. Understanding the
importance of 3D structure has been lost in the milieu of science but by regaining this
understanding metabolic profiling of complex tissues can be utilized for multiple different
aspects of research, medicine and multiple disease types.
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Figure 1: Metabolic profiling of 2D vs. 3D cell culture model. (1A) Schematic of the microtissue perfusion
insert placed in each well of a seahorse flux pack to enable localization of a spheroid during metabolic
profiling. (B) Representative image (4X magnification) of an HCT116 spheroid within a microtissue perfusion
insert. Average diameter 829.332 ± 27.13 µM. (C) OCR of HCT116 spheroids over time plotted individually
(n = 16). (D) Oxygen Consumption Rate (OCR) of the spheroids as a group, OCR is maintained over a period
of 140 mins. (E) Mitochondrial stress test in an HCT116 colorectal cancer 2D monolayer 12.5k cells per well,
undertaken using Seahorse XFe96 Extracellular Flux Analyzer. Oligomycin (1 uM), FCCP (1 uM) and
Rotenone/Antimycin A(1 uM) used to test mitochondrial metabolism. (F) Mitochondrial stress test in an
HCT116 colorectal cancer 3D spheroid model. G: Coefficient of variation <20% within the spheroid OCR
values observed. Error bars represent + -SEM.
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Figure 2: Generation of microtissues from human xenograft HCT116 tumors and Mia PaCa-2 tumors.
(A) Microtissue production image using a vibratome with a sapphire knife to generate tumor slices for
microtissue generation using a 1 mm unicore punch. (B) HCT116 tissue slice (0.5 uM thick) with microtissues
harvested using 1 mm Harris Uni-core punch. (C) HCT 116 Spheroid (D) Definiens software border detection
analysis of HCT 116 spheroid. (E) Average mass of microtissues (n = 3) from 3 tumor slices, no significant
difference. (F) Definiens total pixel count analysis of microtissue, n = 3 CV 7.5% SD ns. (G) Average OCR of
MIA PaCa-2 tumor derived microtissues (n = 26). (H) Corresponding ECAR of each microtissue from Fig. 3G.
(I) Scatter plot of OCR vs ECAR of each microtissue, a linear trend is observed but not significant.
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Figure 3: Microtissue viability correlates to metabolic phenotype. (A) Oxygen Consumption Rate (OCR)
of three individual HCT116 derived tumor microtissues. (B) ECAR of three individual HCT116 derived tumor
microtissues. (C–E) Hematoxylin and Eosin staining of tumor microtissue slices. (F) Digital Quantification of
necrotic regions. (G) Positive Correlation of percent viable tissue from H and E staining with metabolic
oxygen consumption rate, n = 6.
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Figure 4: Effects of 5FU on 3D spheroid metabolic phenotype versus 2D monolayer in HCT116
colorectal cancer cell line. (A) Basal OCR as a percent of control (untreated 2D or 3D) upon treatment with 2
or 20 mM 5-Fluorouracil in 2D or 3D cell culture model. (B) Basal ECAR as a percent of control (untreated
2D or 3D) upon treatment with 2 or 20 mM 5-Fluorouracil in 2D or 3D cell culture model. (C) Group Key for
Panel A, B,D,E. (D) OCR:PPR ratio of 2D or 3D cell model with 5FU treatment (2 or 20 mM). (E) Percentage
viability of cells over time in the 2D or 3D model upon exposure to 2 or 20 mM 5FU using Cell Titer Glo
assay. (F) A549 spheroid incubated with fluorescent dextran after washing. (G) A549 spheroid treated with
fluorescent dextran and 5nM paclitaxel (pseudo-color yellow).

71

Figure 5: Profiling of microtissues from organs. (A, B) OCR and PPR of mouse heart microtissues
generated using the same method for producing tumor microtissues, profiled over 60 minutes (n = 30). (C, D)
OCR and PPR of mouse kidney microtissues profiled over 60 minutes (n = 30). (E) Average OCR vs PPR of
heart and kidney microtissues after 60 minutes (n = 10 per group).
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Figure 6: Toxicity studies in mouse heart and kidney microtissues. (A) Pre and 24 hr post drug basal OCR
measurements of heart microtissues as % control n = 5, Stdev shown (Cyclophosphamide 200 uM, sorafenib
50 uM). (B) Pre- and 24 hr post drug basal PPR measurements of heart microtissues as % control n = 5, Stdev
shown. Cyclophosphamide 200 uM, sorafenib 50 uM (C) Pre and 24 hr post drug basal OCR measurements of
heart microtissues as % control n = 5, Stdev shown (2-DG 60 mM, BDM 30 mM). (D) Pre- and 24 hr post drug
basal PPR measurements of heart microtissues as % control n = 5, Stdev shown (2-DG 60 mM, BDM 30 mM).
(E) Pre and 24 hr post drug basal OCR measurements of heart microtissues as % control n = 5, Stdev shown.
Zoledronic acid 1 mM, Oligomycin 1 uM, Rot/Ant A 2 uM (F) Pre and 24 hr post drug basal PPR
measurements of heart microtissues as % control n = 5, Stdev shown (Zoledronic acid 1 mM, Oligomycin
1 uM, Rot/Ant A 2 uM).
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Supplemental Figure 1: A-F: Immunohistochemistry staining for Cleaved Caspase 3, Ki67 and
hematoxylin and eosin of 2 individual microtissues from HCT116 mouse xenograft tumors.
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Supplemental Figure 2: Longevity studies of microtissues. A: 0hr ex vivo basal OCR measurements of
MiaPaCa-2 microtissues. B: Post 24hr ex vivo incubation OCR rate of MiaPaCa-2 microtissues. C: Lewis lung
cancer (LL2) microtissues post 24hr ex vivo incubation, basal OCR. D: Lewis lung cancer (LL2) microtissues
post 24hr ex vivo incubation, basal PPR.
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Supplemental Figure 3: HCT116 spheroids with 5FU treatment. A: Brightfield images of HCT116
spheroids treated with 2mM 5-FU for 96 hours, taken every 24 hours showing disruption of outer layer of
cells. After removal of 5-FU treatment spheroids were unable to recover, cells disaggregated. N=6 per time
point. Representative images shown. B: H & E staining of HCT116 spheroids untreated. C: H & E staining of
HCT116 spheroids treated with 2mM 5Fu for 96hrs.
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Supplemental Figure 4: Effects of 5FU on 3D spheroid metabolic phenotype versus 2D monolayer in
HCT116 colorectal cancer cell line A: Mitochondrial stress test on HCT116 monolayer treated with
increasing 5FU concentrations, 0-30mM for 48hr. N=5 per group SD. B: Time course of 5FU treatment with
2mM or 20mM on HCT116 spheroids. Concentration decided from monolayer data. N=5 per group, SEM
shown. C: Cell titer-Glo Luminescent Cell Viability ATP assay of HCT116 monolayer over 96hrs with 2 or
20mM 5FU treatment. D: Cell titer-Glo Luminescent Cell Viability ATP assay of HCT116 spheroid over 96hrs
with 2 or 20mM 5FU treatment. N=5, SD shown.
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Supplemental Figure 5: HCT 116 monolayer and spheroid metabolic phenotype after 48hr 5FU
treatment. A: HCT116 monolayer ATP linked OCR with 5FU treatment. B: HCT116 spheroid ATP linked
OCR with 5FU treatment. ATP linked OCR determined from difference between basal OCR and decrease
upon oligomycin addition C: HCT116 monolayer mitochondrial spare respiratory capacity with 5FU treatment.
D: HCT116 spheroid mitochondrial spare respiratory capacity with 5FU treatment. E: Basal ECAR of HCT116
monolayer prior to stress test after 48 hrs 5FU treatment. F: Basal ECAR of HCT116 spheroid monolayer after
48 hrs 5FU treatment. N=5, SEM shown. ***- p<0.00. G: OCR: ECAR energy profile of HCT116 spheroid vs
monolayer of response to 5FU treatment.
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Supplemental Figure 6: Effects of rapamycin on 3D spheroid metabolic phenotype versus 2D monolayer
in HCT116 colorectal cancer cell line. A: Mitochondrial stress test on HCT116 monolayer treated with
increasing rapamycin concentrations, 0-5µM overnight. N=5 per group SD. B: Mitochondrial stress test on
HCT116 spheroids treated with 5µM or 0.3µM of rapamycin overnight. N=5 per group, SEM shown.
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E

Supplemental Figure 7: Effects of foretanib on 3D spheroid metabolic phenotype versus 2D monolayer
in A549 human lung adenocarcinoma epithelial cell line. A: Mitochondrial stress test on A549 monolayer
treated with 2uM or 20uM o foretanib over 96hrs. N=5 per group, SD shown. B: Mitochondrial stress test on
A549 spheroids treated with 2uM or 20uM of foretanib over 96hrs. N=5 per group, SD shown. C: Basal OCR
as % control (from measurement 6) at each time point with 2 or 20uM foretanib treatment, 2D vs 3D. D: Basal
PPR as % control (from measurement 6) at each time point with 2 or 20uM foretanib treatment, 2D vs 3D. E:
OCR: ECAR energy profile of A549 spheroid vs monolayer in response to 20uM foretanib treatment over
96hrs. SD shown.
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Supplemental Figure 8: Effects of pemetrexed on 3D spheroid metabolic phenotype versus 2D
monolayer in A549 human lung adenocarcinoma epithelial cell line. A: Mitochondrial stress test on A549
monolayer treated with 2uM or 20uM pemetrexed over 96hrs. N=5 per group, SD shown. B: Mitochondrial
stress test on A549 spheroids treated with 2uM or 20uM pemetrexed over 96hrs. N=5 per group, SD shown.
C: Basal OCR as % control (from measurement 6) at each time point with 2 or 20uM pemetrexed treatment,
2D vs 3D. D: Basal PPR as % control (from measurement 6) at each time point with 2 or 20uM pemetrexed
treatment, 2D vs 3D.
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Supplemental Figure 9: Effects of dual treatment with paclitaxel and pemetrexed on spheroid
metabolism. A: Mitochondrial stress test of HCT116 spheroids treated in combination with 5 or 25nM
paclitaxel and 20uM pemetrexed. B: Basal OCR, % control of monolayer and spheroid HCT116 with 5 or
25nM paclitaxel plus 20uM pemetrexed treatment for 48hr. C: Basal PPR, % control of monolayer and
spheroid HCT116 with 5 or 25nM paclitaxel plus 20uM pemetrexed treatment for 48hr.
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Supplemental Figure 10: Effects of cisplatin on 3D spheroid metabolic phenotype versus 2D monolayer
in A549 human lung adenocarcinoma epithelial cell line. A: Mitochondrial stress test on A549 monolayer
treated with 25uM or 50uM cisplatin over 96hrs. N=5 per group, SD shown. B: Mitochondrial stress test on
A549 spheroids treated with 25uM or 50uM cisplatin over 96hrs. N=5 per group, SD shown. C: Cell titer-Glo
Luminescent Cell Viability ATP assay of A549 monolayer over 96hrs with 25 or 50uM cisplatin treatment. B:
Cell titer-Glo Luminescent Cell Viability ATP assay of A549 spheroid over 96hrs with 25 or 50uM cisplatin
treatment. N=5, SD shown.E: Basal OCR as % control (from measurement 6) at each time point with 25 or
50uM cisplatin treatment, 2D vs 3D. F: Basal PPR as % control (from measurement 6) at each time point with
25 or 50uM cisplatin treatment, 2D vs 3D.

83

Supplemental Figure 11: Effects of cisplatin and pemetrexed on 3D spheroid metabolic phenotype
versus 2D monolayer in A549 human lung adenocarcinoma epithelial cell line. A: Mitochondrial stress test
on A549 monolayer treated with 25uM or 50uM cisplatin plus 20uM pemetrexed over 96hrs. N=5 per group,
SD shown. B: Mitochondrial stress test on A549 spheroids treated with 25uM or 50uM cisplatin plus 20uM
pemetrexed over 96hrs. N=5 per group, SD shown. C: Cell titer-Glo Luminescent Cell Viability ATP assay of
A549 monolayer over 96hrs with 25 or 50uM cisplatin treatment plus 20uM pemetrexed. D: Cell titer-Glo
Luminescent Cell Viability ATP assay of A549 spheroid over 96hrs with 25 or 50uM cisplatin treatment plus
20uM pemetrexed. N=5, SD shown. E: Basal OCR as % control (from measurement 6) at each time point with
25 or 50uM cisplatin treatment plus 20uM pemetrexed, 2D vs 3D. F: Basal PPR as % control (from
measurement 6) at each time point with 25 or 50uM cisplatin treatment plus 20uM pemetrexed, 2D vs 3D.
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Supplemental Figure 12: Metabolic heterogeneity of MiaPaCa-2 tumor microtissues. A: OCR of
microtissues generated from a 400mm3 tumor with Injection 1 (FCCP 1uM) and Injection 2
(Rotenone/Antimycin A 1uM) inhibitors. B: OCR of microtissues generated from a 2000mm3 tumor.
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Chapter 3: MDA-MB-231 breast cancer cells fuel osteoclast metabolism and activity: a new
rationale for the pathogenesis of osteolytic bone metastases
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Novelty and impact
This study explored the role of tumor-derived lactate in the pathogenesis of bone
metastases (BM). We report that osteoclasts uptake and oxidatively metabolize lactate produced
by glycolytic breast cancer cells to fuel bone resorption activity. Since lactate uptake by
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osteoclasts depends on MCT1, pharmacological MCT1 inhibition robustly impaired lactateinduced bone resorption. Lactate is thus at the core of breast cancer cell - osteoclast interplay
which implicates MCT1 as a promising target to treat osteolytic BM.

Introduction
Bone is one of the most common sites of solid tumor metastasis, especially for breast
carcinomas that cause osteolytic lesions in 80% of patients with stage IV metastatic disease.274
Osteolytic metastases are characterized by increased osteoclastic activity and bone destruction.
To efficiently resorb bone, cancer cells also activate bone cells that are physiologically engaged
in bone remodeling, the osteoclasts.275 Osteoclasts derive from hematopoietic precursors that
differentiate into multinucleated cells upon stimulation by receptor activator of NF-κB ligand
(RANKL) and macrophage colony-stimulating factor (M-CSF).276 Osteolytic bone metastases
(BM) are associated with significant morbidity, including hypercalcemia,277 intractable pain,
pathological fractures, and spinal cord and nerve root compression,278 ultimately resulting in
restricted mobility and a strongly reduced quality of life. Current therapies are mainly palliative
and are based on a multidisciplinary approach that includes analgesia, radio/chemotherapy,
surgery, hormonal therapy, opioids and bisphosphonates. To date, no specific treatment that
sufficiently and effectively target BM has been developed.
BM develop during the late stages of tumor progression as a result of a multistep process
that relies on overcoming multiple barriers to cancer cell dissemination. For a successful
metastasis to occur, cancer cells enter into blood and lymphatic vessels to reach preferred sites
that are characterized by specific local interactions with host cells.279 When cancer cells arrive in
bones, cell-cell interactions increase in complexity,280 and the hypoxic conditions of this
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environment, that are particularly favorable for tumor growth and invasion,281 possibly also play
a role. Cancer cells and host cells of bone microenvironment establish an active crosstalk that
promotes a vicious circle of tumor growth and bone resorption.282 Cancer cells secrete factors
that stimulate osteoclast-mediated bone resorption, which, in turn, promotes the release of
numerous factors from the bone matrix that prompt cancer cells to adopt a more aggressive
phenotype.283 Among these factors, parathyroid hormone-related peptide (PTHrP)284 binds to
receptors expressed on cells of the osteoblastic lineage that in turn release RANKL and M-CSF
and reduce the production of the RANK decoy receptor osteoprotegerin (OPG). RANKL binds
its RANK receptor on both osteoclast precursors and mature osteoclasts, promoting osteoclast
recruitment and formation as well as bone resorption activity. In addition, other cytokines in the
tumor microenvironment stimulate bone resorption, including tumor necrosis factor-a (TNFa),285 interleukin-6 (IL-6)286 and additional growth factors including insulin-like growth factor-2
(IGF-2)287 and transforming growth factor-β (TGF-b).288
Anti-RANKL strategies are effective at reducing tumor-induced osteoclast formation.289
However, inhibitors of RANK signaling, such as the anti-RANKL antibody denosumab, are only
partially effective and display several side effects.290 In addition to peptide/proteic factors,
specific metabolites are also produced by the metabolically altered cancer cells, and these
metabolites are relevant for the pathogenesis of BM. Several oncogenes and tumor suppressor
signaling pathways are key regulators of cancer metabolism and modulate the cellular response
to alterations of the extracellular microenvironment during tumor progression.291,292 For example,
intratumoral hypoxia causes cancer cells to rely on glycolysis for survival, anabolic growth and
proliferation.293 Notably, proliferating cancer cells often rely on glycolysis also irrespectively of
the presence of oxygen (Warburg effect).294 Aerobic glycolysis is a hallmark of advanced
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cancers,295 and is characterized by an increase in glucose uptake, lactate production, and proton
release in the tumor microenvironment.296 Lactate is not a mere waste product of glycolysis, but
rather a major player in tumor aggressiveness. Notably, elevated serum lactate in cancer patients
is associated with a poor prognosis.297 Lactate can indeed be captured by oxidative cancer cells,
as well as by cells of the tumor-associated stroma, including endothelial cells298,299 and tumorassociated mesenchymal stromal cells300 that oxidize it into pyruvate to feed the tricarboxylic
acid (TCA) cycle.301
We have recently demonstrated that osteoclast differentiation is mainly supported by
mitochondrial oxidative metabolism which operates in combination with glycolysis to support
peripheral cellular activities, including bone matrix degradation, and ensures cell survival during
the energy-consuming process of bone destruction.302
Here, we report that lactate produced by BM-prone glycolytic breast carcinoma cells
fuels the oxidative metabolism of osteoclasts, thereby promoting osteolysis. As models of breast
carcinoma cells with different metastatic potentials, we used human metastatic triple-negative
(estrogen receptor- [ER]), progesterone receptor- [PR-], human growth factor receptor 2- [Her2]) MDA-MB-231 cells that express high levels of monocarboxylate transporter 4 (MCT4),303 and
ER-positive304 non-invasive304 MCF7 cells.

Materials and methods
Cell culture
Human MDA-MB-231 and MCF-7 breast carcinoma cell lines (American Type Culture
Collection) were maintained in Iscove’s modified Dulbecco’s medium (IMDM, Gibco), plus 20
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U/mL penicillin, 100 mg/mL streptomycin, and 10% heat-inactivated FBS (complete IMDM),
and cultured at 37°C in a humidified 5% CO2 atmosphere. Conditioned medium (CM) was
collected from MDA-MB-231 cells cultured in DMEM (Sigma) with 25 mM glucose (Merck),
10% heat-inactivated characterized FBS (Celbio), plus 20 U/mL penicillin, 100 mg/mL
streptomycin (Euroclone) for 72 h, centrifuged and stored at −20°C until use.

Human osteoclast cultures
Primary cultures of osteoclasts were obtained from monocytic precursors isolated from
fresh buffy coats of 35 healthy volunteers (AVIS, Bologna, Italy; Saint-Luc University Clinics,
Brussels, Belgium), as previously described.302 Buffy coats obtained from AVIS were collected
after their expiration date (1 day after harvesting), and those from Saint-Luc University Clinics
immediately after harvesting. Protocols were approved by Institutional Review Boards. Briefly,
peripheral blood mononuclear cells (PBMC) were layered over Hystopaque (GE Healthcare) and
seeded (3,000,000 cells/cm2) in DMEM (Sigma) supplemented with 25 mM glucose (Merck),
10% heat-inactivated characterized FBS (Celbio), plus 20 U/mL penicillin and 100 mg/mL
streptomycin (Euroclone), and incubated at 37°C in a humidified 5% CO2 atmosphere. All
experiments were performed in pyruvate-, lactate-, and glutamine-free medium (complete
DMEM), unless stated otherwise.
After 2 h, medium was discarded and replaced with new pro-osteoclastogenic media with
a composition depending on the experimental conditions. To evaluate MCT expression and
osteoclast metabolism, complete DMEM with glucose (25 m), RANKL (50 ng/mL) and M-CSF
(10 ng/mL) (Peprotech) (pro-osteoclastogenic medium) was used. To evaluate osteoclastogenesis
and osteoclast activity in the presence of exogenous or tumor-derived lactate, medium contained
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2 mM glucose and either 10 mM of sodium lactate (Sigma) or 25% of CM from MDA-MB-231
cells. Where indicated, MCT1 inhibitor 7-(N-benzyl-N-methylamino)-2-oxo-2H-chromene-3carboxylic acid (7ACC2) was used at 1 μM concentration.305 7ACC2 were kindly provided by
Olivier Feron (Université Catholique de Louvain). To verify osteoclast differentiation occurring
after 5–7 days of culture, cells were analyzed for tartrate-resistant acid phosphatase (TRAP)
activity by cytochemistry (Acid phosphatase leukocyte assay, Sigma) and stained with Hoechst
33258 (Sigma). Only TRAP-positive cells with more than three nuclei were considered as
osteoclasts.

qRT-PCR
Total RNA was extracted using the NucleoSpin RNA II (Macherey-Nagel). On-column
DNase digestion was performed according to manufacturer’s instructions. When RNA was
isolated from cells under hypoxic conditions (1% O2), cells were first plated and incubated for 24
h in a standard incubator, then transferred to a hypoxic incubator (Invivo2-400; Ruskin
Technologies) and maintained at 1% O2 for an additional 24 h. Total RNA (1 μg) was reversetranscribed into cDNA using MuLV reverse transcriptase and RNase inhibitor (Applied
Biosystems) and random hexamers (Applied Biosystems). qRT-PCR was performed by using a
Light Cycler instrument and the universal probe library system (Roche Applied Science). Probes
and primers are listed in Table 1. PCR protocol was: 95°C for 10 min; 95°C for 10 s, 60°C for 30
s, and 72°C for 1 s for 45 cycles; 40°C for 30 s. Expression of genes of interest was normalized
using β-actin as a reference gene for MDA-MB-231 and MCF7 cell lines, and TATA-binding
protein (TBP) for osteoclasts and precursor cells.306 Relative expression of candidate genes was
calculated using the ΔΔCt model.307
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SDS-PAGE and immunoblotting
PBMC were seeded on cell culture dishes and maintained in pro-osteoclastogenic media
up to 14 days. MDA-MB-231 and MCF7 cells were seeded in 100-mm culture dishes in
complete IMDM for 24 h. Cells were harvested in RIPA buffer [50 mM Tris pH 7.6, 150 mM
NaCl, 5% Triton X-100, 0.25% sodium deoxycholate, 1 mM EGTA pH 8, 1 mM NaF] (Sigma)
containing protease and phosphatase inhibitor cocktails (Roche). Protein lysates were quantified
by using the BCA protein assay (Pierce), subjected to reducing SDS-PAGE on polyacrylamide
gels and transferred onto nitrocellulose membranes (Thermo Fisher Scientific). Membranes were
stained with Ponceau red (Sigma) to confirm equal protein loading. Blots were probed with antiMCT1 (Chemicon, AB3538P), MCT4 (Santa Cruz, sc-50329), TBP (Santa Cruz, sc-204), and βactin (Cell Signaling, 4970s) primary antibodies, followed by horseradish peroxidase-conjugated
secondary anti-mouse and anti-rabbit antibodies (GE Healthcare), as appropriate. To detect
MCT1 and MCT4 on the same blot, nitrocellulose membranes were stripped with Restore
Western blot stripping buffer (Thermo Fisher Scientiﬁc) and reprobed. Proteins were visualized
with a chemiluminescence substrate (ECL Western blotting detection reagent, GE Healthcare).
The signal of each band was quantiﬁed by the VisionWorksLS analysis software (Biospectrum,
UVP) for densitometric evaluation. Results are representative of four biological replicates.

Immunofluorescence analysis
Experiments using human tumor biopsies were approved by the local Ethical Committee
(approval No 0037602 of 14 November 2013) and performed with the informed consent of the
patient. Human BM samples were obtained during the surgical excision of the tumor mass of 4
patients with breast carcinoma, and immediately frozen. Biopsies were embedded in Optimal
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Cutting Temperature compound (Miles Laboratories), and frozen on dry ice before sectioning.
Immunofluorescence assays were performed on the tumor sections and on PBMCs cultured on
glass coverslips with pro-osteoclastogenic medium until osteoclasts formed. Sections with a
thickness of 7 μm were mounted on glass slides covered with 2% saline solution in acetone, and
stored at -20°C. Osteoclasts were fixed in 4% paraformaldehyde. Defrosted sections and
osteoclasts were permeabilized with 0.2% Triton X-100, blocked with 1% BSA, and then
incubated with primary rabbit anti-MCT4 (sc-50329, Santa Cruz), anti-MCT1 (HPA003324,
Sigma), and mouse anti-cytokeratin (M0821, Dako) antibodies. As secondary antibodies, we
used anti-rabbit Alexa Fluor 488 nm (A1108, Life Technologies), anti-rabbit Alexa Fluor 568
nm (A11011, Life Technologies) and anti-mouse Alexa Fluor 488 (A10680, Life Technologies).
Nuclei were stained with Hoechst 33258 (Sigma). For the staining of polymeric actin (F-actin),
we used phalloidin-TRITC (Sigma). Images were acquired by using confocal microscopy Nikon
TI-E.

Oxygen consumption and extracellular acidification
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were
determined using a Seahorse XF96 extracellular flux analyzer and a Mito Stress kit (Seahorse
Biosciences). PBMC were seeded on XF96 microplates in pro-osteoclastogenic medium until
osteoclasts formed. Then, the medium was replaced by fresh complete medium with/without 10
mM of sodium lactate. Cells were analyzed 7 days later. MDA-MB-231 and MCF-7 cells were
seeded on XF96 microplates in complete IMDM for 24 h. Culture media were replaced by base
medium (non-buffered DMEM supplemented with 25 mM glucose) 1 h before analysis.
Selective inhibitors were injected during measurements: oligomycin (2 μM), carbonyl cyanide 494

trifluoromethoxy phenylhydrazone (FCCP; 0.9 μM), rotenone (1 μM), antimycin A (1 μM) and
2-deoxy-glucose (100 mM). Mitochondrial OCR (mtOCR) was calculated by subtracting nonmitochondrial OCR (the level obtained after injection of rotenone and antimycin A) from total
OCR levels. ATP coupling was calculated by subtracting total OCR from oligomycin readings.
Data were normalized for total protein content using the Bradford protein assay (Bio-Rad).

NADH/NAD+ analysis
NAD+ and NADH levels were measured using a NAD+/NADH quantitation kit (Sigma).
Briefly, 2 × 105 MDA-MB-231 or MCF7 cells were lysed according to manufacturer's
instructions. NAD+ levels were measured by subtracting NADH concentration from total NAD
concentration. Data were normalized to total protein content determined using the BCA protein
assay.

Lactate measurements
For enzymatic lactate determination, 4.5 × 104 cells/cm2 were plated into 12-well plates in
complete IMDM. After 24 h, medium was replced by IMDM containing 2% FBS, which was
harvested 48 h later to measure the L-lactate concentration using a EnzyChrom L-lactate assay
kit (BioAssay Systems) according to manufacturer's instructions. Normalization was performed
to total protein content measured by BCA protein assay.
Lactate and glucose consumption were also measured enzymatically by analyzing
deproteinized cell culture supernatants. PBMCs were seeded on 96-well plates in proosteoclastogenic medium and cultured until multinucleated TRAP+ cells were formed. Media
was replaced by fresh complete medium with or without sodium lactate (10 mM). Supernatant
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fractions were collected 7 days later. Metabolite concentrations were quantified using specific
enzymatic assays on CMA600 analyzer (CMA Microdialysis AB). Glucose consumption and
lactate production were normalized to total protein content measured by a Bradford protein
assay.
For

14

C-lactate uptake assays, PBMC were seeded on 24-well plates and maintained in

pro-osteoclastogenic

medium

until

osteoclast

differentiation

was

confirmed.

When

multinucleated TRAP+ cells were formed, culture medium was replaced by pro-osteoclastogenic
medium containing sodium lactate (10 mM) and cells were incubated overnight for metabolic
adaptation. Cells were then rinsed with a modified Krebs solution containing sodium lactate (10
mM) without glucose, and exposed to increasing concentrations of 14C-L-Lactate (1, 2, 4, 8, and
16 μM) or control Krebs solution at 37°C for 12 min. Cells were rinsed with ice-cold D-lactatecontaining Krebs solution and lysed with 0.1 M NaOH. Sample aliquots were then incubated in
liquid scintillation solution (Microscint 40) into 96-well plates (Optiplate). After 1 h of stirring,
radioactivity was measured on a PerkinElmer Topcount. Cpm values are normalized for protein
content measured with a Bradford protein assay.

Mitochondrial potential measurement
The mitochondrial potential of mature osteoclasts was measured using the cationic dye
5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimi-dazolylcarbocyanine

iodide

(JC-1),

which

exhibits potential-dependent accumulation in mitochondria as revealed by a fluorescence
emission shift from green (540 nm) to red (590 nm). PBMCs were cultured in proosteoclastogenic medium until osteoclasts formed. Then, medium was replaced by fresh,
complete medium with or without sodium lactate (10 mM). Cells were analyzed 7 days later.
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Cells were incubated with JC-1 (10 μg/ml) for 10 min at 37°C, then washed with PB, and
analyzed in complete cell culture medium. Analysis was performed using a TiE spectral confocal
laser microscope (A1R, Nikon).

Bone resorption assay
The bone resorption activity of osteoclasts was measured by using the OsteoLyse kit
(Lonza). PBMC were cultured in pro-osteoclastogenic medium with or without sodium lactate
(10 mM) and with or without MCT1 inhibitor 7ACC2 (1 μM). The effects of these compounds
on the activity of MDA-MB-231 cell supernatants on osteoclast behavior were evaluated by
culturing PBMC in complete DMEM containing glucose (2 mM) and 25% of CM from MDAMB-231 cells, with or without 7ACC2 (1 μM).305 Cells were cultured until osteoclasts formed.
Then, media were renewed for 72 h. Supernatant fractions were collected after 10 days, and the
amount of Type I collagen was quantified by the emission of Europium-labelled collagen
fragments via time-resolved fluorescence (Infinite 200 PRO, Tecan).

Statistical analysis
Statistical analyses were performed using GraphPad Prism version 5.00 for Windows
(GraphPad Software, San Diego California USA, www.graphpad.com). Due to the low number
of observations, data were considered to be not normally distributed, and nonparametric
statistical tests were used. Specifically, the Mann-Whitney U test were used for differences
between two groups, and the Spearman Rank test was used for the analysis of correlation
between two different parameters. Results were reported as mean±standard error of mean (SE).
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N indicates the number of independent experiments and n the total number replicates per
treatment condition. For all the analyses, only p≤0.05 were considered signiﬁcant.

Results
Glycolysis and lactate release are increased in aggressive breast carcinoma cells
To study metabolic regulation of BM, we first determined the extracellular acidification
rate (ECAR) as a measure of glycolysis and the oxygen consumption rate (OCR) as a measure of
oxidative phosphorylation of breast carcinoma cells. We found that metastasis-prone MDA-MB231 cells have higher ECAR and lower OCR than non-invasive MCF7 cells (Fig. 1A) and, in
more detail, a higher glucose-dependent glycolysis mtOCR (Fig. 1B, p<0.0001). Consistent with
these data, MDA-MB-231 also had a higher NADH/NAD+ ratio than MCF7 cells (Fig. 1C,
p=0.0476). Moreover, MDA-MB-231 displayed higher mRNA expression of the glucose
transporter GLUT1 than MCF7 cells (Fig. 1D, p=0.0143). GLUT1 expression increased under
hypoxic conditions for both cell lines (Fig. 1D, p=0.0143). MDA-MB-231 cells released in the
supernatant significantly higher levels of lactate than MCF-7 cells. These levels reached the
concentrations of 10 mM (Fig. 1E). Notably, hypoxic conditions increased the release of lactate
and reduced the release of pyruvate by MDA-MB-231 cells (Fig. 1F, for pyruvate p=0.0022, for
lactate p=0.0206). These results indicate that metastatic MDA-MB-231 cells have high
glycolytic metabolism and abundantly release lactate to the extracellular microenvironment,
especially in hypoxic conditions, whereas non-invasive MCF7 cells are more oxidative.
To confirm the glycolytic phenotype of MDA-MB-231 cells, we measured the expression
of MCT4, a lactate transporter adapted for lactate release to the extracellular space.308 We found
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high levels of MCT4 mRNA and protein expression in MDA-MB-231 cells, whereas MCT1,
which usually conveys lactate uptake,309 was almost undetectable (Fig. 1G and 1H).
Comparatively, MCF7 cells expressed significantly lower levels of MTC4 mRNA than MDAMB-231 cells (Fig. 1G, p=0.0128) and significantly higher levels of MCT1 mRNA (p=0.0143).
Hypoxia significantly increased the mRNA expression of MCT4 only in MDA-MB-231 cells
(Fig. 1G, p=0.0186), and significantly reduced MCT1 mRNA expression in MCF7 cells (Fig.
1G, p=0.0286). These results imply that low oxygen tension enhances glycolysis in both cancer
cell lines although at a higher extent for MDA-MB-231 cells. Western blot of MCT4 confirmed
the data obtained under normoxia for mRNA analysis (Fig. 1H, p=0.0286). Finally, we analysed
the localization of MCT4 in a BM tissue sample from patients with breast carcinoma and used
cytokeratin to distinguish cancer cells from the surrounding stroma. MCT4 staining strongly
overlapped with cytokeratin staining (Fig. 2, yellow color in the merged images), suggesting that
aggressive breast cancer cells also abundantly express MCT4 at the bone metastatic site.

Exogenous lactate fuels the oxidative metabolism of mature osteoclasts
Next, to investigate the ability of human osteoclasts to recycle tumor-derived lactate as an
energetic fuel, we used sodium L-lactate at 10 mM concentration, within the range of
concentration frequently measured in breast carcinoma tumors in vivo.310 This concentration is
also the amount released by MDA-MB-231 cells in vitro (Fig. 1E). Osteoclasts took up
exogenous 14C- lactate (Fig. 3A, p<0.0001), and, when treated with lactate, showed significantly
higher ECAR, and even higher mtOCR and ATP coupling efficiency. The increase for mtOCR
and ATP coupling efficiency was almost double in respect to not treated cells (Fig. 3B, p=0.0465
for ECAR; p=0.001 for mtOCR and ATP coupling).
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The mitochondrial transmembrane potential (Δψ) assessed by the fluorescent probe JC-1,
and the glycolytic efficiency (lactate production/glucose consumption)302 confirmed the data
obtained with the Seahorse analysis. In fact, lactate uptake significantly increased the Δψ of
mature osteoclasts (Fig. 3C, p=0.0003), and promoted a significantly lower glycolytic efficiency
(Fig. 3D, p<0.0001). We excluded form the calculation the amount of lactate that is autocrinally
released by exogenous-lactate free osteoclast cultures (1 mmol/100 µL). These data suggest that
exogenous lactate transported into mature human osteoclasts is an oxidative fuel for these cells.

MCT1 expression increases during osteoclastogenesis
MCT1 is ubiquitously expressed in cells that consume lactate, and we thus evaluated if
this assumption is also true for osteoclasts. We analyzed the expression of MCT1 and MCT4 in
precursor cells (day 0 at seeding) and mature osteoclasts (at day 7 and after, from seeding).
MCT1 mRNA expression increased during osteoclast differentiation, whereas MCT4 mRNA
expression was not affected (Fig. 4A). Similarly, MCT1 protein expression was significantly
higher in osteoclasts than in precursor cells (Fig. 4B, p<0.05). MCTs localized at the plasma
membrane of mature multinucleated osteoclasts (Fig. 4C), and close to the actin ring (as verified
for MCT1, yellow color for co-localization in the merged images in Fig. 4D). These results
collectively establish that the expression of MCT1 increases during osteoclastogenesis, and that
it is localized at the plasma membrane of fully differentiated osteoclasts.

Targeting MCT1 impairs lactate-promoted osteoclast activity
We next aimed to study the functional consequences of lactate uptake by osteoclasts, and
focused on the bone resorption activity that is commonly associated with BM. Osteoclast
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precursors were seeded on a layer of collagenous matrix and exposed to 10 mM of sodium
lactate. Lactate-based treatment significantly increased Type I collagen degradation (Fig. 5A,
p=0.0003) confirming our hypothesis: glycolytic breast cancer cells in the bone
microenvironment release lactate that is taken up and consumed oxidatively by bone resorbing
osteoclasts. Notably, we have recently demonstrated that bone resorption activity of osteoclasts
is indirectly dependent by oxidative metabolism since this metabolic pathway is fundamental to
maintain osteoclast survival.302 Furthermore, it may be hypothesized that an increase of oxidative
metabolism at the presence of simultaneously active glycolysis directly fuels the highly energy
consuming biological process of bone resorption. According to this hypothesis, we tested
whether 7ACC2, an inhibitor of lactate uptake that does not inhibit lactate export,305 may
decrease osteoclast differentiation and activity. For this aim, we used conditioned medium (CM)
obtained from MDA-MB-231 cells, containing about 10 mM lactate (Fig. 1E), or proosteoclastogenic medium supplemented with sodium lactate at the same concentration, and found
that MDA-MB-231 supernatant induced osteoclastogenesis (Fig. 5B). Inhibition of lactate uptake
with 7ACC2 did not affect osteoclast formation in CM-treated or lactate-treated conditions (Fig.
5B-C), which was confirmed by showing a small and not significant trend of decreased
expression of the osteoclast-related marker cathepsin K and no change in the mRNA expression
of matrix metalloproteinase 9 (MMP9) (Fig. 5D). Thus, CM promoted osteoclastogenesis in a
lactate-independent manner. Conversely, Type I collagen degradation was inhibited by 7ACC2,
that significantly decreased both tumor-promoted and lactate-promoted Type I collagen
resorption (Fig. 5E, p=0.0175 and p=0.0006, respectively). Taken together, our results highlight
that lactate released by MDA-MB-231 cells fuels the bone resorption activity of osteoclasts

101

without stimulating osteoclastogenesis, and that MCT1 targeting impairs bone resorption in
osteolytic BM (Fig. 5F).

Discussion
Several lines of evidence suggest that the acquisition of the metastatic phenotype is
associated with a series of metabolic adaptations of cancer cells. For example, an altered
metabolic flux increases the release of lactate into the tumor microenvironment, which is
associated with a higher metastatic potential in several types of cancer.297 However, despite the
efforts spent exploring the effect of lactate on tumor progression, its exact role in cancer, and
especially in BM, remains elusive. Using two human breast carcinoma models with different
levels of aggressiveness, we demonstrate that the most aggressive cell line, that is capable to
develop BM in vivo, display a Warburg phenotype311,312 characterized by an increased
NADH/NAD+ ratio, GLUT1 expression, glycolytic rate, and, as a result, increased release of
lactate in the extracellular microenvironment. On the contrary, the metabolism of the lessaggressive breast carcinoma cells is mainly based on oxidative phosphorylation.
According to previous reports, extracellular lactate can be used as an energy source when
it is imported by oxidative cells in a process facilitated by passive lactate-proton symporters of
the MCT family.313 Among different isoforms, MCT1 is the most widely expressed and has been
detected at the plasma membrane of skeletal muscle fibers, hepatocytes, and cardiac cells, where
it mediates lactate uptake.314 Conversely, MCT4 facilitates the release of lactate into the
extracellular environment, is detected at the plasma membrane of glycolytic cells, including
white muscle fibers, and its expression is induced by hypoxia.315 Our data confirm that in MDAMB-231 cells MCT1 is poorly expressed, possibly because the CpG island in the 5’ upstream
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region of the MCT1 gene is methylated,316 whereas MCT4 expression is quite high, both under
hypoxic and normoxic conditions. These results thus suggest that MDA-MB-231 cells own a
Warburg phenotype. Notably, we also showed MCT4 expression in cancer cells metastatic to the
bone. Recent reports have indicated that lactate acts as an energy-transfer molecule in the tumor
microenvironment by fueling several energy-consuming processes in cancer-associated stromal
cells300 and by promoting a metabolic symbiosis between glycolytic and oxidative cells.301 In
particular, fibroblasts and mesenchymal stromal cells can use lactate released by cancer cells as
an energy source,36 whereas endothelial cells use lactate both as a signaling molecule and as a
metabolic intermediate that stimulates neo- angiogenesis.299 Likewise, our study demonstrate that
lactate produced by glycolytic cancer cells is a metabolic fuel also for osteoclasts. We have
previously reported that differentiated osteoclasts are in a high energy state and that the energy
required for osteoclastogenesis is mainly derived from mitochondrial metabolism. In addition, in
active osteoclasts during bone resorption, mitochondrial metabolism is also associated with
glycolysis,302 as high glucose concentration (20 mM) fuels the resorption activity of
osteoclasts.302 However, when metastatic carcinoma cells colonize bone, they are exposed to a
hypoxic environment317 that further prompts them to consume large amounts of glucose that fuel
glycolytic metabolism and enhance lactate production. Consequently, in the BM environment
osteoclasts rely on low levels of glucose and high levels of extracellular lactate. Accordingly, to
recapitulate the BM microenvironment in vitro, we developed a medium with reduced glucose (2
mM),318 balanced with 10 mM of lactate, a concentration that is frequently detected in breast
carcinoma,310 and that also corresponds to the concentration observed in the supernatant of
aggressive breast carcinoma cells MDA-MB-231.
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As a confirmation of the exchange of lactate between cancer cells and osteoclasts, we
found that osteoclasts internalize exogenous lactate that promoted a higher bioenergetic state by
fueling mitochondrial metabolism, as demonstrated by enhanced OCR, enhanced ATP coupling,
enhanced mitochondrial membrane potential, and reduced glycolytic efficiency. As a
consequence of lactate uptake, the differentiation process was not affected, whereas Type I
collagen degradation activity was significantly enhanced. We also provide evidence that
osteoclasts may uptake the extracellular lactate via MCT1 since, as previously shown,319 the
expression levels of MCT1 are increased whereas MCT4 expression is not changed.
Thus, as a subsequent step, we tested and validated the role of MCT1 as a major player in
lactate metabolic coupling between cancer cells and osteoclasts and as a possible therapeutic
target for the treatment of patients with BM. Recently, Draoui et al.305 have identified several 7aminocarboxycoumarin compounds that are able to inhibit MCTs (IC50=11 nM on

14

C-lactate

flux inhibition). In particular, AZD39965, a dual MCT1 and MCT2 inhibitor, is being evaluated
as anticancer agent in a Phase I clinical trial for patients with advanced prostate cancer, gastric
cancer, or diffuse large B cell lymphoma (ClinicalTrials.gov NCT01791595). In vivo,
AZD39965 enhanced the sensitivity of solid tumors to radiotherapy, suggesting that combining
anti-MCT therapies with other treatments is a promising therapeutic approach.320 Furthermore,
7ACC2 delayed the growth of human cervix SiHa, colorectal HCT116 and orthotopic MCF-7
breast cancer in vivo.305 In our study, treatment with 7ACC2 did not affect osteoclast formation
in the presence of lactate-containing conditioned medium of breast carcinoma cells or lactateenriched medium.
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Similarly, the mRNA expression of osteoclast-markers cathepsin K321 and MMP9322 was
unchanged after treatment with a MCT1 inhibitor. In contrast, the pharmacological inhibition of
lactate uptake by 7ACC2 impaired the bone resorption activity of osteoclasts, either stimulated
by tumor-derived lactate or by lactate present in the CM of human breast cancer cells.
The new concept of osteolytic BM here envisioned goes beyond the classical “vicious
cycle model,” according to which osteoclast stimulation is triggered only by a paracrine secretion
of cytokines and protein factors from cancer cells. Our concept identifies key players of tumorstroma metabolic interplay, such as MCT1, as novel and promising therapeutic targets for this
condition. Indeed, in our model, oxidative osteoclasts recycle lactate that is produced by
glycolytic cancer cells via MCT1, ultimately supporting cancer-associated osteolytic lesions and
fostering a more aggressive tumor phenotype.
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Table 1. Probes and primers.

Gene

Full name

Accession

Primers

Probe

F = ccaccgcgagaagatga

64

Number
β-actin

Actin, beta

NM_001101.2

R = ccagaggcgtacagggatag
TBP

TATA-binding

NM_00117208

F = ttgggttttccagctaagttct

protein

5.1

R = ccaggaaataactctggctca

NM_003051.3

F = ggattggtgaccattgtgg

MCT1/SLC16A1 Monocarboxylate
transporter 1

24

56

R = catgtcattgagccgaccta
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Table 1. Probes and primers.(Continued)

MCT4/SLC16A3 Monocarboxylate
transporter 4
GLUT1

MMP9

NM_00120695

F = gagtttgggatcggctacag

2

R = cggttcacgcacacactg

Glucose transporter NM_006516.2

F = ggttgtgccatactcatgacc

1

R=cagataggacatccagggtagc

Matrix

NM_004994.2

metallopeptidase 9
CTSK

Cathepsin K

F = gaaccaatctcaccgacagg

58

67

6

R= gccacccgagtgtaaccata
NM_000396.3

F=ggatatgttactcctgtcaaaaatca

37

R = tgccagttttcttcttgagttg

107

Figure 1.1: Energetic metabolism in breast carcinoma cells with different aggressiveness. BM-prone
MDA-MB-231 cells were metabolically compared with MCF7 cells that are not able to form BM. (a)
Representative graphs showing extracellular acidification rate (for ECAR: 1, 2, 3 are the time-points for the
injection of glucose, oligomycin and 2-deoxy-d-glucose, respectively) and oxygen consumption rate (for OCR:
1, 2, 3 are the time-points for the injection of oligomycin, FCCP, antimycin A and rotenone, respectively).
(b) Glycolysis and mitochondrial OCR (mtOCR). Mean ± SE, N = 3, n = 7. ***p < 0.0001 vs MCF7. (c)
NADH/NAD+ ratio. Mean ± SE, n = 5, *p < 0.05 vs MCF7. (d) GLUT1 mRNA expression under normoxia
and hypoxia (1% O2). Mean ± SE, N = 2, n = 2 #p < 0.05 vs MCF7; *p < 0.05 vs hypoxia.
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Figure 1.2: Energetic metabolism in breast carcinoma cells with different aggressiveness (e) Glucose
consumed and lactate released in cell supernatants over time. Mean ± SE, N = 3, n = 2, *p < 0.05 vs 24 h,
#p < 0.05 vs48 h, §p < 0.05 vs MCF7. The experiment was repeated 3 times with similar results. (f) Lactate
released

in

MDA-MB-231

and

MCF7

cell

supernatant

under

normoxia

and

hypoxia

(1%).

Mean ± SE, N = 3, n = 2. *p < 0.05 vs. hypoxia, #p < 0.05 vs MCF7. (g) MCT4 and MCT1 mRNA expression
under

normoxic

and

hypoxic

(1%)

conditions.

Mean ± SE, N = 3, n = 2.

*p < 0.05 vs hypoxia,

##p < 0.01 vs MDA-MB-213. (h) Western blot analysis of MCT4 expression under normoxia and hypoxia
(1%). Lower panel, densitometric quantification. Upper panel, representative image. Mean ± SE, N = 4,
*p < 0.05 vs MDA-MB-231, p = ns vs hypoxia.
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Figure 2.1: MCT4 is expressed at the plasma membrane of carcinoma cells in mouse model of BM and
in BM clinical samples. (a) Immunostaining of MCT4 in osteolytic bone metastases obtained by the injection
in the tibia of human breast carcinoma cells (MDA- MB-231). Scale bar 50 μm. (b) TRACP staining of the
same tissue obtained from BM mouse model. The red mark shows a positive multinucleated osteoclast. Scale
bar 50 μm. (c) Immunostaining of MCT1 in consecutive tissue section showed in panel b. Red mark shows the
same area marked in panel b. Scale bar 50μm.
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Figure 2.2: MCT4 is expressed at the plasma membrane of carcinoma cells in mouse model of BM and
in BM clinical samples. (d) Representative fields of immuno- fluorescence staining of MCT4 and confocal
analysis of BM sections from different patients with a pre- vious diagnosis of breast cancer. Specific antibodies
against cytokeratin (green) and MCT4 (red) were used. Nuclei were counterstained with Hoechst 33258 (blue).
Scale bar 50 μm. (e) Image of the analysis of co-localization of MCT4 and Cytokeratin immunostaining by
Pearson's correlation test per- formed in a representative cell of the tissue section showed in panel d.
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Figure 3.1: Lactate fuels the oxidative metabolism of mature osteoclasts. (a) Radiolabeled lactate influx
determined by measuring the amount of 14C-lactate that was captured by mature osteoclasts. Mean ± SE, n=6.
The experiment was repeated 3 times with similar results. (b) Extracellular acidification rate (ECAR),
mitochondrial oxygen consumption rate (mtOCR) and ATP coupling of mature osteoclasts cultured with 10
mM lactate or untreated. Mean ± SE, N=3, n=7. *p<0.05 and **p<0.01 vs untreated.
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Figure 3.2: Lactate fuels the oxidative metabolism of mature osteoclasts. ( (c) Emission spectra of JC-1 to
measure the mitochondrial potential of osteoclasts cultured with lactate or untreated. JC-1 monomers emit
green fluorescence (540 nm); aggregates emit orange-red fluorescence (590 nm). Upper panel, graph showing
the ratio of 590/540 emission. Lower panel, representative images and the spectra from the mitochondria of a
single cell in the respective conditions. Scale bar, 30 μm. Mean ± SE, n=42 cells. ***p<0.001 vs untreated. (d)
Glycolytic efficiency (glucose consumption/lactate production ratio) of osteoclasts cultured with 10 mM
lactate or untreated. Mean ± SE, N=3, n =5. ****p<0.0001 vs untreated.
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Figure 4: MCT1 expression increases along the osteoclast differentiation process. (a) MCT1 and MCT4
mRNA expression of osteoclast precursors (0 day of differentiation) and mature osteoclasts (7 days of
differentiation). Mean ± SE, N=3. (b) Western blot analysis of MCT1 expression in osteoclast precursors (0
day), mature osteoclasts (7 days) and fully differentiated osteoclasts (14 days). Right panel, representative
image. Mean ± SE, N=3. *p<0.05 vs 0 day, #p<0.05 vs. 7 days of differentiation. (c-d) Representative images
of confocal analysis of immunofluorescence staining of MCT1 or MCT4 (green) in cell cultures of mature
osteoclasts. The osteoclast phenotype was confirmed by multinuclearity (blue) (c) and actin ring (red) (d).
MCTs are localized at the plasma membrane (white arrows). Scale bar for panel C, 20 μm; scale bar for panel
d, 10 μm.
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Figure 5.1: Lactate uptake inhibitor 7ACC2 impairs lactate-induced bone resorption by osteoclasts
without affecting osteoclastogenesis. Different conditions were used to study differentiated osteoclasts,
including incubation with MDA-MB-231 supernatant (conditioned media, CM) or with pro-osteoclastogenic
medium supplemented with lactate with or without 7ACC2. (a) Type I collagen degradation by osteoclasts
cultured with 10 mM of sodium lactate or untreated. Mean ± SE, N=2, n=4, ***p<0.001 vs untreated. (b)
Representative images of TRAP and nuclear staining of osteoclast cultures. White arrows show multinucleated
TRAP+ cells. (c) Number of obtained osteoclasts. Mean ± SE, N=3. (d) Cathepsin K (CTSK) and
metalloproteinase 9 (MMP9) mRNA expression in mature osteoclasts. Mean ± SE, N=2, n=2.
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Figure 5.2: Lactate uptake inhibitor 7ACC2 impairs lactate-induced bone resorption by osteoclasts
without affecting osteoclastogenesis. (e) Type I collagen degradation activity. Mean ± SE, N=2, n=4.
*p<0.05 and ***p<0.001 vs untreated. (f) Schematic representation of the coupling between breast carcinoma
cells and mature osteoclasts in the microenvironment of a bone metastasis. Lactate released by glycolytic
cancer cells via MCT4 is taken up by oxidative osteoclasts via MCT1, where it fuels the TCA cycle. Lactate
influx inhibitor 7ACC2 inhibits this process.
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Chapter 4: Intratumoral acidosis fosters cancer-induced bone pain through the activation
of the mesenchymal tumor-associated stroma in bone metastasis from breast carcinoma
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Introduction
Skeletal involvement is a frequent and troublesome complication affecting many patients
with advanced cancer. Bone is the third most common metastatic site

323

: up to 85% of patients

that die from breast, prostate, or lung cancer have bone involvement at autopsy

324,325

. Once

tumor cells become housed in the skeleton, the disease is usually considered incurable, and
treatment is only palliative. One of the most intolerable symptoms is cancer-induced bone pain
(CIBP), which has a strong impact on quality of life. CIBP causes difficulty in ambulation,
neurologic deficits, depression, and anxiety. Current therapies based on radiotherapy, nonsteroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, and opioids are often ineffective
and cause unacceptable side effects

325-327

. Opioids often cause excessive sedation and lack of

responsiveness, and a strong evidence base for the use of NSAIDs is still lacking 328. Therefore,
new and effective palliative measures are required to maintain an acceptable quality of life.
A novel approach focusing on recent insights into the molecular mechanisms of CIBP
and the peculiar features of the microenvironment of bone metastases (BM) might help improve
therapy options. The pathophysiology of bone pain is unique and complex

329

. CIBP is a mixed

type of chronic pain involving both inflammatory nociceptive and neuropathic pain, and it can be
breakthrough, a transitory flare of pain in the setting of chronic pain managed with opioid drugs.
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Neuropathic pain is evoked by the compression and invasion of sensory nerves by cancer cells,
whereas mechanical pain is induced by the stretching of the periosteum for tumor expansion, or
by microfractures that occur as a consequence of increased bone resorption

324,330

. Sensory

neurons (nociceptors) densely innervate the bone marrow and the periosteal surfaces of the
cortical bone and can sense diverse noxious stimuli. Nociceptors are activated through acidsensing receptors, [i.e, acid-sensing ion channels (ASICs) and the transient receptor potential
channel-vanilloid subfamily members (TRPVs)] 193. Therefore, protons are important mediators
of nociceptor stimulation to evoke an allogenic signal

331,332

. Local acidosis is common in BM

and is independent of the inflammatory reaction, because it derives from the extracellular
acidification caused by inter alia, mesenchymal stromal cells, bone-resorbing osteoclasts, and
metastatic cancer cells. The relative contributions of these diverse sources of acid to CIBP are
not well characterized. Because of their elevated level of aerobic glycolysis, aggressive cancer
cells secrete substantial amounts of protons

333

through an armamentarium of

pumps and

transporters, including vacuolar H+-ATPase (V-ATPase) that is directly associated with tumor
invasion and metastasis

333,334

. Further, tumor can induce osteoclasts that dissolve bone through

the secretion of large amounts of protons, also via V-ATPase, into the resorption lacunae,
reaching pH levels around 4.5 335. Thus, these large amounts of protons in the extracellular space
can directly stimulate nociceptors through acid-sensing ion channels. We explored intratumoral
acidification as a novel target for palliative treatment in patients with BM also by investigating
on the role of mesenchymal stromal cells in mediating nociceptive stimulation in the acidic BM
microenvironment.
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Materials and methods
Reagents
Unless otherwise indicated, all reagents were obtained from SigmA: IMDM, penicillin,
streptomycin, Trizol, unbuffered RPMI-1640 (Life Technologies); anti-fibroblast magnetic
microbeads (Miltenyi Biotech); FBS, DMEM (Euroclone); glucose (Merk); MuLV Reverse
Transcriptase (Applied Biosystems); RANKL, M-CSF (Peprotech); nitrocellulose membrane, Dluciferin (Thermo Fisher Scientific); BCA protein assay, Restore Western Blot Stripping buffer,
Pierce ECL 2 Western Blotting Substrate (Pierce); TruSeq RNA Sample Prep Kit v2, Cycle
Sequencing v4 regents (Illumina); Human IL6 DuoSet ELISA Kit, Human CXCL8/IL8
Quantikine ELISA Kit, Human Free BDNF Quantikine ELISA kit (R&D Systems Inc.). The
antibodies used were: anti-rabbit Alexafluor, anti-mouse Alexafluor (Molecular Probes); AntiMCT4 (sc-50329), anti-TBP (sc-204, Santa Cruz Biotechnology); anti-cytokeratin (M0821,
Dako); anti-cytokeratin-TRITC (41-9003, Affimetrix eBioscience); anti-LAMP2 (HPA029100);
anti-IL8 (AB18672, Abcam); anti-vimentin (sc-6260, Santa Cruz Biotechnology); omeprazole
(Sandoz); ketamine (MSD Animal Health Srl). Horseradish peroxidase-conjugated anti-mouse
and anti-rabbit were obtained from GE Healthcare.

Cell cultures
SH-SY5Y and MDA-MB-231 (MDA) cell lines were purchased from the American Type
Cell Culture Collection (ATCC). The subclone (bmMDA) was previously derived from the
parental MDA cell line

336,337

. We used mesenchymal stromal cells (MSCs) from bone marrow

(BM-MSCs, 5 lots, Lonza) and from adipose tissue (AD-MSCs, 1 lot, ATCC), osteoblasts
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(HOBs, 1 lot, VWR International PBI) from healthy donors, and cancer-associated fibroblasts
(CAFs) as models of the human mesenchymal stroma of BM.
Human skin fibroblasts (Fb, 2 lots) were provided by the Japanese Collection of Research
Bioresources. We isolated CAFs from BM biopsies using anti-fibroblast magnetic microbeads
after obtaining signed informed consent and approval from the Rizzoli Orthopaedic Institute
Ethical Committee (n. 0037602 of 14.11.2013). To obtain CAFs, we mechanically minced BM
samples of breast carcinoma, and the obtained cell suspension was then seeded. When semiconfluence was reached, after cell trypsinisation, we used anti-fibroblast magnetic microbeads
and MiniMACS™ separation (Miltenyi Biotec). CAF phenotype was confirmed by the analysis
of smooth muscle alpha (α)-2 actin (ACTA2) and Fibroblast Activation Protein Alpha (FAP)
expression in respect to normal human skin fibroblasts, at mRNA level (Suppl. Fig. 2, *p=0.0209
for both ACTA2 and FAP), with Q-RT-PCR. Osteoclast cultures were derived from buffy coats
of healthy donors (AVIS, Bologna) 287.
To obtain osteoclast cultures, buffy coats were collected after their expiration date (1
days after harvesting). Peripheral blood mononuclear cells (PBMC) from healthy donors were
layered on Ficoll-Hystopaque gradient. The isolated mononuclear precursors were then seeded in
8-well chamber slides (3x106 cells/cm2) in DMEM supplemented with glucose [25 mM], 10%
characterized FBS, plus penicillin [20 U/mL], streptomycin [100 mg/mL]. After 1 h, nonadherent cells were removed and replaced with new medium added with RANKL [50 ng/mL]
and M-CSF [10 ng/mL] (differentiation medium). In order to verify osteoclast differentiation,
after 5 to 7 days of cell culture, cells were analyzed for tartrate-resistant acid phosphatase
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(TRAP) activity by Acid Phosphatase Leukocyte assay and nuclei were stained with Hoechst
33258. Only TRAP positive cells with more than 3 nuclei were considered as osteoclasts.
MDA, bmMDA, and SH-SY5Y were maintained in complete IMDM, MSCs in complete
Alpha-MEM, HOBs and CAFs in complete DMEM, and osteoclasts in complete DMEM high
glucose medium. Cells were cultured at 37°C, 5% CO2. Complete media were supplemented
with 10% FBS, plus 100 units/mL penicillin, and 100 mg/mL streptomycin. Unless otherwise
indicated, primary cultures and cell lines were maintained at pH 7.4. To create acidic conditions,
we adjusted the pH of the medium to 6.5 or 6.8 using specific concentrations of sodium
bicarbonate as previously described

338

. At the end-point of each experiment, we measured the

pH of the culture supernatants to confirm the maintenance of the prefixed pH values during the
incubation period. We used only MSCs, HOBs, and CAFs that had been passaged no more than
six times. Osteoclasts were used only at passage 0.

qRT-PCR
Total RNA was extracted using Trizol and reverse transcribed using MuLV Reverse
Transcriptase. Specific genes were amplified by Real-Time PCR. The primers and probes are
listed in Table 1. For RNA isolation under hypoxia, we incubated the cells with 1% O2 (Invivo2400 hypoxic incubator; Ruskin Technologies) for 24 h. Real-Time PCR was performed by
amplifying 1 µg of cDNA using the Light Cycler instrument and the Universal Probe Library
system (Roche Applied Science). Probes and primers were selected using the web-based assay
design software (ProbeFinder: http://www.roche-applied-science.com). Results were normalized
to Hydroxymethylbilane synthase (HMBS) or beta-Actin (b-actin), according to the 2−ΔΔCT
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method. We performed each assay with at least two technical replicates and two biological
replicates.

Western blotting
We lysed the cells at semi-confluence with boiling buffer containing 1% sodium dodecyl
sulfate (SDS), Tris pH 7.4 (20 mM), 2-Mercaptoethanol (5%), and sodium orthovanadate (1
mM). We then quantified the protein content by BCA assay. Equal amounts of proteins were
subjected to SDS-PAGE, blotted on nitrocellulose membranes, and then incubated with specific
primary and secondary antibodies. The reactions were revealed by Pierce ECL 2 Western
Blotting Substrate. To detect different proteins on the same blot, we stripped the nitrocellulose
membranes with Restore Western Blot Stripping buffer and then reprobed them. We quantified
the signals using the VisionWorksLS Analysis Software (Biospectrum, UVP). The results
presented are representative of four biological replicates.

Lactate assay
For the lactate assay, we plated 6x104 cells/cm2 on 12-well plates in complete IMDM.
After 24 h, we changed the media with new media containing 2% FBS. After 48 h, we harvested
the culture supernatants and measured the L-lactate concentration using the EnzyChrom LLactate Assay Kit (BioAssay Systems, ECLC-100). For the hypoxic condition, we incubated the
cells for 48 h after seeding as previously described. Normalization was performed with respect to
the total protein content, as measured by BCA protein assay. The experiments were performed
with four technical replicates.
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pHMed assay
We measured the pH of the culture medium using a micro-electrode

338

. Cells were

(16×106 cells) washed twice in pHMed solution (80% normal saline, 10% unbuffered RPMI1640 and 10% FBS), and incubated in pHMed in suspension for 3 hrs at 37°C. Cells were then
centrifuged (10 min at 500xg), and supernatant was collected for pH measurement. pH was
immediately measured by a digital pH-meter (pH 301, HANNA Instruments). The difference of
pH of pHMed solution alone (negative control) and the cell supernatants was analyzed. The
experiment was repeated with six biological replicates.

Confocal spectral analysis of the lysosomal pH
We used the emission spectra of the pH-sensitive dye acridine orange to measure slight
pH variation in the intracellular acidic organelles

334

. Twenty-four h after seeding, cells were

incubated at pH 6.5 for 30 min with or without omeprazole (100 μM) and then washed and
analyzed. Osteoclasts at 7 days of culture or MDA or bmMDA at semi-confluence were
incubated with acridine orange [0.5 µg/mL] for 15 min. After one wash, x,y emission spectra
from a confocal section within a living cell were recorded using a confocal laser
microspectrofluorimeter (Nikon, TI), equipped with an argon-ion laser. Cells were focused with
x40 lens, 1.3 NA (S Fluor, Nikon) and excited at 457 nm, and the resulting fluorescence
emission in the 500-700 nm range was collected. For intracellular measurements of acridine
orange emission the pinhole size was fixed to a diameter of 54 μm. To characterize the profile of
acridine orange emission spectra, the red band contribution (R%) within the whole emission
spectrum has been calculated as follows: R%=100*I655/ (I655 + I530) where I655 and I530 are the
green (520-540 nm) and the red (645-665 nm) integrated emission intensities, respectively. The
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R% was calculated for all the acidic organelles within a single cell, and the average R% of acidic
organelles of one single cell was considered. We averaged of the measured signals from all the
lysosomes in at least fourteen single cells.

In vivo study
Procedures involving animals and their care were conducted with institutional approval
and conformed to national and international laws and policies (EEC Council Directive 86/609,
OJ L 358, 1, Dec. 12, 1987; Italian Legislative Decree 116/92, Gazzetta Ufficiale della
Repubblica Italiana n. 40, Feb. 18, 1992; NIH guide for the Care and Use of Laboratory
Animals, NIH Publication No. 85–23, 1985). Four-week-old female BALB/cnu/nu mice were
anaesthetized with ketamine/xylazine (75 mg/Kg body weight + 15 mg/Kg body weight,
respectively), injected monolaterally with bmMDA (5×104 cells/10 µl PBS) in the medullar
cavity of the left tibia and then treated i.p. with vehicle (0.9% NaCl) or omeprazole (40 mg/kg
body weight). Treatment was administered 5 days per week for 4 weeks, starting the day after
tumor cells inoculation.
To calculate the entity of osteolytic lesions we anaesthetised mice as described, laid them
flat on a x-ray-sensitive film and exposed them in an x-ray cabinet (Faxitron, Tucson, AZ, USA)
to obtain standard 2D x-ray scans. After developing the films, we took high resolution images of
them and analysed osteolytic lesions by manually selecting the osteolytic areas using the
software ImageJ (NIH).
For CIBP assessment, we tested the mice every week through the Linton instrumentation
incapacitance tester (Suppl. Fig. 3) 339. Briefly, mice were placed in the measurement chamber in
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an upright position, with the non-inoculated and inoculated limbs placed on 2 separate microscales. 5 measurements of weight distribution between the two hindlimbs were carried out.
Changes in hind paw weight distribution between the right (tumor bearing) and left (contralateral
control) limbs were utilized as an index of joint discomfort due to tumor growth. The change in
hind paw weight distribution was calculated by determining the difference (expressed as percent
difference) in the amount of weight (g) between the left and right limbs.

Illumina genome analyzer sequencing and data analysis
mRNA expression was evaluated by extracting total RNA using Trizol from cells
cultured at pH 6.5 and ph 7.4 for 24 h. We quantified the RNA using a Bioanalyzer (Agilent).
The RNA integrity numbers (RIN) and A260/A280 ratios were all equal to 10, and greater than
1.8, respectively. We converted the total RNA to a library of template molecules for highthroughput DNA sequencing using the TruSeq RNA Sample Prep Kit v2. We quantified the
library using a Bioanalyzer. Library (7 pM) was subjected to cluster amplification to cluster
generation on a Single Read Flow Cell v4 with a cluster generation instrument (Illumina).
Sequencing was performed on a Genome Analyzer GAIIx for 76 cycles using Cycle Sequencing
v4 regents. Image analysis and base calling were performed using Off-Line Basecaller Software
1.6 (Illumina). Reads were aligned using ELAND v2 of CASAVA Software 1.7 with the
sequence data sets. Human genome build 19 (hg19) were downloaded from University of
California, Santa Cruz genome browser (http://genome.ucsc.edu/) as the analytic reference.
Transcript coverage for every gene locus was calculated from the total number passing filter
reads that mapped, by ELAND-RNA, to exons. These analyses were performed using default
parameters. The advanced analysis for quantification with Quantile normalization algorithm was
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performed using Avadis NGS software (version1.5, Strand Scientific Intelligence Inc., San
Francisco, CA). The filtering was performed using default parameters. We registered the
obtained data at DDBJ/EMBL/GenBank (DRA004087 and DRA004091).

ELISA assay
We quantified IL6, IL8, and BDNF in culture supernatants and serum samples using the
Human IL6 DuoSet, Human CXCL8/IL8 and Free BDNF Quantikine ELISA Kits, respectively.
To generate the supernatants, we seeded cells at 1.5x104 cells/cm2, and after adhesion, incubated
them for 20 h in Alpha-MEM plus 0.1% FBS. We then washed the cells and incubated them in
acidic (pH 6.8) or physiological (pH 7.4) Alpha-MEM plus 0.1% FBS. After 24 h, the
supernatants were collected. Normalization was performed with respect to the total protein
content measured by BCA protein assay. We obtained blood samples from nine healthy controls
and 36 patients with newly diagnosed BM at the time of diagnosis (7 breast carcinomas, 10 from
lung carcinomas, n. 19 from undefined carcinoma) and that were seen at the Rizzoli Orthopaedic
Institute or were enrolled from the ANT foundation in Bologna from February 2014 through July
2016. To identify patients suffering from breakthrough pain at presentation, we administered a
pain questionnaire to a subgroup of 22 patients that suffering from pain (Appendix 1). Blood and
pain questionnaires were collected at clinical presentation, before surgical treatment of the bone
lesion, with signed informed consent and with institutional ethical committee approval (n.
0037602 of 14.11.2013). Breakthrough pain was considered short duration (less than 15 min)
pain perceived in the last 24 h that significantly affected the quality of life 328.
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Immunofluorescence
We obtained tissue samples from 1 patient that was seen at the Rizzoli Orthopaedic
Institute and with newly diagnosed BM at the time of diagnosis with a past diagnosis of breast
carcinomas. Tumor tissue was collected during surgical treatment of the bone lesion, with signed
informed consent and with institutional ethical committee approval (n. 0037602 of 14.11.2013).
We embedded BM samples at optimal cutting temperature (OCT) and frozen them on dry ice
before sectioning. We sectioned the samples at 10 μm and put them on a glass slide covered with
2% acetone in saline. The slides were stored at -80°C until immunostaining. Defrosted sections
were permeabilized for 15 min with PBS containing 0.1% TritonX-100, blocked with 1% BSA
for 1 h, and incubated with primary antibodies overnight. Then the sections were incubated with
fluorochrome-conjugated secondary antibodies and Hoechst 33258 for nuclear staining and
mounted and observed by confocal microscopy (Nikon TI-E).

Statistical analysis
Because of the small number of observations, we did not consider the data to be normally
distributed and therefore used non-parametric tests. We performed statistical analysis using the
StatView 5.0.1 software (SAS Institute Inc.). For the difference between two groups, we used the
Mann-Whitney U test. For the correlations between breakthrough pain and the simultaneous
presence of high serum IL6 and high BDNF levels, we used the Fisher’s exact test. We
considered IL6 and BDNF levels high when they were above the 40th percentile of the patient
group with pain (0 pg/mL and 22,519 pg/mL, respectively). For the in vivo studies Student's ttest was used with α=0.05. We expressed values as the means±SE and only p<0.05 values were
considered to be statistically significant.
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Results
Breast carcinoma cells that prefer the bone as a metastatic site strongly acidify the extracellular
microenvironment
Breast carcinoma cells strongly acidify the tumor microenvironment
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. Such

acidification might promote the pathogenic process in bone; however, the association between
the ability to localize in the bone and the ability to secrete high levels of protons has never been
evaluated. We compared the MDA cell line with the bmMDA clone, which is more prone to
form BM when injected into the left ventricle of nude mice

337

. Compared with the parental

MDA cells, the bmMDA cells showed higher mRNA (Fig. 1A) expression of key regulators of
intracellular pH

333,340

, such as carbonic anhydrase 9 (CA9; mRNA p = 0.0209) and

monocarboxylate transporter 4 (MCT4; mRNA p=0.0209, protein p=0.0495), and glucose
transporter 1 (GLUT-1; mRNA p=0.045), an indirect marker of glycolysis. Results were
confirmed also at protein level for MCT4 (Fig. 1B). Moreover, the supernatants of the bmMDA
cultures displayed greater release of L-Lactate (p=0.0209; Fig. 1C). Further, a reduced-oxygen
condition enhanced the mRNA expression of the analyzed genes and the release of L-Lactate
(Fig. 1A and C).
In association with the increased glycolytic activity and lactate release, the bmMDA cells
accumulated more protons in the lysosomes and extruded more protons into the extracellular
space than the parental MDA cells. Compared with the MDA cells, the bmMDA cells has
significantly more pumped protons (pH decrement, p=0.0476 Fig 1D), and expressed a higher
level of the V-ATPase, especially under hypoxia for the V1B2 and V0C subunits, or already at
normoxia for the V1G1 subunit (p=0.0209, p=0.0209, and p=0.0495, respectively; Fig. 1E).
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These results suggested that the breast carcinoma cells that are more prone to metastasize to the
bone are positively selected from the original tumor-cell population based on their pronounced
aptitude to release protons outside the cell. The extracellular acidification by breast cancer cells
and tumor-induced osteoclasts could thus be directly responsible for the stimulation of acidsensing ion channels in the nociceptors that innervate the bone, ultimately leading to bone pain.

The targeting of intratumoral acidification reduces CIBP
Omeprazole, a gastric H+/K(+)-ATPase inhibitor that can also block V-ATPase
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has

recently sparked great interest in relation to extracellular acidification in tumors. Acridine orange
staining and spectroconfocal microscopy verified that the treatment effectively inhibited
lysosomal acidification both in human osteoclasts and in bmMDA cells (p=0.023 and p=0.0373,
respectively; Fig. 1F and G, Suppl. Fig. 1).
We evaluated the effect of omeprazole on CIBP in vivo (Fig. 2) with intratibially injected
bmMDA. The omeprazole treatment did not alter tumor-promoted osteolysis (Fig. 2B) since,
with the exception of the last endpoint, a non-significant trend of reduction in the area of
osteolytic lesions was observed (Fig. 2B). However, omeprazole treatment significantly reduced
CIBP, as detected by the incapacitance tester. This type of assay measures changes in hind paw
weight distribution between the right (tumor bearing) and left (contralateral control) limbs, a
parameter that is correlated with pain (p=0.023; Fig. 2C) [53].

Role of mesenchymal cells in acid-induced CIBP and hyperalgesia
We investigated the mechanism of the treatment-resistant and hyperalgesic component of
CIBP. We hypothesized that the tumor-associated mesenchymal stroma in the BM is involved in
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pain-related biological processes. As in vitro models, we used HOBs and MSCs from healthy
donors, and CAFs isolated from BM biopsies. First, we assessed whether the mesenchymal cells
of the BM microenvironment can detect the lowering of extracellular pH. MSCs, HOBs, and
CAFs express ASIC4/ACCN4, ASIC3/ACCN3, GPR65, and GPR4 at levels often comparable to
or even higher to those expressed by cells of neuronal origin (Fig. 3A). Notably, the
ASIC4/ACCN4 and GPR65 levels in MSCs were further increased after a short (6 h) incubation
under acidosis (p=0.0064 and p=0.025, respectively; Fig. 3B). Thus, these data indicate that BMassociated mesenchymal cells have mechanisms in place to perceive the acidification of the BM
microenvironment. The incubation of MSCs at a low pH for 24 h induced the mRNA
transcription of nociceptive mediators (NGF and BDNF) and inflammatory cytokines (CCL20,
CCL3, CCL5, IL15, IL1a, IL1b, IL23A, IL34, IL6, IL8, TNF, TGFA; Fig. 4).
qRT-PCR in MSCs, HOBs, and CAFs partially confirmed the deep-sequencing results
(Fig. 5A); the low pH caused a significant increase in BDNF (MSCs p=0.025, HOBs p=0.0039,
CAFs p=0.0209), NGF (HOBs p=0.0039, CAFs p=0.0209), CCL5 (MSCs p=0.0003, CAFs
p=0.0209), IL1b (MSCs p=0.0039), IL6 (MSCs p=0.0002, HOB p=0.0209, CAFs p=0.0202),
and IL8 (MSCs p=0.0018, CAFs p=0.0356). The expression levels of the nociceptive mediators
NGF and BDNF were higher than those in the tumor cell line bmMDA under acidosis (Fig. 5B),
and of cells of neuronal origin at pH 7.4 (Fig. 5A). Protein analysis confirmed the secretion of
IL6 and IL8 into the media (IL6 p=0.0177 for MSCs, p=0.0039 for HOBs, and p=0.0209 for
CAFs; IL8: p=0.0116 for MSCs, p=0.0039 for HOBs, and p=0.0209 for CAFs; Fig. 5C).
Furthermore, the induction of IL6 and IL8 mRNA expression by the low pH was very
rapid, appearing after only 3 h in each cell type (Fig. 6A), and was possibly mediated by NF-kB
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pathway activation because either NF-kB1, RelA, or RelB mRNA significantly increased at
similar time-points, especially in the MSCs (Fig. 6B). In contrast to untransformed cells, the
breast cancer cells had a very low expression of the cytokines, at both at neutral (IL6:
0.004±0.002; IL8: 0.044±0.005) and acidic (IL6: 0.004±0.001; IL8: 0.049±0.007) pH values.
Our data suggest a novel mechanistic model for untreatable CIBP that involves
mesenchymal cells in patients with BM: the acidification of the BM microenvironment activates
an auto-feeding process of pain by inducing of the secretion of nociceptive and inflammatory
modulators from mesenchymal cells and thereby promoting hyperalgesia, leading ultimately to
continuous sensitization of the nociceptors in the bone (Fig. 7).
The model matched evidence obtained from clinical samples. The serum levels of IL6
and IL8 in patients with BM of breast, lung and undefined carcinoma were significantly higher
than those in healthy controls (p=0.0335 and p=0.0472, respectively; Fig. 8A). Furthermore,
although BDNF serum levels were lower in patients versus control (Fig. 8B), high serum levels
of IL6 and BDNF as well as high IL6 level alone were significantly correlated in patients with
breakthrough pain vs patients without breakthrough pain (p=0.0131 and p=0.0354, respectively;
Fig. 8C). High serum levels of IL6 and IL8 in patients with cancer are assumed to be derived
from strong local secretion from tumors. In contrast to that assumption, in vitro analysis and
deep-sequencing screens including breast cancers (MCF7, T47D, and SKBR3 cell lines, data not
shown), revealed consistent and strong expression of IL6 and IL8 by mesenchymal stromal cells
and not by carcinoma cells, particularly when the mesenchymal cells were exposed to
extracellular acidosis.
We looked for IL8 localization in tissue sections of BM from breast carcinoma and also
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in relation to intratumoral acidosis. We used cytokeratin and vimentin staining to identify the
carcinoma cells and the surrounding mesenchymal stroma, respectively (Fig. 9, first string from
the top). We used LAMP2 staining as a marker of the acidic microenvironment

196

, which was

confined to the carcinoma cells, as indicated by a complete overlapping with the cytokeratin
signal (Fig. 9, yellow color in the merged image of the second string). Similarly, IL8 localized
very closely to the LAMP2-positive tumor area, but with only a partial overlap (Fig. 9, third
string), possibly because IL8 is secreted close to the acidic area of the BM microenvironment
and mostly by untransformed mesenchymal stromal cells. The IL8 and cytokeratin staining only
a partially overlapping (Fig. 9, fourth string), as was more clearly evident at a higher
magnification (Fig. 9, fifth string).

Discussion
The identification of novel therapies that specifically and better target the pathogenic
mechanism of CIBP more effectively than the currently available therapies is an urgent
challenge. Within that context, the acidification of the interstitial pH of BM microenvironment
into acidic values might play a major role because sensor neurons in the bone express acidsensing nociceptors 110.
Recent studies suggest that CIBP is directly caused by bone resorption due to proton
secretion by bone-resorbing osteoclasts, the altered metabolism of highly glycolytic and
acidifying tumor cells, and the tumor-promoted inflammation that further enhances tissue
acidosis

110,341

. We analyzed and confirmed the acidification activity of carcinoma cells, with

particular regard for those that form BM. As a preclinical model, we used a subclone of the
triple-negative breast carcinoma cell line MDA-MB-231, which has a higher tendency than the
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parental cells to form osteolytic lesions in xenografts
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. The bmMDA cells showed a greater

ability and aptitude than the parental cells to secrete protons and to express ion/proton
transporters related to the acid-base balance (CA9, MCT4, and V-ATPase V1G1). The increased
acidification activity derives from a high rate of glycolysis, as indirectly suggested by higher
GLUT-1 expression and lactate release. The glycolytic activity and the extracellular acidification
potential of both bmMDA cells and MDA cells were further enhanced by hypoxia which was not
unexpected because low oxygen tension further promotes glycolysis. The bone marrow is a quite
hypoxic tissue (1-6% O2) 342, and hypoxia is a crucial microenvironmental factor that provides a
platform for circulating breast carcinoma cells to colonize the bone and form BM

343

. Our data

are in agreement with previous studies showing that the tendency of breast carcinoma to invade
and form distant metastases strongly depends on tumor acidification
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, and on highly acidic

lysosomes 344. The acidification of extracellular space is a selective advantage in bone because it
enhances the activity of extracellular-matrix degradation by cancer-secreted metalloproteinases
333,345

, and is associated with increased invadopodia formation

osteoclast-mediated bone resorption
the bone matrix

333

347,348

346

and with the induction of

, ultimately leading to an enhancement of erosion of

. Both tumor cells and osteoclasts acidify the extracellular space using V-

ATPase, which is expressed on the lysosomal and plasma membranes

335,344

.V-ATPase

expression, and particularly that of the V1G1 subunit, which is highly expressed in bmMDA cells,
has been related to tumor invasiveness 333,344 and worse prognosis 349.
Previous attempts to target CIBP with bafilomycin A1, a toxic V-ATPase inhibitor, were
successful in preclinical settings

350

.Therefore, we planned to target tumor extracellular

acidification and acid-induced pain with omeprazole. Omeprazole and related drugs inhibit the
grastric H+-ATPase and can also target V-ATPase at high concentration, through the binding to
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the V1A subunit

334,351,352

, and are widely prescribed as pivotal treatments in association with

NSAIDs to reduce gastric side effects in advanced cancer patients. Once we confirmed in vitro
that omeprazole significantly reduced lysosomal acidification of both osteoclasts and bmMDA
cells, we treated BM and corresponding CIBP
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with omeprazole intraperitoneally and at a

higher dose than the standard dose conventionally used in humans. Omeprazole reduced pain 2
weeks before the inhibition of osteolysis with no evident side effects. It comes as no surprise that
osteolysis was affected later than pain as the pathogenic mechanism of osteolysis in BM is a
more long-lasting process than the neuronal stimulation. Our results on preclinical models
suggest that the use of anti-acid or anti-glycolytic therapies may be effective for the future to
treat CIBP in patients with bone metastasis. In this context, the use of i.g. proton pump
inhibitors, as we explored, or of rapamycin, an already clinically available drug that has been
demonstrated to decrease lactate production and acidosis by decreasing glycolysis [34, 35], is
very promising.
CIBP is a very complex phenomenon that is poorly understood. CIBP is the result of
background pain combined with breakthrough pain that is rapid in onset and transient in nature.
In contrast to background pain, breakthrough pain cannot be controlled by conventional
analgesics

354

and, hence, interferes greatly with aspects of life

328

. Breakthrough pain has been

more associated with CIBP than background pain. We speculated that, especially for the
breakthrough component, pain stimulation and sensitization are related to the effect of acidity on
the different cellular elements of the BM microenvironment. Indeed, in addition to being
important algogenic mediators 329, protons might induce an inflammatory response in the tumorassociated reactive mesenchymal stroma, leading to the release of a plethora of inflammatory
modulators at the injured site. Tissue acidification is commonly associated with inflammation
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because it acts as a driving force for mesenchymal stem cells during the regenerative process 355.
Similarly, in cancer, cells of mesenchymal origin are important components of the general host
response to tumor-induced tissue damage, including tissue acidosis

103

. Osteoclasts

329,356,357

and

cells of mesenchymal origin share with cells of neuronal origin the expression of acid-sensors.
For example, osteoblasts express ASICs

356

and TRPV1

329

. Thus, mesenchymal cells can

perceive a low extracellular pH like nociceptors can. We also confirmed the expression of
ASIC3 and ASIC4 acid-sensing channels, as well as GPRs in all the mesenchymal cells
analyzed, MSCs and osteoblasts, and CAFs that were directly isolated from BM of breast
carcinoma. Furthermore, in osteoblasts, extracellular acidosis enhanced the expression of GPR65
and ASIC4. To perform this type of in vitro assays, we used pH 6.8 since, although osteoclast
activity might produce a pH around 3, this very high concentration of protons is
compartmentalized in the Howship lacunae, and released in the extracellular space only at the
end of the resorption activity, and immediately buffered with less acidic extracellular fluids.
Once mesenchymal cells detect extracellular acidosis, in addition to the release of
metalloproteinases [41] that can concur to bone degradation, it may follow the activation and
subsequent release of inflammatory mediators that might impact both on the tumor-related
immune response and on pain induction (Fig. 7). Indeed, we observed a consistent increase of
CCL5, IL1b, IL6, and IL8. That induction was partially mediated by NF-kb pathway activation,
as NF-κB nuclear translocation was increased. The secretion of cytokines and chemokines has
been clearly associated with the modulation of nociceptor activation and sensitization that, in
turn, are responsible for the transmission of inflammatory pain and for evoking even greater
responses

358,359

. For a patient that means that a painful stimulus (allodynia) generates greater

pain (hyperalgesia). Furthermore, recent studies have pointed out that cells of mesenchymal
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origin can directly release neuromodulators. For example, during bone damage, cartilage cells
release nerve growth factor (NGF)
NGF and BDNF

361

360

. Similarly, MSCs can release the neurotrophic factors

and, according to our data, their expression is potently induced by

extracellular acidosis. NGF and BDNF regulate the survival, development, and function of
sensory and sympathetic neurons, which are essential for the retention and generation of pain 359.
NGF evokes inflammatory hyperalgesia by promoting changes in the conductive properties of
axons, by modulating the direct phosphorylation and membrane trafficking of TRPV1 by TrkA,
and by modulating the expression of Na channels and ASIC 362. Hence, the increased expression
of ASIC4 that we observed in acid-induced MSCs might derive from an NGF autocrine pathway.
Finally, it was clearly demonstrated in a rat model of CIBP that BDNF induces and maintains
hypersensitivity

363

. In conclusion, according to our results, it is possible to assume that in

patients with BM and suffering for pain, CIBP is also mediated by extracellular environment that
in bone, in respect to the primary site, is particularly more acid due to the presence of both active
tumor cells and osteoclasts, and is possibly differently innervated with acid-sensitive nerve
fibers. As a consequence of the alterations of the tumor microenvironment, the acid-induced
release of inflammatory mediators and neuromediators also possibly explains the lack of
responsiveness to conventional anti-analgesic drugs in patients with BM and with breakthrough
pain. Hence, in addition to anti-acid strategies, the use of anti-NGF antibodies that are in the
clinical phase of development for pain relief could be explored

364

. In agreement with our

hypothesis, human studies indicated that the tumor microenvironment causes an abnormal
remodeling of nearby sensory fibers, which is perceived as pain by patients

359

. Furthermore,

previous literature reported high circulating levels of IL6 and IL8 in patients with BM

365

, and

that patients suffering from pain with advanced breast cancer have high systemic levels of the
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inflammatory mediators TNF, IL-1b, and IL6 366. Similarly, serum concentration of IL6 and IL8
in patients with bone metastasis of breast, lung and undefined carcinoma that we enrolled had
significantly higher levels for IL6 and IL8 than healthy controls.
To specifically assess the correlation between biomarkers in clinical samples and the
biomarkers that we identified in mesenchymal cells in vitro, we quantified the serum levels of
BDNF; however, those showed an opposite trend possibly because low levels of BDNF have
been associated with depression and anxiety, which are quite common in patients with BM 367,368.
Despite that, we found a trend of increased BDNF and a significant increase of IL8 in patients
with breakthrough pain. Furthermore, when we considered IL6 together with BDNF, the
combined high serum levels of those two biomarkers were significantly correlated with
breakthrough pain.
Finally, the analysis of tissue sections of BM from breast carcinoma suggest that
carcinoma cells are highly acidic, as demonstrated by the strong LAMP2 staining
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in

carcinoma cells, and furthermore, that IL8 appeared to be secreted for the most part by the
mesenchymal stroma, close to the acidic area of the tumor, rather than by the tumor itself.
Therefore, the higher levels of IL8 in patients with advanced cancer with BM and breakthrough
pain possibly and partially originate from the mesenchymal stroma adjacent to the tumor cells
and within the acidic microenvironment.
In conclusion, we have pointed out for the first time that intratumoral acidosis and the
mesenchymal stromal reaction to tumor-associated acidosis might trigger CIBP, especially in
BM, underlining once more that cancer-associated fibroblasts and mesenchymal stromal cells
coming from the host are of the foremost importance in cancer progression. With this study, we
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offer intratumoral acidosis as a promising target for novel and more effective palliative
treatments for patients with advanced cancer.
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Patient Survey

1) In the last 24 hours, how severe was your worse pain? (please, circle how severe the pain has been).
0

1

2

3

4

5

2) In the last 24 hours, how severe was your weaker pain? (please, circle how severe the pain has been).
0
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3) In the last 24 hours, on average, how severe was your pain? (please, circle how severe the pain has been).
0
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4) In the last 24 hours, on average, how long does your pain last?:
(less than 5 min)

(less than 15 min)

(more than 15 min)

5) You're asked to rank on a scale of zero (non-functioning) to 10 (normal quality of life) how much your pain interfered during the last
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Table 1. Probes and primers.
Gene

Full name

Accession Number

Primers

Probe

HMBS

Hydroxymethylbilane

NM_000190.3

F = tgtggtgggaaccagctc

26

synthase
CA9

R = tgttgaggtttccccgaat

Carbonic anhydrase 9

NM_001216.2

F = tgcctatgagcagttgctgt

73

R = ccagtcctgggacctgagt

GLUT1

Glucose

transporter-like

AY034633.1

protein I

MCT4

F = ggttgtgccatactcatgacc

67

R = cagataggacatccagggtagc

Solute carrier family 16

NM_001206952.1,

member 4

NM_004207.3,
NM_001042422.2,

R = gagtttgggatcggctacag

58

F = cggttcacgcacacactg

NM_001042423.2,
NM_001206950.1,
NM_001206951.1
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Table 1. Probes and primers.(Continued)
BDNF

Brain-derived

neurotrophic

factor

NM_170731.3,

R = gtaacggcggcagacaaa

86

NM_170732.3,
NM_170733.2,

F = gaccttttcaaggactgtgacc

NM_170734.2,
NM_170735.4,
NM_001709.3
NGF

Nerve growth factor

NM_002506.2

R = agtggtcgtgcagtccaag

42

F = ggacattacgctatgcacctc
CCL5

Chemokine

(C-C

motif)

NM_002985.2

ligand 5
IL1B

F = tgcccacatcaaggagtattt

59

R = ctttcgggtgacaaagacg

Interleukin 1, beta

NM_000576.2

R = aaagcttggtgatgtctggtc

10

F = ggacatggagaacaccacttg
TNF

Tumor necrosis factor

NM_000594.2

R = cagcctcttctccttcctgat

29

F = gccagagggctgattagaga
IL6

Interleukin 6

NM_000600.3

F = gatgagtacaaaagtcctgatcca

40

R = ctgcagccactggttctgt
IL8/CXCL8

C-X-C

motif

chemokine

NM_000584.3

ligand 8
ACCN4

Acid sensing ion channel

Acid sensing ion channel

NM_182847.2

G protein-coupled receptor
65

R = gacagatgggcctgttcatt

67

F = ccatacccgcttcagtcg
NM_004769.2

subunit 3
GPR65

72

R = atggttccttccggtggt

subunit family member 4
ACCN3

F = gagcactccataaggcacaaa

R = ccttgtgggcctgagaac

43

F = cccatgccacccctagta
NM_003608.3

R = gggcagatcgccttaggt

54

F = caggtctggcacatttttga
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Table 1. Probes and primers.(Continued)
GPR4

G protein-coupled receptor 4

EU432116.1

R = ttccgccatccctctacat

44

F = ccacagagccaggcagtt
ATP6V1B2

ATPase H+ transporting V1

NM_001693.3

subunit B2
ATP6V0C

6

F = ccgaaatgccagtctgaatc

ATPase, H+ transporting,
lysosomal

R = tggccgaagacttccttg

16kDa,

NM_001694.2

V0

R = ttcgtttttcgccgtcat

76

F = ccactgggatgatggacttc

subunit c
ATP6V1G1

ATPase H+ transporting V1

NM_004888.3

subunit G1
ACTA2

FAP

Actin,

alpha

NM_001141945.1,

R = ctgttccagccatccttcat

muscle, aorta

NM_001613.2

F = tcatgatgctgttgtaggtggt

Fibroblast activation protein,

NM_004460.2

R = tggcgatgaacaatatcctaga

Nuclear

2,

smooth

factor

kappa

B

NM_003998.3

19

RELA proto-oncogene, NF-

RELB proto-oncogene, NFkB subunit

F = cctggaaccacgcctcta

49

R = ggctcatatggtttcccattta
NM_021975.3

kB subunit
RelB

58

F = atccgaacaacgggattctt

subunit 1
RelA

75

F = tcagcctgagcttcttctttg

alpha
NFKB1

R = tcagtctcaggggattcagc

F = actgtgtgacaaggtgcagaa

64

R = cacttgtcggtgcacatca
NM_006509.3

F = gattgtcgagcccgtgac
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Figure 1.1: Breast carcinoma bmMDA cells show a higher glycolytic metabolism with a higher
extracellular acidification activity than the parental MDA. a) mRNA analysis of CA9, GLUT1, and MCT4
expression under different O2 tensions. (N = 2 technical and N = 3 biological replicates for GLUT1 and
MCT4, and N = 2 technical and N = 2 biological replicates for CA9). b) Western blotting analysis of MCT4
(upper panel, representative experiment; lower panel, densitometric quantification of

N = 4 biological

replicates); c) L-Lactate concentration in the culture supernatants under different O2 tensions (N = 4 technical
replicates); d) pH decrement of the culture supernatant by electrode measurement (N = 6 biological replicates);
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Figure 1.2: Breast carcinoma bmMDA cells show a higher glycolytic metabolism with a higher
extracellular acidification activity than the parental MDA. e) mRNA analysis of the expression of VATPase subunits under different O2 tensions (normoxia, normo; hypoxia, hypo) (N = 2 technical and N = 3
biological replicates for V1B2 and V1G1, and, N = 2 technical and N = 2 biological replicates for V0C); f)
Representative image of acridine orange staining (left panel) and graphical representation of the emission
spectrum by confocal analysis (right panel) of all the lysosomes per cell of one representative osteoclast in the
treated or not treated cultures with omeprazole; g) lysosomal pH of cells treated with omeprazole as evaluated
by acridine orange staining and spectral confocal microscopy and expressed as R% (N = 14 biological
replicates). Mean ± SE, **p < 0.01 and *p < 0.05 for bmMDA vs MDA, and # p < 0.05 for normoxia (normo)
vs hypoxia (hypo).
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Figure 2: In vivo treatment with omeprazole. bmMDA cells were inoculated by intratibial injection and then
mice were treated with omeprazole (OME) or vehicle (VEH, 0.9% NaCl). a) Schematic representation of the
treatment; b) Analysis of osteolytic areas evaluated via software image analyses (left panel) and representative
x-ray scans (right panels, dashed line: osteolytic area); c) Pain was evaluated by measuring changes in hind
paw weight distribution (weight bearing) by using an incapacitance tester at different time points after tumor
injection and during the treatment with omeprazole. Mice were placed in the measurement chamber of the
incapacitance tester in an upright position, with the non-inoculated and inoculated limbs placed on 2 separate
micro-scales. The changes in hind paw weight distribution was calculated by determining the difference
(expressed as percent difference) in the amount of weight (g) between the left and right limbs. Mean ±
SE*p<0.05 vs vehicle treated. N=6 per group.
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Figure 3: Expression of ion channels in BM-associated mesenchymal cells. a) mRNA analysis of the basal
level of expression of ACCN4, ACCN3, GPR65, and GPR4 in MSCs, HOBs, and CAFs. Mean ± SE (N = 2
technical replicates and N = 3 biological replicates for MSCs and HOBs, and N = 2 technical replicates and N
= 2 biological replicates for CAFs); b) ACCN4 and GPR65 mRNA analysis of MSCs after 6 hours of culture
in acidic medium. Mean ± SE (N = 2 technical replicates and N = 3 biological replicates); **p < 0.01, and *p <
0.05.
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Figure 4: Short exposure to acidosis induces the release of inflammatory and nociceptive mediators in
mesenchymal stromal cells of the BM microenvironment (deep sequencing of MSCs). a) Heat map
representation of the fold increase, by deep-sequencing analysis, of the mRNA levels of inflammatory and
nociceptive mediators of normal stromal cells (4 lots of BM-MSCs) after short-term acidosis (pH 6.5)
compared to physiological medium (pH 7.4). Colors on the heat map indicate the log2 ratios of expression
(representing normalized read counts). Red, upregulation; green, downregulation; b) Short-term acidosis
activates inflammatory and nociceptive mediators in normal mesenchymal cells. Graphical representation of
transcriptional fold increases after short-term acidosis (24 hrs at pH 6.5) of inflammatory and nociceptive
mediators genes, in respect to physiological medium (pH 7.4), in normal stromal cells as revealed by deepsequencing analysis. Mean ± SE (N = 4 lots of BM-MSCs). *p < 0.05.
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Figure 5.1: Short exposure to acidosis induces the release of inflammatory and nociceptive mediators in
mesenchymal stromal cells of the BM microenvironment (MSCs, HOBs, and CAFs). a) mRNA analysis of
inflammatory and nociceptive mediators. Mean ± SE (N = 3 lots with N = 2 technical and N = 2 biological
replicates each lot for MSCs and HOBs, and only 1 lot for CAFs with the same number of biological and
technical replicates) ***p<0.001, **p < 0.01, and *p < 0.05

149

Figure 5.2: Short exposure to acidosis induces the release of inflammatory and nociceptive mediators in
mesenchymal stromal cells of the BM microenvironment (MSCs, HOBs, and CAFs). b) mRNA expression
of BDNF and NGF in bmMDA cells in respect to HOBs exposed for 24 hrs to low pH (= K, 100%); c) ELISA
quantification of IL6 and IL8 in the culture supernatants. Mean ± SE (N = 3 lots with N = 2 technical each lot
for MSCs and HOBs, and only 1 lot for CAFs with N = 2 technical and N = 2 biological replicates) **p < 0.01
and *p < 0.05.
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Figure 6: Short-term acidosis activates the expression of inflammatory mediators in BM-associated
mesenchymal cells. Graphical representation of mRNA expression over the time, starting from the acidosis
exposure (medium at pH 6.8), of IL6 and IL8 (a) and of NF-kB transcription factors (b) in normal stromal
cells, as revealed by Q-RT-PCR analysis. Mean ± SE (for MSC and HOB, N = 3 different lots, and for each
lot, N =2 biological replicates, and N = 2 technical replicates; for CAF N = 1 lot, N = 2 biological replicates,
N = 2 technical replicates). ***p<0.001, **p<0.01, and *p<0.05 versus the expression of the specified gene at
the timing immediately before medium change with acidic medium in the same cells.
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Figure 7: Graphical summary of the proposed model of the induction of pain and of hyperalgesia and
nociceptor sensitization in the BM microenvironment. In the BM microenvironment, carcinoma cells and
tumor-induced osteoclasts pump in the extracellular space a high amount of protons that on one side stimulate
ion channels on the membrane of the nociceptor terminal in bone, on the other side, promote the release of
inflammatory and nociceptive mediators from the tumor-associated mesenchymal cells, including MSCs,
HOBs, and CAFs that further enhance CIBP by promoting hyperalgesia and nociceptor sensitization.
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Figure 8: Serum levels of IL6 and IL8 and pain. a) IL6 and IL8 serum levels in BM patients versus healthy
control subjects. Mean ± SE (N = 36 for patients, and N = 9 for controls, *p<0.05); b) Serum levels of BDNF
in patients with BM in respect to healthy control donors. Mean±SE (n=22 for patients, and N = 9 for controls,
**p < 0.01); c) IL6 and BDNF serum levels in respect to breakthrough pain in BM patients (yes, patients
suffering for breakthrough pain; no, patients not suffering for breakthrough pain). Mean ± SE (N = 13 and N =
9, respectively, *p<0.05).
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Figure 9: IL8 localization in BM tissue samples Immunofluorescence staining with different antigens and
confocal analysis of a BM sections from a patient with a previous diagnosis of breast cancer. Intratumoral
acidosis was revealed by LAMP2 staining. Cells were counterstained with Hoechst 33258 for nuclear blue
signal (white bar corresponds to 50 μm, but in the last string at the bottom that corresponds to 10 μm).
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Intratumoral acidosis fosters cancer-induced bone pain through
the activation of the mesenchymal tumor-associated stroma in
bone metastasis from breast carcinoma
SUPPLEMENTARY FIGURES AND APPENDIX

Supplementary Figure 1: Representative image of acridine orange staining (left panel) and graphical representation
of the emission spectrum by confocal analysis (right panel) of all the lysosomes per cell of one representative cell of the
bmMDA cellSupplemental
line, in the treatedFigure
or not treated
cultures with omeprazole.
1: Representative
image of acridine orange staining (left

panel) and graphical

representation of the emission spectrum by confocal analysis (right panel) of all the lysosomes per cell of one
representative cell of the bmMDA cell line, in the treated or not treated cultures with omeprazole.

155

Supplemental Figure 2: Q-RT-PCR analysis of smooth muscle alpha (α)-2 actin (ACTA2) and Fibroblast
Activation Protein Alpha (FAP) revealed that cancer-associated broblasts (CAF) isolated from a BM of human
breast carcinoma have signi cantly higher expression of these markers than normal human broblasts (Fb).
Mean ± SE (N = 2 biological replicates, N = 2 technical replicates). *p < 0.05.
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Supplemental Figure 3: The incapacitance tester used in this study, in order to assess the reduction of pain
in xenograft orthotopic model of BM treated with omeprazole, both for both preventive and curative protocols.
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Chapter 5: Defining cancer subpopulations by adaptive strategies rather than molecular
properties provides novel insights into intratumoral evolution
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Quick guide to mathematical model
Here we build upon a previously developed and experimentally validated a hybrid
multiscale mathematical model of cancer growth that incorporates production of acid and
acquired resistance to extracellular pH

40,369

. This model simulates a two-dimensional slice

through a tumor and includes cellular metabolism and a dynamic vasculature. The scales of
intracellular metabolism, cellular behavior, and tissue microenvironment are coupled by using a
cellular automaton (CA) along with partial differential equations (PDEs). The model is fully
described in the reference provided and summarized here.
The model consists of normal cells, tumor cells, vasculature, and empty space. The
vasculature is a set of point sources spread through the 2D domain, seeded with a spacing
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consistent with those measured in normal stroma. These serve as boundary conditions that
deliver nutrients into the surrounding tissue via diffusion and act as sinks for extracellular acid.
Molecular concentrations are calculated using a set of reaction-diffusion PDEs. Since the
timescales of metabolism and cellular behavior such as proliferation are significantly different,
we solve the PDEs to reach steady state between each step of the CA.
The internal metabolic network of each cell consists of glycolysis, oxidative
phosphorylation, and acid production.

Oxygen conditions dictate the baseline metabolism,

essentially inducing a Pasteur effect when hypoxia develops; therefore, all cells exhibit a range
of metabolic behaviors depending on the microenvironmental conditions. The concentration of
diffusible molecules (oxygen (O), glucose (G), and protons (H)) are described by the set of PDE
𝜕𝐶
= 𝐷∇' 𝐶 + 𝑓(𝑥, 𝑡)
𝜕𝑡
where C is the concentration, D is the diffusion constant, and f(x,t) is the consumption or
production rate of the particular molecule. Oxygen consumption (fO) by cells is given by

𝑓. = −𝑉.

𝑂
𝑂 + 𝑘.

where VO is the maximal oxygen consumption by cells and kO is the concentration at which halfmaximal consumption occurs. Glucose consumption (fG) by cells is given by
𝑝3 𝐴7 27𝑓.
𝐺
𝑓3 = − 4
+
<
2
10 𝐺 + 𝑘3
where Ao is the normal target ATP production rate, kG is the concentration at which half-maximal
consumption occurs, and pG is the cell parameter representing aerobic glycolysis. For normal
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cells, pG=1, while for tumor cells it is one of the phenotypes allowed to change upon
proliferation (see below). The ATP production rate (fA) is given by

𝑓> = − 42𝑓3 +

27𝑓.
<
5

and proton production (fH) is given by
29(𝑝3 𝑉. + 𝑓. )
𝑓@ = 𝑘@ A
C
5
where kH is a buffering parameter.
Figure 3A shows the mechanistic interactions between normal cells, tumor cells, the
vasculature, and diffusible substances that were used in the model. Normal cells only proliferate
if the density of its neighbors falls below a certain amount (~80%); tumor cells can proliferate to
fill all available space. Tumor cells can evolve across two phenotypic traits: the glycolytic
capacity (x-axis of panel (C) with drift rate ΔG, and the resistance to acidosis (y-axis) with drift
rate ΔH. Increased glycolysis in a tumor cell essentially increases the absolute levels of glucose
consumption by the cell, while still being sensitive to hypoxic influence through the Pasteur
Effect. Increases in glycolysis cause an excess of pyruvate leading to generation of acidosis. We
do not model the other pathways such as pentose-phosphate that are also beneficiaries of
increased glycolysis. Resistance to acidosis is a development of lower pH thresholds in the
model for which the cell enters quiescence or apoptosis due to the acidity. Drift rates are
unbiased, so that any change in median phenotype of the population is due to selection.
The CA decision flowchart is shown in Figure 3B. The primary function of the
vasculature in this model is to spatiotemporally deliver nutrients, drugs and remove waste
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products, and while the point-source system is simplification, it is sufficient to create gradients of
pH and nutrient concentrations that are dependent on vessel density. The vasculature is dynamic:
angiogenesis will add blood vessels to hypoxic regions until normoxia is attained, and vessels
can be degraded by the growth of nearby tumor cells (representing blood vessel leakiness,
collapse, and constriction, e.g.).
We include a cost associated with the acquisition of these two traits: 1. Cells with
maximal acid resistance will have a cell cycle duration that is double that of normal cells. 2.
Cells with the highest glycolytic capacity will have double the cell cycle time compared to
metabolically normal cells. These costs are independent and multiplicative, so that a cell with
maximal acquisition of both traits will take four times longer to divide. The cost varies linearly
between the phenotypic extremes. In the present model, we doubled the rates of phenotypic drift,
ΔH and ΔG, to 0.003 and 0.15 respectively, as compared to the previously published work.
The initial condition used for the simulations of primary tumor growth is a hollow duct
with a layer of metabolically normal tumor cells along the duct wall. The duct contains no blood
vessels; outside the duct are normal cells and vasculature. For metastatic simulations, a single
cell was seeded into a normal tissue initial condition. Additional model details are given in the
Supplement along with a table of parameters (Table S1).

Introduction
Several recent studies have demonstrated multiple genetically-distinct populations within
human cancers

370,371

as a result of ongoing evolution.

We note, however, that genetic

characteristics alone provide little insight into the environmental selection pressures and cellular
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adaptive strategies that are the logical cause → effect links that govern Darwinian dynamics 372.
Here we approach intratumoral evolution as a dynamical interaction among subpopulations
defined not by their molecular properties but by adaptive strategies and the interactions of those
strategies with microenvironmental properties.
We address three general questions: 1. Can we define adaptive strategies that are
common among different cancers? 2. What are the evolutionary dynamics that govern the
intratumoral competition among subpopulations? 3. How do these Darwinian interactions at
cellular and molecular scales affect tissue-scale changes in tumor growth?
We address the first question by investigating tumor subpopulations obtained from
tumors in TRAMP, PTEN and KPC animals that are genetically engineered to form primary
cancers

373-375

. In some cases (PTEN and TRAMP) subpopulations were derived from the same

tumors. In each tumor, we find two coexisting subpopulations with different adaptive strategies
that remain stable in culture:
1.

An invasive phenotype that produces excess acid through upregulation of
fermentative glucose pathways even in the presence of oxygen.

2.

A non-invasive, angiogenic, non-motile phenotype that maintains near-normal
glucose metabolism.

Co-existent invasive and angiogenic subpopulations have been reported in other mouse
tumors 376 as well clinical breast cancers 45, colon cancers 377, skin cancers 378, and Glioblastoma
Multiforme 379 suggesting this is a general phenomenon.
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We address the second question by applying a multiscale mathematical model (vide
supra)

40,369,380

to define the eco-evolutionary competition among the adaptive strategies. Model

simulations demonstrated the invasive glycolytic subpopulation is typically fitter and, thus, more
abundant within most tumor environments. However, model simulations also demonstrated that,
if this cost/benefit ratio for the invasive phenotype is inverted by small increases in cost or
decreases in benefit, the Darwinian dynamics could be reversed causing a marked decline in the
invasive population.
These predictions were tested in the TRAMP mouse model, which develops primary
prostate cancers at ~12 weeks of age and dies of disseminated disease within 52 weeks. Immunohistochemistry of the subpopulations in primary and metastatic lesions confirmed model
predictions that the invasive, acid-producing, glycolytic phenotype (termed C2) is the most
abundant population. We then increased intratumoral pHe 0.2 units by adding 200 mM NaHCO3
to the drinking water 381,382 at age 4 weeks when tumors were confined to the ducts (i.e. in situ or
Prostate Intra-epithelial neoplasia [PIN] lesions). At necropsy this produced a significant
population shift favoring the non-invasive, angiogenic, non-acid producing (termed C3)
phenotype. A similar increase in pHe of established tumors required 400mM NaHCO3 added to
the water and, at necropsy, the C3 phenotype was the dominant population in these tumors.
To address the third question, we observed that, in the 4 week treated cohort, because the
C3 phenotypes did not penetrate the basement membrane, the tumor remained almost entirely
intra-ductal, preventing development of invasive primary tumors. Similarly, in the cohort with
established tumors, primary and metastatic growth was significantly reduced.
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We further investigated questions 2 and 3 in an experimental tumor constructed from a
mixture of the invasive human breast cancer cell line MDA-MB-231 and the non-invasive
human breast cancer cell line MCF-7 co-injected into the mammary fat pad of nude mice. In
vitro the MDA-MB-231 cells exhibited a C2-like phenotype with high levels of motility and
significantly up-regulated aerobic glycolysis and acid production. The MCF7 cells were C3-like
with near-normal glucose metabolism and low levels of motility and invasion. In vivo, MCF7
cells and are highly angiogenic

383

. Similar to C2/C3 dichotomy, MDA-MB-231 cells were the

dominant population in untreated animals. However, when NaHCO3 was added to the drinking
water, the MCF7 population greatly increased and the MDA-MB-231 population decreased and
tumor growth markedly slowed.

Materials and methods
Cell culture
Experiments were performed using; Mouse TRAMP-C2, TRAMP-C3 cell lines, obtained
from ATCC (ATC, CRL-2731, - 2733, Manassas, VA). Both cell lines were grown in DMEM
media

supplemented

with

10%

FBS,

1%

Penicillin

Streptomycin,

100

nM

Dehydroepiandrosterone (DHEA), and 0.005 µgm/ml insulin. The MCF7 cells, MDA-MB-231,
PTEN-P8, and PTEN-CaP8 cell lines were acquired from American Type Culture Collection
(ATCC, CRL-3033, -3031, Manassas, VA) and maintained in RPMI medium 1640 (Life
Technologies Gibco®, 11875-093) supplemented with 10% FBS (Hyclone Laboratories, UT)
under standard cell culture conditions. UN-KPC-960 and UN-KPC-961 pancreatic cell lines were
obtained via MTA from Dr. Batra (University of Nebraska Medical Center , Omaha, NE), and
maintained in DMEM containing heat inactivated FBS, L-Glutamine (200 mM), 100x non165

essential amino acids (100 mM), sodium bicarbonate, HEPES buffer, Gentamicin (50 mg/ml),
and Penicillin/Streptomycin (100 µg/ml).All cells were maintained in 37°C and 5% CO2. All
steps were performed under sterile conditions in a tissue culture hood. All cells were used within
6 months of purchase and have been re-authenticated by STR analysis.

Animals, breeding, and treatment
The TRAMP mice breeding was described previously
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. In brief, the breeding colony

was developed using the heterozygous female mice expressing the TRAMP transgene crossed
with non-transgenic C587BL/6 male mice (also obtained from Jackson Laboratory, ME) and the
progeny subjected to ear punch genotyping. Animals were maintained in a clean facility (USF
Vivarium, at the Moffitt Cancer Research Center, Tampa, FL) in accordance to NIH Guide for
the Care and Use of Laboratory Animal and the local Institutional Animal Care and Use
Committee (IACUC) guidelines. The 4 weeks old obtained TRAMP mice were randomly
distributed in to positive control, and treated groups. 200 mM or 400 mM Sodium Bicarbonate
was dissolved in tap water and given to the TRAMP mice to drink starting at either 4 weeks old
and or 10 weeks old. The water consumption and weight of the mice was monitored, and
compared to mice drinking tap water (controls). Non transgenic mice were included as a negative
control. Numbers of animals used are included in figure legend of corresponding experiment.
A cohort of 30 nu/nu mice (Harlan) was injected in the mammary fat pad with: 10 million
of MDA-MB-231cells, or 10 million of MCF-7 cells, or a mix composed by 5 million of each of
the previous cell lines. One week prior to the cells injections, an estrogen pellet (0.72 mg low
release, Innovative Research of America, Sarasota, FL) was implanted in all mice. Three days
after tumor injection the mice were randomly separated in treated and non-treated (control)
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groups: n=4 for control groups, and n=6 for treated groups. Treated mice were having 400 mM
of bicarbonate in the drinking water, while the others had regular tap water. Tumors volume
were measured once a week using MRI T2-fast spin echo pulse sequence (TE/TR= 60/900 ms),
with an axial in-plane resolution of 273 µm, and a slice thickness of 1.5 mm. 5 weeks after
experiment started, tumors were collected and stained for H&E and ER expression. The IHC
slices were analyzed as it is explained below in Histology section.

Oxygen consumption and extracellular acidification measurements
Real-time basal oxygen consumption (OCR) and extracellular acidification rates (ECAR)
for TRAMP-C2 and C3, MCF7 , MDA-MB231, PTEN-P8 , PTEN-CaP8, KPC 960, KPC 961
cell lines and normal human primary prostate epithelial cells (PCS) were determined using the
Seahorse Extracellular Flux (XF-96) analyzer (Seahorse Bioscience, Chicopee, MA). The XF-96
measures the concentration of oxygen and free protons in the medium above a monolayer of cells
in real-time. Cells seeded in a XF microplate were cultured for 2 hours in the presence or
absence of 2 g/L D-glucose prior to OCR and ECAR measurements. Protein concentration was
determined for each well using a standard BCA protein assay. OCR and ECAR values were
normalized to mg/protein and plotted as the mean +/- standard deviation. Sample size was not
computed prior to assay design. In Seahorse assays, on any given day, multiple independent
wells (sample replicates) are assayed per group; and each measurement is repeated 3-5 times per
condition (technical replicate; and the assays were performed independently multiple times
(biological replicates). For PTEN-P8 and PTEN-CaP8 cells, there were three biological, five
assay, and four technical replicates per group per test per assay. Among these, two different
concentrations of oligomycin were used in order to ensure maximal effective doses were
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achieved (1 and 2uM). Both doses yielded identical results, so 1 uM oligomycin was used for
subsequent biological replicates. For KPC 960 and KPC961, respectively: 1 biological, 11 and 8
sample, and 4 technical replicates were assayed.

For MCF-7, MDA-MB-231, TRAMP C2,

TRAMP C3, and PCS, two biological, 8 sample, and 3-4 technical replicates were used per cell
line per assay. Statistical analysis used unpaired t-test with Welch’s correction assuming
Gaussian distribution.

Blood sodium measurement
The blood sodium concentration was obtained using an iSTAT portable clinical Analyzer
(Abaxis) with CG8+ cartridges. Blood samples (about 200 uL) were obtained from cardiac stick
of the mouse and inserted to the cartridge and readings were recorded according to
manufacturer’s specifications.

Measurements of MMPsense680 activity in vivo
TRAMP mice from Tap, 400 mM NaHCO3 at 4 weeks and 10 weeks (n= 6 for each
cohort) were imaged at 32 weeks old.

24 hours before imaging, mice were injected

intravenously with activatable fluorescent probe, MMPsense680 (Perkin Elmer). Mice were then
imaged in vivo using the FMT2500 (Perkin Elmer) tomographic imaging system. Region of
interest (ROI) was quantified and normalized using an internal standard.

Quantitative PCR
All qRT-PCRs were performed on a 7900HT Fast-Real-Time System (Life Technologies
Applied Biosystems®) using an iScript Real-Rime PCR kit with SYBR Green (BioRad, 170168

8893). GAPDH expression was used as an internal control. 100 ng of mRNA was used per 20 uL
reaction. Trizol (Life Technologies InvitrogenTM) was used according to the manufacturer’s
directions for all RNA purification. RNA was isolated from TRAMP-C2 at physiological pH 7.4,
and from low pH (6.7) treated cell pellets using RNeasy Mini Kit (Qiagen). Primers for MMP-2
and MMP-9 were obtained from Srikumar Chellepan (H. Lee Moffitt Cancer Center and
Research Institute). Primers sequences are included in supplemental materials and methods.

Histology and image analysis
At necropsy, the Lung/Heart, liver, and genitourinary system were collected. Tissues were
processed, embedded in paraffin, and 4 - 5 µm slices of the tissues were obtained. Slides were
stained with hematoxylin and eosin (H&E) stain and were graded by a pathologist for presence
of tumor tissue. Histology slides were scanned using the Aperio™ (Vista, CA) ScanScope XT
with a 20x/0.8NA objective lens (200 x) at a rate of 2 minutes per slide via Basler tri-lineararray. An Aperio (Vista, CA) Positive Pixel Count® v9.0

algorithm with the following

thresholds: [Hue Value =.1; Hue Width =.5; Color Saturation Threshold =0.04; IWP(High) =
220; Iwp(Low)=Ip(High) = 175; Ip(low) =Isp(High) =100 Isp(Low) =0] was used to segment
positive staining of various intensities. The algorithm was applied to the entire digital core image
to determine the percentage of positive biomarker staining by applicable area.

Antibodies
Polyclonal rabbit anti mouse GLUT-1 antibody was purchased from Millipore (07-1401
used at concentration of 1:800. Rabbit antibody that reacts to CD31 was purchased from Abcam
(ab28364; used at concentration of 1:200); Rabbit antibody that reacts to SMA was purchased
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from Abcam (ab32575; used at concentration of1: 250); Rabbit antibody that reacts to VEGF
was purchased from Abcam (ab46154, used at concentration of 1:1500).Rabbit antibody to reacts
to ER was purchased from Abcam (ab32063, used at concentration of 1:250). Slides were
stained using a Ventana Discovery XT automated system (Ventana Medical Systems, Tucson) as
per manufacturer's protocol with proprietary reagents.

In vitro assay for cell migration and invasion
In vitro motility and invasiveness of C2- and C3-TRAMP cell lines and in vitro motility
of MDA-MB 231, and MCF-7 were compared by using xCelligence real-time cell analyzer
(RTCA, ACEA, CA). For migration assay, cells were plated on the upper chamber containing
serum-free media at 2x104 cell/well of CIM16 plate of which lower chambers were filled with
serum-free media (negative control) or media containing 10% FBS. The number of cells which
migrated toward the lower face of the filter between two chambers were monitored in real time
by measuring impedance produced by the cells, cell index. For invasion assay, the filter of the
upper chamber was pre-coated with 10% of basement membrane extract (BME) from Cultrex.
Cell index changes were monitored up to 24 h for the migration and 72 h for the invasion.
Migration and invasion assays (Xcelligene) have 3 biological replicates and n=8 per cell line per
test per assay.

Data processing
Microsoft Excel and Graph pad Prism were used for data processing and to calculate
statistical significance which was set at p ≤ 0.05.
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Statistical analyses
A two-tailed unpaired student t-test was employed to determine statistical
significance. P-value less than 0.05 were considered statistically significant or otherwise
indicated. Mann Whitney test is a non-parametric statistic, similar to family of rank-based test
was used for migration and invasion assays.

Supplemental methods and materials
Ultrasound imaging
Ultrasound Imaging was performed on a VEVO 2100 high-resolution small animal
ultrasound imaging system (VisualSonics Inc., Toronto, Ontario, Canada). Animals were
prepared for imaging as described previously

37

. Three dimensional images were then obtained

using the 3D functionality of the VEVO2100. Prostate volume was calculated from processed
images using the VEVO2100 1.1.1 software.

DCE-MRI imaging
We used MRI
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to asses prostate and tumor sizes for all TRAMP mice by T2-weighted

Spin Echo data sets using TE/TR= 60/900 ms, FOV= 90 X 45mm, Matrix = 256 x 128, and 9
slices with a thickness of 1 mm. To non-invasively asses changes in tumor vasculature (perfusion
and permeability) by gadolinium (Gd)–based dynamic contrast enhanced (DCE)-MRI, fast spin
echo T1-weighted images were continuously acquired following a bolus injection of 0.2
mmol/kg Gd-DTPA (Omniscan®) via a tail vein catheter. DCE–MR images were acquired using
T1-weighted and 2-dimensional SEMS datasets with TE/TR = 10/233 ms and 40 repetitions.
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Data analysis for initial area under the curve (AUC) of the signal intensity was performed using
MatLab (Script by X. Zhang), in addition to Aedes (based on MatLab) was also used to analyze
the DCE-MRI experiments (figure 3A). This program can be found on its website:
http://aedes.uef.fi/. Data analysis for the enhancement, VOIs for each tumor were drawn one
timepoint and applied to all timepoints and were done using all slices containing the tumor. We
computed percent standard deviation, enhancement, skewness and kurtosis using pixel values
within the VOIs, for timepoint 0, timepoint 1, timepoint 2 and timepoint 3. Therefore, for each
mouse, there are 4 values for skewness, 4 – for Stdev, 4 for kurtosis and 4 – for percent
enhancement.

Sequences of primers
The sequence of primers used was as follows: for MMP-2 forward primer, 5’AGATCTTCTTCTTCAAGGACCGCTT-3’;
GGCTGGTCAGTGGCTTGGGGTA-3’,

reverse
for

MMP-3

AAGTTCCTCGGGTTGGAGATGACA-3’;reverse
ACCAACATCAGGAACACCACACCT-3’;

for

primer,
forward

primer

5’
,

primer
MMP-9

forward

5’5’-

primer,

5’-

CGGAGCACGGAGACGGGTATC-3’, reverse primer 5’-GGCAGAGTAGGAGCGGCCCT3’,for MMP-13 forward primer 5’-TGGCTTAGAGGTGACTGGCAAACT-3; reverse primer 5’TATTCACCCACATCAGGCACTCCA-3’.

Additional details of the mathematical model
Diffusion was solved using an ADI scheme. The boundary conditions imposed by the
point-source vessels caused us to use a low Courant number of 0.2 for stability. Typical
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convergence to a relative tolerance of 10-4 was achieved in less than 100 steps of the ADI,
typically 20-30, once the transients from initial conditions settled. The boundary conditions were
set to the average concentration of a normal tissue, in the absence of a tumor. In other words, a
normal tissue was initialized and advanced through the simulation, updating the boundary
condition to match the average value of the concentrations across the entire domain. Once all the
cells and concentrations reached relaxed into dynamic equilibrium, those values then served as
the fixed boundary concentrations for the simulations shown herein. The simulation was
performed in MATLAB on an iMac.
The cellular automaton (CA) uses the following rules and assumptions. Each grid space
can either be empty or contain one cell, of the types normal, tumor, necrotic, or blood vessel. The
algorithm loops through the cell positions in a random order to avoid bias when determining cell
behaviors such as proliferation. Cells can only proliferate into empty space if they have
completed a cell cycle.

The cell cycle is advanced by a sigmoidal function of the ATP

production rate (fA), with higher ATP rates leading to faster progression through the cycle (up to
a limit). Once the cycle is complete, the cell can proliferate on any subsequent step of the CA,
when space is available. If fA is less that the quiescent threshold Aq, the cycle is not advanced on
that step. If fA is less than the death threshold Ad, then the cell has a chance of becoming necrotic
on that step. Necrotic cells occupy space and degrade into empty space with rate pn but do not
have any metabolic function.
Initially, blood vessels are seeded into the tissue using a circle packing algorithm, with an
average density taken from histological sections. Vessels are not placed closer than the minimum
distance of σmin. During the simulation, vessels are added to hypoxic areas based on the size of
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the area, with larger areas increasing the probability that a new vessel will be placed randomly
within the hypoxic. Naturally, vessels added as such will begin to deliver oxygen and lessen the
hypoxia; this serves to slow the angiogenic process as normal vascular density is reached.
Vessels are degraded by growing tumor cells. New vessels are seeded with a vessel stability
parameter vmean. If a tumor has no space to divide on a time step, and it is next to a vessel, it will
lower the value of this parameter by 1. If that parameter for that vessel reaches 0, it is removed
from the simulation. By adjusting the strengths of the angiogenic probabilities and the vessel
stability parameter, tumors with different vascular dynamics can be simulated.Buffer therapy
was simulated by changing the baseline vascular pH by 0.2 units and by increasing the diffusion
rate of protons by double (200mM therapy) and triple (400mM therapy). These values were
chosen so that the change in intratumoral pH matched those observed in experiments.
TABLE S1. Parameters for mathematical model
Param Value
δx
20
pD
0.005
pδ
0.7
5x10-4
pn
DO
1820
DG
500
DH
1080
Oo
0.056
Go
5
pHo
7.4
VO
0.012
kO
0.005
kG
0.04
kH
2.5x10-4
6.65
βN
βT,min
6.1
pG,max
50
∆H
0.003

Units
μm
1/day
1/day
1/day
μm2/s
μm2/s
μm22/s
μm
mM/s
mM
pH
mM/s
mM
mM
–
pH
pH
–
–

Description
Reference
Diameter of CA grid point
Model specific
Normal cell death rate
Misell 2005 Br Can Res Treat
Prob. of death in poor
Model specific
dsd
Necrotic turnover rate
Model specific
conditions
Diffusion
rate O2
Nichols 1994 Phys Med Bio
Diffusion rate G
Groebe 1994 Adv Exp Med Bio
Diffusion rate protons
Patel 2001 J Theo Bio
O2 concentration in vessels
Vaupel 1989 Canc Res
G concentration in vessels Zierler 1999 Am J Phys-End
Blood vessel pH
Model specific
Metab
Max O2 consumption
Vaupel 1989
Canc Res
Half-max O2 consumption
Casciari 1992 J Cell Physiol
Half-max G consumption
Casciari 1992 J Cell Physiol
Buffering parameter
Patel 2001 J Theo Bio
Normal cell acid resistance
Park 1999 Brit J Canc
Max tumor cell acid res.
Casciari 1992 J Cell Physiol
Max glycolytic parameter
Kallinowski 1988 Canc Res
Drift rate acid resistance
Model specific
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TABLE S1. Parameters for Mathematical Model (Continued)
∆G
0.15
–
Drift rate glycolysis
Model specific
Ad
0.3
–
ATP rate threshold for death
Model specific
Aq
0.8
–
ATP rate threshold for
Model specific
τmin
0.8
day
Min cell cycle time
Casciari 1992 J Cell Physiol
quiescence
σmin
80
μm
Min vessel spacing
Dewhirst 1989 Int J Rad Onc
σmean
158
μm
Mean vessel spacing
Dewhirst 1989 Int J Rad Onc
Biospecific
Ph
νmean
20
mM
Vessel stability parameter
Model
Biospecific
Ph
pang
0.3
–
Angiogenesis rate
Model
Results
Competing intratumoral populations: C2 and C3 tumor phenotypes
TRAMP-C3 and TRAMP-C2 cell lines were established from different clones isolated
from a heterogeneous 32-week TRAMP mouse tumor
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. Both cell lines proliferate in culture

and maintain a stable phenotype. In vivo the TRAMP-C2 line forms invasive tumors while
TRAMP-C3 does not. To examine their metabolic profiles, both cell lines were glucose-starved
for 2 hours and subsequently analyzed using a Seahorse extracellular flux (XF) analyzer. As
shown in Figure 1A TRAMP-C2 cells had significantly (p=0.027) higher glucose-stimulated
acidification rates, compared to TRAMP-C3, indicating higher rates of basal glycolysis. Further,
TRAMP-C3 cells were shown to be at near-maximal glycolytic capacity at basal conditions,
whereas TRAMP-C2 cells were far from capacity under identical conditions. The basal oxygen
consumption rates of the C2 cell line was also slightly, but significantly (p=0.0054) higher than
that of the C3 cells (Figure 1B). Combined, the data from Figures 1A and 1B indicate a much
higher ATP turnover rate for C2 cells, along with much higher reliance on glycolytic
fermentation. Addition of the mitochondrial un-coupler, FCCP, yields a maximum potential
oxygen consumption rate as a measure of electron transport kinetics and demonstrated
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significantly higher (p=0.0082) mitochondrial capacity in the TRAMP-C3, compared to
TRAMP-C2 cells.
Combined with the glycolytic analysis (Figures 1A, 1B), these results demonstrate that
the C3 line produced energy primarily through respiration (i.e. oxidative metabolism) while the
C2 cells, typical of an acid-adapted phenotype, were highly glycolytic. Metabolic profiles of the
C2 TRAMP cell line in comparison to normal prostate epithelial cell line (PCS) were also
measured. The C2 line showed increased glycolytic capacity and significantly (p<0.0001) lower
ECAR after 2-DG compared to PCS. Further, C2 cells also had higher oxygen consumption
rates, indicating the metabolic rates and hence, ATP consumption rates of C2 cells were
significantly (p<0.0001) elevated compared to normal prostate epithelial cells, PCS
(Supplemental Figure 1A-D). The high rates of glycolysis in C2 cells, rather than satisfying
global cellular ATP demand, may be more indicative of compartmentalized need for ATP
production at the plasma membrane, as described in (16).
Expression of GLUT-1 is often, but not always, observed in cells with increased
glycolysis. Our IHC results (Supplemental Figure 2A,B) show elevated GLUT-1 in the more
malignant TRAMP tumor tissue of TAP treated mice, and significantly (p=0.002) less in the less
malignant tumors of Bicarbonate-treated mice (vide infra). We interpret these findings to
indicate the more malignant TRAMP tumors with higher GLUT-1 levels also have higher rates
of glucose stimulated acid production.
High rates of glycolysis and acid production in cancer cells supports rapid, invasive and
metastatic growth
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. Therefore, we investigated the migration and invasive capacity of both

cell lines using the xCELLigence label-free platform (see Methods). Figure 1C shows migratory
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capacity as a measure of impedance (Cell Index) for each cell line in the presence and absence of
FBS. C2 cells had significantly (p=0.0015) high rates of migration, which was reduced in the
absence of FBS, while C3 cells exhibited no migratory capacity under either condition. Figure
1D shows the increase in impedance in a trans-well migration assay, wherein cells have to cross
a Matrigel barrier towards the lower well containing FBS as a chemoattractant to generate a
signal. Similar to the migration assays, the C2 cell line was significantly (p=0.0007) more
invasive compared to C3.

Do invasive niche engineering phenotypes compete with non-invasive, non-acid producing
populations in other cancers?
“Niche-construction” is an ecological term to describe the modification of a
microenvironment to benefit an invading or established species. We co-opt this term to describe
the ability of invading cancer cells to modify their local microenvironments in ways that provide
them with maximal benefit, while reducing the fitness of the host tissues. As noted above, the
observation of significantly increased glucose uptake on FdG PET imaging in the vast majority
of human cancers suggest that the niche-construction phenotype is a common property of in vivo
cancers. It is beyond the scope of this report to systematically investigate all cancer types.
However, we did investigate prostate epithelial cells isolated from PTEN-null transgenic mice
that were either heterozygous (PTEN-P8) or homozygous (PTEN-CaP8) for PTEN deletion
(Supplemental figure 3 A, B)374, and epithelial pancreatic cell lines derived from
KrasG12D;Trp53R172H;Pdx1-Cre

(KPC)model,

UN-KPC-960,

and

UN-KPC-

961(supplemental figure 4 A, B)375.
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We observed, similar to the C2/C3 phenotypic dichotomy, that PTEN-P8 cells are nontumorigenic and UN-KPC -960 are non-metastatic and both relied on oxidative metabolism,
while the tumorigenic PTEN-CaP8 and metastatic UN-KPC- 961 cells were highly glycolytic
(p<0.01 and p<0.001 respectively). Co-existent invasive and angiogenic subpopulations have
been reported in other mouse tumors (6) as well clinical breast (7), colon (8), and skin (9)
cancers, as well as Glioblastoma Multiforme (10). These data suggest a dichotomy in metabolic
phenotypes in cancer cells within the same tumor may be a generalizable phenomenon.

The C3 phenotype increases blood flow in TRAMP mice
We view the acid production of C2-type cells as a form of niche construction which
permits the cells to invade into surrounding tissue presumably co-opting their blood vessels. We
note, however, that C3-type cells may also be engaged in a relatively non-invasive niche
construction strategy in which they maximize proliferation by promoting ingrowth of functioning
blood vessels. In vivo investigations using dynamic contrast enhanced (DCE)-MRI (Figure 2AB) demonstrated that significantly (p<0.0001) increased and more spatially homogeneous blood
flow was observed in bicarbonate-treated tumors (with predominantly C3 phenotype, vide infra)
compared to controls (Figure 2C).
Further IHC analyses of the tumors following sacrifice demonstrated that the bicarbonate
treated-tumors had a significantly higher number of vessels per unit area( p=0.0004), smaller
vessel diameter (p=0.029), higher expression of smooth muscle actin (p=0.04), and decreased
VEGF expression (p=0.03), also consistent with a vascular normalization (supplemental
Figures 5 A-F).
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Mathematical model of the evolutionary dynamics of intratumoral competition
To examine the Darwinian dynamics governing the interactions of these competing
subpopulations, we extended our multiscale mathematical model 40,369, based on a hybrid cellular
automaton (HCA) paradigm, to incorporate a ductal geometry. This model captures the complex
spatiotemporal interactions of competing tumor cell phenotypes and microenvironmental
selection forces such as oxygen, glucose, and acidosis (Figure3A-B). Details of the model have
been published previously 40,247,369 but the core elements are explained in Figure 3A-B, the guide
to equations, and the supplemental methods. The model simulations demonstrate that the niche
construction phenotype will be the dominant tumor subpopulation and the invasive properties of
this phenotype are critical for transition from in situ to invasive cancer and aggressive growth of
primary and metastatic tumors (Figure 3C-E).
We hypothesized that the cost/benefit ratio of the invasive, niche-construction phenotype
might be sufficiently close to unity that a small change in the numerator or denominator could
reduce the population fitness and select for the competing noninvasive phenotype. We tested the
hypothesis in silico by examining the intratumoral evolutionary dynamics following a small
increase in extracellular pHe through administration of systemic buffers at 40 or 150 days. The
time plot in Figure 3 and supplemental movie show the growth dynamics for the treatments and
control. The control has two phases of growth: initially growth of the tumor population is
constrained by competition with the surrounding normal cells. At about t=120 days, the C2-like
invasive niche-construction phenotype has evolved, increasing the growth rate by a factor of 7.
The simulation outcomes at t=200 days for treatments of pre-invasive, in situ tumors are shown
in panels 1 and 2 of Figure 3D. Both high and low dose treatments were examined and were
sufficient to prevent evolution of the niche-construction phenotype such that the C3-like non179

invasive phenotype remains dominant in the population and the tumor never becomes invasive.
Thus, this strategy of promoting the C3-like cells at the expense of the C2-like competitors
prevents the development of an invasive cancer.
We then examined environmental perturbations in growing primary cancers. Here, the
C2-like invasive phenotype has evolved and, because of its fitness advantage, become the
dominant population while the C3-like non-invasive cells are only present in a small population.
Final median phenotypes for the tumor following administration of high and low doses of
systemic buffer are shown in Figure 3C. In these models, untreated tumors were dominated by
C2-like cells and administrations of low dose buffers did not significantly alter the population
dynamics. However, as demonstrated in Figure 3C and the supplemental movie, higher dose
buffer significantly alters the median phenotypes (cyan dot) and in particular the dominant
population moves from C2-like back towards C3-like during treatment. Hence, the model
predicts that relatively small perturbations in environmental conditions can induce a population
phase transition and specifically select for non-invasive cancer cell phenotypes.

Testing model predictions in TRAMP tumors
The mathematical model makes two explicit predictions relevant for in vivo population
dynamics in TRAMP mice: 1. Small changes in the pHe of in situ tumors will select of the noninvasive C3-like phenotype and this will prevent the development of invasive cancer and 2.
Changes in the pHe of invasive cancers can produce a population phase transition favoring the
C3-like phenotype and significantly reduce the tumor growth rate. We tested prediction 1 by
adding 200 mM of NaHCO3 to the drinking water, which increased (p<0.04) intra-prostatic pHe
by a mean of 0.2 (+/- 0.04) pH units. Increases in intra-prostatic pHe with different concentration
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of bicarbonate was measured by electrode (Figure4 A).

Serum sodium concentrations

(supplemental Figure 6 A) were identical in both groups, indicating that the systemic metabolic
alkalosis was fully compensated.

As observed in prior studies

178,194,195

, mice weight was not

significantly different in the treatment cohorts when compared to the control cohort; water intake
was increased in mice on sodium bicarbonate, apparently as a consequence of sodium
(Supplemental figure 6B and C).
Consistent with prior observations, we found the addition of systemic buffers at 4 weeks
prevented the transition from in situ to invasive cancers. IHC evaluation of the treated and
untreated tumors (see below) confirmed that the C2 phenotype dominated the untreated tumor
population while the tumor cells in the treated animals, which remained intra-ductal (i.e. did not
break through the basement membrane) exhibited a phenotype similar to C3 cells (supplemental
Figures 7A). Prediction 2 was tested by adding sodium bicarbonate to drinking water at 10
weeks of age and, therefore, in invasive tumors already dominated by C2 cells. Consistent with
mathematical model predictions, the group treated with 400mM of sodium bicarbonate starting at
10 weeks showed a significant (p=0.03) slowing of the primary tumor growth compared to
controls at the 24-week time point (Figure 4B). At necropsy, IHC demonstrated the dominant
population in the treated tumors was the C3 phenotype (Supplemental figures 2, 5). This
population transition, in addition to slower growth, manifested a significant (p= 0.03) decreased
histological grade compared to controls (Figures 4C).

Selection for the C3 phenotype reduces metastases
Since growth of metastatic tumors requires invasive growth both at the site of the primary
tumor and in the site of metastases, we hypothesized that selection for the non-invasive C3
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phenotype would decrease the formation of secondary tumors. To model this, we simulated the
effect of buffer therapy on a range of metastatic tumor seeds by placing single cells with
different phenotypes into a field of normal tissue, under conditions of high dose, low dose, and
no therapy. The simulations were run until t=120 days, at which point the size of the metastasis
was measured. The results (Figure 5A) showed that the overall effect of high-dose systemic
buffers will depend on the distribution of circulating phenotypes and sizes at the time of
treatment. However, as with the primary tumors, the model predicts that high doses of systemic
buffers will significantly suppress metastatic tumor growth. Based on these mathematical model
results, we then investigated whether a higher dose (400mM) of NaHCO3 initiated at 10 weeks
could inhibit development of metastasis. There were fewer metastases to lung and liver, and their
quantification showed a significant (p<0.03) decrease in in the treated cohorts compared to
controls (Figure 5B, C).
Metastasis requires release of various proteases including metallo-proteases

384,385

. To

examine MMP activity in vivo, we injected with an MMP-activatable fluorescent probe
(MMPSense680®, see Methods) via the tail vein 24 hours before analysis at 28 weeks
(Supplemental figure 8A). Quantification of images demonstrated significantly ( p<0.05) lower
activity in both the 4- and 10-weeks bicarbonate treated cohorts, compared to controls
(Supplemental figure 8B). In vitro controls have previously shown that the activity of these
probes is not pH dependent in the range of these experiments386. Using qRT-PCR we
demonstrated MMP-9 mRNA expression was specifically upregulated by acidosis in C2, in
contrast to MMP-2, -3, and -13 (Supplemental Figure 8C).
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Can the results in TRAMP mice be reproduced in other experimental models?
To test the broad applicability of our results in the TRAMP mice, we designed an
experiment that investigated the in vivo competition of two metabolically different breast cancer
cell lines: non- invasive MCF-7 and highly invasive MDA-MB-231. In vitro, we demonstrated
(Supplemental figure 9A-C) that the MDA-MB231 cells were highly glycolytic (p<0.0001) ,
acid producing, motile and invasive similar to C2 cells while the MCF7 cells were non-invasive,
non-motile and exhibited near-normal glucose metabolism similar to C3 cells. IHC results
showing significantly (p=0.0013) elevated GLUT-1 in the more malignant MDA-MB231 tumor
tissue compared to MCF-7 cells (Supplemental Figure 9D).
We engineered MCF7 and MDA-MB-231 cells to express eGFP and RFP, respectively.
In vitro, we formed spheroids with the two populations, which were initially well-mixed with or
without Matrigel (n=8 per condition). Within hours, the cells moved rapidly to establish a
distinct and consistent spatial mix in which the MDA-MB-231 cells formed the surface of the
spheroids and MCF7 cells were exclusively within the central regions of the spheroids
(Supplemental Figure 10).
Well mixed cells from the two cell lines were co-injected in equal numbers into the
mammary fat pad of recipient SCID mice. An estrogen pellet was placed subcutaneously prior to
tumor injection to allow growth of the ER+ MCF7 cells. Relative GFP and RFP fluorescence
was used to qualitatively monitor tumor growth in these animals, and identified the appropriate
time for end point evaluation. The animals were sacrificed 21 days following implantation and
sections were scored for ER-positivity by IHC to identify MCF-7 cells within the population.
IHC analysis of ER expression is a preferred endpoint in these studies as it is highly reproducible
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in a CLIA environment and can be quantified in a binary fashion on a pixel by pixel basis. In
contrast GFP and RFP fluorescence is difficult to quantify due to light penetration and scatter,
and the known effects of microenvironment (pH and oxygen) on fluorescent protein Maturation.
In the control animals, the ER-negative MDA-MB-231 cells were the dominant population at the
endpoint. However, in mice treated with 400 mM NaHCO3, the number of ER-positive MCF-7
cells was significantly (p<0.0001) increased in the treated group (Figure 6 A-B and
supplemental figure 11). Furthermore, this population phase transition coincided with a
decrease in the tumor growth rate (Figure 6C).
Thus, our model demonstrates the dominant population in control tumors exhibited both
metabolic and invasive strategies of the C2 phenotype while the dominant tumor population in
the treated cohorts demonstrated the C3 phenotype, consistent with effects on tumor size,
histological grade, and metastases (Figure 7).

Discussion
It is clear that intratumoral evolution produces multiple genetically-defined competing
subpopulations. Here we investigate the adaptive strategies of these subpopulations and, while
there are likely many, focus on two phenotypes that were stably maintained in culture following
extraction from 3 different spontaneous tumor models.
Each population engineers the local ecology to favor its own proliferation and undermine
competitors. The angiogenic phenotype promotes ingrowth of vessels to increase the carrying
capacity and increases proliferation. However, this phenotype promotes relatively compact and
slow tumor growth. Model predictions are consistent with histological observations of a
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“pushing” tumor edge which typically confers a favorable prognosis

387

. In contrast, the

invasive phenotype, through acidification of the environment, benefits by the acid-mediated
suppression of competing cancer cell adaptive strategies, inhibition of immune response to tumor
antigens, and degradation of the extracellular matrix, which promotes invasion. Prior studies
have demonstrated that increased acid production is intimately coupled to invasion

60

and a

recent genome-wide computational analysis has shown high correlation between aerobic
glycolysis and cell motility
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. Histologically, this phenotype will manifest as an “infiltrating”

border, which confers a poor prognosis387.
In ongoing intratumoral evolution, the benefits of each adaptive strategy are weighed
against the costs. For the invasive strategy, costs include diminished efficiency of energy
production due to aerobic glycolysis and the metabolic demands (due to membrane proton
pumps, for example) of adapting to an acidic environment. It seems likely that the benefits of
niche-construction generally outweigh the costs, as the vast majority of primary and metastatic
cancers exhibit increased glucose accumulation in FdG PET imaging.
Here we asked: How robust to external perturbations is this apparent advantage?
Complex dynamical systems, such as cancers, are typically dominated by non-linear interactions
– dynamics that are difficult to anticipate intuitively. Thus, the experimental work was guided by
mathematical models, which demonstrated even small changes in the pHe could reduce the
fitness advantage of the invasive, glycolytic phenotype leading to a population phase transition
(Figure 3) favoring non-acid producing, non-invasive phenotypes.
This prediction was confirmed in TRAMP mice as small changes in intraprostatic or
intratumoral pHe promoted non-invasive phenotypes and significantly altered tumor growth
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patterns. To explicitly investigate competition between these two adaptive strategies, we
constructed an experimental tumor using two breast cancer cell lines: lowly invasive,
metabolically near-normal, angiogenic MCF7 cells and highly invasive, highly glycolytic, acidsecreting MDA-MB-231 cells. Consistent with model predictions and observations in TRAMP
mice, we found that the MDA-MB-231 cells became the dominant population in vivo. However,
when the experiment was repeated with 400 mM of NaHCO3 added to the drinking water, MCF7
cells became favored and the tumor growth slowed significantly (Figure 6 and supplemental
figure11).
In summary, we demonstrate that cancers, like other complex dynamical systems, can be
steered into a less aggressive course through application of relatively small but highly selective
biological “force”. This can be achieved even in the absence of comprehensive understanding of
every component in the system through application of mathematical models that capture the key
underlying non-linear Darwinian dynamics.
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Figure 1: In vitro profiling of the tumorigenic TRAMP-C2 and nontumorigenic TRAMP-C3 cell
lines. A, Metabolic flux analysis of ECAR was measured in real-time using a Seahorse XFe-96 Analyzer. C2
cells exhibited increased glycolysis, compared with C3 cell line. *, P = 0.0274. Glycolytic capacity was higher
in the C2 cells. **, P = 0.001. B, the basal OCR of the two cell lines was not different. The C3 cells had a
slight, albeit, significant increase in respiratory capacity. **, P = 0.0082. C, in vitro motility, which was
measured by impedance that was caused by migration in both cell lines and recorded by the xCELLigence
Real-Time Cell Analyzer instrument, C2 cells had high migration, and C3 line was not motile. ***, P =
0.0007. D, Invasiveness comparison between C2- and C3- cells measured by increases in impedance;
following transwell migration assay, the C2 cells were more invasive. **, P = 0.0015. A Mann–Whitney
statistical test was used to show that the two time series curves are from different populations. Both migration
and invasion were normalized to proliferation rate.
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Figure 2: Effect of bicarbonate on perfusion in TRAMP. (A-C). Tumor vasculature (perfusion and
permeability) was assessed using gadolinium (Gd)–based dynamic contrast enhanced (DCE)-MRI, A.
Representative Images of DCE-MRI images in coronal plane of the TRAMP prostate tumor in Tap group and
200 mM bicarbonate group are shown. Images were obtained at time 0 (prior to Gd injections), and at 4, 7,
and 10 minutes post Gd injections. The color scale represents incremental increase in signal intensity in the
prostate. B. Data analysis for initial area under the curve (AUC) of the signal intensity was performed using
Matlab, showing higher blood flow in the 200 mM bicarbonate treated group (****P<0.0001).C. .Statistical
analyses of enhancement at 10 minutes, showing mean signal intensity ± SD, as well as the skewness of the
histogram of enhancement values ± SD. The mean values indicate significantly increased enhancement
(p=0.001), in the treated, compared to the Tap controls. Further, the enhancing pixels in the tap group were
more normally distributed, compared to the bicarbonate group (p=0.03), which we interpret as recruitment of
new vasculature that is skewed towards higher perfusion values. Two-tailed Student’s t-tests were used to
calculate statistical significance.
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Figure 3: Results from a multiscale mathematical model of tumor growth for different starting times
and doses of sodium bicarbonate. A. Modeled interactions between microenvironmental components, in
yellow (vasculature, oxygen, acidosis) and tumor cell phenotypes (aerobic (green), acid-resistant (blue),
glycolytic (red), glycolytic and acid-resistant (pink)). B. Cell life-cycle flowchart that every tumor cell obeys,
showing input parameters of oxygen, pH, ATP and space, and resulting cell decisions of quiescence, death, or
proliferation. C. Phenotype space and D. Physical space is shown at t=200 days for the following treatment
conditions: 1) low dose bicarbonate given early (t=40d), 2) high dose given early, 3) low dose given late
(t=150d), 4) high dose given late, 5) no treatment. Initial conditions for each simulation are identical and
shown as inset S in each figure D. For each simulation, the colors of the tumor cells correspond to their
position in phenotype space, (panel C) where the horizontal axis is the level of glycolytic capacity and the
vertical axis is the amount of acid resistance. Estimated regions corresponding to C2 (blue/magenta) and C3
(green) phenotypes are indicated. E. Corresponding growth curves, with tumor size (area in mm2) and time in
days. The simulation windows (D) are approximately 4.5 by 4.5 mm in size. (See Movie provided as a
supplemental Figure).
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Figure 4: Reduction of tumor growth in TRAMP model. A. In vivo measurements of the pH of the prostate
in tap, 200mM bicarbonate-treated groups, and 400mM bicarbonate treated group (n=3 for each cohort) were
obtained immediately prior to euthanasia. pH was measured using single-barrel pH microelectrode, MI-419
(Microelectrode, Inc., Londonderry NH). The results indicate a statistically significant increase in pH in the
bicarbonate treated animals compared to the tap animals; * p=0.015. * p =0.04. Mean ± standard error of the
mean (SEM) are shown. B. Prostate volume measurements of different treatments; non-transgenic ( n=5), TAP
(n=7) , late start 200mM bicarbonate treatment ( n=5) , early treatment at 200mM bicarbonate (n=5) and late
treated with 400mM bicarbonate (n=7) cohorts obtained through US imaging. Data show that mice treated
with higher dose (400mM sodium bicarbonate ) at 4 weeks of age maintained reduced prostate volumes
throughout study (*p=0.016), while the late treated mice (started at 10 weeks) only showed reduced volume at
24 weeks (*p=0.03). C. Histological Quantitative analysis of prostate tumors showing percent pixels associated
with benign and malignant phenotypes in prostate tumors of different treatment cohorts.

These show

significant differences in the percent of benign and malignant tumors observed in the 4 week old treated mice
and late treated with increased does compared to other groups; * p=0.017, and *p=0.03 respectively. A twotailed Student’s t-test was used to calculate statistical significance.
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Figure 5: Reduction of tumor metastasis in TRAMP model. A. Simulated growth of metastases under
untreated (green curve), low dose (red) and high dose (blue) buffer therapy. The horizontal axis represents the
phenotype of the initial metastatic seed cell. Seeds were selected from positions along the diagonal white line
in the phenotype plot of Figure 4 (panel C), where the value of 0 in this plot corresponds to position S (normal
phenotype) and the value of 1 corresponds to the most glycolytic and acid resistant phenotype, the upper right
corner of Figure 4A. For reference, the color gradient represents the seed phenotypes, with C3 and C2 cell
types as marked. The vertical axis shows the final size of the metastasis in mm2, measured at t=120d after the
metastatic cell was seeded. The buffer therapy was administered from t=0 until the end of the simulation.
Each point is the average of 4 runs. High dose therapy suppresses metastases of all seed types; aggressive C2
seeds still grow under low dose therapy. B. Lungs and liver metastasis images (A respectively from three
different treatment cohorts. In Tap cohort we observed metastasis, while in bicarbonate treated cohorts,
minimal metastases were observed. Black arrow is normal tissue, white arrow is metastasis. C. Quantification
of metastasis in lungs and Liver of three different cohorts, showing significant decrease in lung metastasis
(**p= 0.001) in early treatment and (*p=0.03) in late treatment groups compared to tap. For liver, *p= 0.01 for
early treatment and *p=0.02 for late treatment compared to tap. Mean ± standard error of the mean (SEM) are
shown. A two-tailed Student’s t-test was used to calculate statistical significance.
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Figure 6: In vivo competition of MCF7 and MDA-MB231. A. Top images are H&E images of
representative tumors of each cell line and mix (MDA-MB23 and MCF7, 1:1) under different treatments.
Lower images are ER staining of consecutive slices of the same tumors as in H&E. B. Analysis of ER
expression in all the tumors used in this experiment. Note how ER expression is bigger (p-value = 0.0001) in
those tumors (composed by a mixture of MDA-MB231 and MCF7, 1:1) treated with bicarbonate 400 mM than
in those under Tap water. C. MRI volumetric data of all the tumors used in this experiment. Data are
represented as fold of change in tumor volume versus days after tumor injection. Mean ± standard error of the
mean (SEM) are shown. A two-tailed Student’s t-test was used to calculate statistical significance.
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Figure 7: Model for manipulation of niche construction evolutionary strategy. Our hypotheses is the
tumor consists of two distinct subpopulations of cells , highly glycolytic , acid producing cells ( red cells) , and
non-glycolytic , non-acid producing cells ( blue cells) . Our model predicts that small perturbations in
extracellular pH (pHe) could induce a population phase transition favoring the non-acid-producing, noninvasive cancer populations’
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Supplemental Figure 1: Metabolic profiles of TRAMP C2 cell line compared to normal prostate cell line
(PCS). A. Proton production was measured by measuring real time ECAR using Seahorse XFe-96 analyzer.
The ECAR rate of C2 cell lines increased after Oligomycin and decreased after 2-DG significantly more than
PCS which, suggesting a C2 upregulation of Glycolysis to compensate for ATP production; **** p0.001.B.
Glycolysis was measured as the increase in ECAR following glucose addition, and C. Glycolytic reserve is
measured as increase in ECAR following oligomycin, Showing that Glycolytic flux but not glycolytic capacity
is elevated in C2 relative to PCS; **** p<0.0001. D. Basal OCR was elevated in TRAMP C2 cell line
compared to PCS; **** p< 0.0001. Data are shown as mean ±SEM. A two-tailed Student’s t-test was used to
calculate statistical significance.
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Supplemental Figure 2: A. GLUT-1 Immunohistochemistry staining of prostate tumor from 32 week old
C57BL/6 TRAMP mice treated throughout life with tap (n=5), 200mM sodium bicarbonate started early (at 4
weeks old, n=3) ,and non-transgenic (n=5) , demonstrate prostates with treatment had less expression of
GLUT-1.B. Percent positive pixel quantification showed a significant decrease in expression in non-transgenic
and early treated mice, in comparison to tap and late treated. (**p=0.002 for GLUT-1). Mean ± standard error
of the mean (SEM) are shown.
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Supplemental Figure 3: Metabolic profiling of the prostate cancer PTEN- P8 cell line in comparison to
PTEN-deleted cell line PTEN-CaP8. A. basal Proton Production Rate (PPR) was not different, but that,
PTEN-CaP8 cells are more glycolytic compared to the PTEN wild-type cells PTEN-P8; *** p<0.001. Also,
the Glycolytic capacity, measured after addition of oligomycin, was higher in the CaP8 cell compared to the P8
cells; ** p<0.01. B. Oxygen Consumption rates (OCR) were higher in the PTEN- P8 cells compared to PTENCaP8.; Data are shown as mean ± SEM. A two-tailed Student’s t-test was used to calculate statistical
significance.

196

Supplemental Figure 4: Metabolic profiling of pancreatic cell line UNKPC-960- and UN-KPC-96.
While Basal PPR of KPC-960 was higher compared to KPC 961 *** p<0.0001. A. Glycolysis and B.OCR
were higher in 961 compared to 960; Data are shown as mean ± SEM. A two-tailed Student’s t-test was used to
calculate statistical significance.

197

Supplemental Figure 5: Effect of bicarbonate on vascular biomarkers. IHC staining of A .CD31, B
smooth muscle actin (SMA), and C. VEGF D. Quantification of micro vessel density (MVD), and mean
vessels perimeter, showing D1significantly increased number of vessels per unit area (**p= 0.001), and D2
decreased vessel perimeters (*p=0.02) in 200 mM bicarbonate treated group E. quantification analysis of SMA
, showing increased SMA in 200 mM bicarbonate treated group (*p= 0.04). C IHC staining of, and F.
quantification analysis, showing decreased VEGF expression in 200 mM bicarbonate treated group (*p= 0.03).
100x scale images, n=5 for each treatment group, and Mean ± standard error of the mean (SEM) are shown. A
two-tailed Student’s t-test was used to calculate statistical significance.
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Supplemental Figure 6: Effect of sodium bicarbonate on blood Na+, mouse weight, and water
consumption. A. Blood sodium concentration of the three cohorts treatment: Tap, 200 mM Sodium
bicarbonate and 400 mM sodium bicarbonate (n=5), was measured using i-STAT portable clinical Analyzer
(Abbott Diagnostics). No significant differences between cohorts were observed, indicating compensation. B.
Animal weight average: animals were weighed biweekly throughout the experiment and weekly averages
were graphed: no significant differences were observed between the cohort. C. Water consumption: water
bottles were weighed twice weekly. Water consumption per cage, normalized per mouse per day, is graphed
weekly. Mice on sodium bicarbonate consumed more water, presumably as a consequence of sodium. Mean ±
standard error of the mean (SEM) is shown. A two-tailed Student’s t-test was used to calculate statistical
significance.
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Supplemental Figure 7: H&E representative images of tumor growth in TRAMP model under different
treatments. A. Representative H&E staining of prostate showing poorly differentiated adenocarcinoma of
prostate in TAP (n=7) and late start 200mM bicarbonate treatment ( n=5) , whereas non-transgenic ( n=5) ,
early treatment at 200mM bicarbonate (n=5) and late treated with 400mM bicarbonate (n=7) cohorts showing
normal prostate and PIN lesions.

200

Supplemental Figure 8: In vivo protease activity. A. Representative tomographic fluorescent imaging of
MMP activity using MMPsense 680 fluorescent reporter probe from each treatment cohort (Tap, 400 mM
bicarbonate 4 weeks and 10 weeks initiation, n= 6 for each cohort) showing higher expression in the prostate
and liver of the non-treated mice. The In vivo abdominal and pelvic areas of mice were obtained from 32
weeks old mice (i.e. at endpoint). Mice were injected with MMPSense680 (Perkin Elmer, Inc) and euthanized
24 hours later. Ex vivo images were obtained from prostate (green arrow), seminal vesicles (SV) (red arrow),
bladder (white arrow), and liver using an ART MX-3 timer resolved fluorescence imager. B. Quantification of
MMP activity of the ROI (region of interest normalized using an internal standard) shows significantly lower
MMP activity in early (4 weeks) and late (10 weeks) bicarbonate treated mice (**p<0.006 and *p< 0.05,
respectively, compared to TAP). C. Quantitative expression of MMP (2, 3, 9, and 13) mRNA in TRAMP-C2
cells, normalized to actin. MMP Expression is presented as fold difference in expression at low pH relative to
pH 7.4. MMP-9 expression was higher in low pH in comparison to pH 7. 4. All other MMPs analyzed
showed lower expression in low pH. Two biological replicates, each with n = 6 sample replicates. Means ±
standard error of the mean (SEM) for three different experiments are shown. A two-tailed Student’s t-test was
used to calculate statistical significance.
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Supplemental Figure 9: Metabolic Analysis of MCF7 vs. MDA-MB231. A, B. Metabolic profiling of
MDA-MB231 and MCF7, showing that, A. Proton production was measured by measuring real time ECAR
using Seahorse XFe-96 analyzer MDA-MB231 cells are more glycolytic compared to MCF7 cells; ***
p<0.0001. Further, B. Oxygen Consumption rate (OCR) were higher in the MCF7 cells compared to MDAMB231; ****p<0.0001. Data are shown as mean ± SEM. A two-tailed Student’s t-test was used to calculate
statistical significance. C. In vitro motility, which is measured by impedance that is caused by migration in
both cell lines and recorded by the xCELLigence Real-Time Cell Analyzer (RTCA) instrument. MDA-MB231
had high migration, compare to MCF7 cell line. D, GLUT-1 Immunohistochemistry staining of MFP tumor
injected with MDA-MB231 (n=4) and MCF7 (n=4) and percent positive pixel quantification of the images,
showing significant increase in expression of GLUT-1 in MDA-MB231

in comparison to MCF7

(**p=0.0013). Mean ± standard error of the mean (SEM) are shown.
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Supplemental Figure 10: Co-culture of MCF7-GFP and MDA-mb-231-RFP as spheroids. The sphere was
started with the random mixture of both cell populations and over time individual cells can be observed
moving to their favorable habitat: MDA-mb-231 to the edge and MCF7 to the center. The spheres were
constructed with and without matrigel (8 replicates per group) (Representative of matrigel based spheroids
with 20000 cells).
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Supplemental Figure 11: Mixed cell model response to buffer therapy. A, B quantification of GFP and
RFP expression in tumors of each cell line (MCF7-GFP, and MDA-MB-231-RFP) and mix (MDA-MB23 and
MCF7, 1:1) under different treatments, showing increase MCF7 and increased MDA-MBA-231 in the mixed
tumor treated with bicarbonate in comparison to tap
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Chapter 6: Acidosis in the tumor microenvironment inhibits T cell function and efficacy of
immunotherapy
Note: Parts of this chapter have been previously published in the journal Cancer
Research, Pilon-Thomas, et al. 2015 Dec 30, and on BioRxiv, Wu, et al. 2019 Jul 2 and have
been reproduced in this manuscript with permission from the publisher. My contributions to each
paper include method design, performing and deciding the experimental plan, analysis and
interpretation of data, preparation of data for publication, and revision of the manuscripts.
Abstract
Immunotherapy, specifically checkpoint (PD-1, CTLA4) blockade therapy, has had much
success recently in cancer treatment. This success is due to a deeper understanding of innate and
adaptive immunity and the roles it plays in the etiology of cancer. This understanding has led to
durable responses in cancers such as lung and melanoma, which have historically poor responses
to chemotherapies and targeted therapies. Unfortunately, many tumors types have exhibited
minimal or no response to immunotherapy, and it is unknown why. A prevalent hypothesis states
that cancers with higher levels of neoantigens (i.e., a higher mutational burden) are more
responsive to immunotherapy, yet some tumors with a high mutational burden are unresponsive,
suggesting that there may be microenvironmental factors involved. One phenotype solid tumors
exhibit is an acidic intratumoral pH and, although cancer cells can survive and thrive in such
conditions, acidity is generally inhibitory to stromal cells, including those of the immune system.
To more rigorously characterize this, we have investigated the impact of acidity on T cell
function. We observed that activated murine T cells, who primarily rely on aerobic glycolysis for
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metabolism, have reduced effector function and reduced glycolysis in low pH conditions.
Specifically, we have observed that acid inhibits glycolysis by preventing lactate transport out of
the cell. Lactate transport inhibition increases intracellular lactate and reduces intracellular pH
resulting in downregulation of glycolysis. This finding has therapeutic consequences, as reducing
the acidity of solid tumors using buffer therapy improved efficacy of immunotherapies. These
findings show acidity in solid tumors inhibits T cell effector function which is vital for efficacy
of immunotherapy. By reducing intratumoral acidosis, we can enable immunotherapy to be
successful in tumors which have so far seen little benefit, and this can result in improved clinical
outcomes.

Introduction
We have been extremely fortunate to have made significant advances in cancer therapy in
the 21st century, and immunotherapy will likely be one of, if not, the standout advance in cancer
research of this time. Indeed, advances in checkpoint blockade therapy were recognized by the
Nobel Prize in Physiology or Medicine in 2018. Immunotherapy is not a new concept, however.
Immunotherapy has been pioneered to treat cancer since the late 1800s by William H. Coley,
heralded as the "Father of Immunotherapy". Coley treated patients with bone and soft tissue
sarcomas over many years by injecting streptococcal bacteria directly into the patient's tumor to
elicit an immune response, which sometimes resulted in complete remission of the tumor389. At
the time the mechanism was not understood, so doctors favored surgery and radiotherapy as
treatment for cancer patients.
Over the years, immunotherapy has fallen in and out of favor, primarily because it was
unpredictable. In a small fraction of patients, it worked exceptionally well yet, in other patients,
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it appeared to have hastened their deaths. Thus, understanding the mechanisms of activation and
inhibition of immunotherapy is a critical unmet clinical need. More recently, we have seen
improved responses of immunotherapy due to technological advances and our improved
understanding of the immune system and its role in cancer. The technological advancements
include improved methods to treat patients with adoptive T cell therapy390. Adoptive therapy
includes T cell extraction from patients’ blood, and either engineering T cells to express specific
chimeric antigens (CAR T) or culturing tumor fragments in IL-2 to expand the tumor-infiltrating
lymphocytes. Once enough cells are produced, patients are lymphodepleted and reinfused with
their T cells. Some of the most robust responses occur in hematological malignancies, for
example in acute lymphoblastic leukemia (ALL) with CAR T treatment. Of those ALL patients
treated with CAR T cell therapy, two-thirds were in remission after six months. Unfortunately,
in solid tumors the response is often not as efficacious or sustained
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. Checkpoint blockade

therapy has been equally, if not more successful as an immunotherapy strategy. T cells express
co-inhibitory molecules to prevent recognition of self and autoimmunity. Cancer cells display
corresponding inhibitory ligands on their membrane, as technically they are self, so when
immune cells bind, they will detect cancer as self and be inhibited. Checkpoint blockade therapy
either directly inhibits the checkpoint on the T cell, or prevents ligand-receptor interaction,
enabling T cell activation to persist within the tumor. The most successfully targeted checkpoints
include CTLA-4 and PD-1, but there are numerous other checkpoint receptors and ligands
currently being tested. PD-1, a cell surface receptor, is expressed on T cells and is engaged by
the ligand, PD-L1, on the tumor which reduces the length of time a T cell remains activated.
Recently, PD-L1 therapy has been approved in combination with paclitaxel for the
treatment of triple-negative breast cancer. It is the only approved immunotherapy for breast
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cancer as of August 2019 (Fig. 1). PD-L1 expression on the tumor is the only FDA-approved
biomarker to predict response at present. However, many tumors that are PD-L1 positive still do
not respond to checkpoint blockade for unknown reasons. Furthermore, some PD-L1 negative
tumors do respond, but this is thought to be due to heterogeneous expression and sampling
artifact. Some tumors are termed "cold tumors" whereby T cell infiltration is low392, and they
lack tumor antigens for T cells to recognize and initiate a response. Infiltration of immune cells
may be a factor in whether or not immunotherapy will be efficacious but, even in tumors which
have high T cell infiltration immunotherapy does not always work. This disconnect between T
cell infiltration and immunotherapy success poses the question what else is happening in the
tumor microenvironment that could inhibit immune cell function?
One common phenotype in solid tumors is an acidic intratumoral pH393. Clinically, tumor
pH has been measured as low as pH6.5394. Low pH is tolerated by cancer cells but can be
detrimental to other cells in the tumor microenvironment395. Low pH can promote the switch of
fibroblasts to cancer-promoting fibroblasts, CAF’s 158. Low pH also impacts macrophages in the
tumor polarizing them to be pro-tumorigenic and enhancing tumor progression
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literature shows an acidic microenvironment impacts many other cells in the tumor, this
suggested to us that acidosis could affect the function of T cells.
For T cells to become activated, they detect antigens on antigen-presenting cells such as
dendritic cells, B cells, and macrophages. This detection of foreign antigen triggers expansion
and differentiation into effector or memory T cells. Effector T cells induce death of infected or
cancerous cells. As T cells switch from naïve to effector to memory, their functions change, and
so do their metabolic requirements

396

. Effector T cells proliferate rapidly, known as clonal
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expansion, and this produces multiple copies of T cells with the same T-cell receptor, TCR,
which detects the antigen to prevent the spread of infection quickly. Associated with clonal
expansion, activated effector T cells must switch to more a more glycolytic metabolism. The
reasons for this requirement are not well known but may involve the speed at which glycolysis
can generate ATP on demand. One marker of an activated effector T cell is IFN-γ production,
and this is suppressed when glycolysis is low. It has been shown that GAPDH, a glycolytic
enzyme binds to the 3’ UTR of IFN-γ mRNA to suppress its translation
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. The mechanism

notwithstanding, it is well-accepted that activation of glycolysis is essential to activate naïve T
cell to effector T cells. Notably, the switch to a T memory phenotype is associated with a
metabolic switch characterized by downregulation of glycolysis in favor of glutaminolysis or
fatty acid oxidation
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. Many factors have been shown to enhance T memory phenotype,

including TCR engagement, which promotes a memory T cell phenotype by downregulating
glycolytic metabolism
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. mTORC1 activity enhances glycolysis and inhibiting mTORC1

decreases glycolysis and promotes a memory T cell phenotype400. Additionally, mTORC1 is
partially inhibited by acidic pHe which could affect T cell metabolism in the tumor
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. To

definitively identify the predominant metabolic phenotype, further work is necessary to
understand Memory T cell metabolism. Hence, we postulated whether acidosis in the tumor
could be driving a switch to memory T cells to prevent effector T cells from killing the tumor.
In this study, we exposed activated T cells to acidic pH and asked how this influenced
their effector function and metabolism. We observed acidic pH inhibited T cell effector function
and reduced their glycolytic rate. Moreover, we identified the mechanism of inhibition as being
dependent on the lactate transporter, MCT-1. Finally, we showed that altering intratumoral pH to
be less acidic can improve immunotherapy efficacy in both checkpoint blockade and T cell
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transfer. Therefore, understanding inhibition by acid may enable us to treat patients differently
with immunotherapy in the future as we can take into account the influence the tumor
microenvironment has.

Materials and methods
Cell lines and cell culture
B-16 melanoma cell line (obtained from ATCC) was cultured in complete media (CM):
RPMI media supplemented with 10% heat-inactivated FBS, 0.1 mM nonessential amino acids, 1
mM sodium pyruvate, 2 mM fresh L-glutamine, 100mg/ml streptomycin, 100 U/ml penicillin, 50
mg/ml gentamicin, 0.5 mg/ml fungizone (all from Life Technologies, Rockville, MD), and 0.05
mM 2-ME (Sigma-Aldrich, St. Louis, MO). The cell lines tested negative for mycoplasma
contamination. Cell lines were passaged less than ten times after initial revival from frozen
stocks and were validated in core facilities.

Isolation and activation of T cell
Female 6-8 week old B6 (C57BL/6), Pmel-1, OT-I, OT-II and TDAG8 knockout
(C57BL/6 background) mice were bred and housed at the Animal Research Facility of the H. Lee
Moffitt Cancer Center and Research Institute (Tampa, FL). Mice were euthanized by CO2
inhalation according to the American Veterinary Medical Association Guidelines. Naïve T cells
were isolated from mice spleens using T cell column (R&D system). T cells were cultured in
complete medium plus the following specific components : B6 and TDAG8 KO T-cells
stimulated with 5mg/mL plate-bound anti-CD3/anti-CD28, (ii) OT-I (CD8+) T-cells stimulated
with 10µg/mL OVA257-264 SIINAFEKL peptide, (iii) Pmel-1 (CD8+) T-cells stimulated with
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5µg/mL gp100 peptide, and (iv) OT-II (CD4+) T-cells stimulated with 10µg/mL OVA323-339
ISQAVHAAHAEINEAGR peptide for 48hr prior to experiments. All animal experiments were
approved by the Institutional Animal Care and Use Committee and performed following the U.S.
Public Health Service Policy and National Research Council Guidelines.

Seahorse metabolism studies
Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were
measured by Seahorse XF96 Analyzer (Agilent). Cells were cultured with bicarbonate-free
RPMI-1640 medium with 2mM HEPES and 2mM MES at pHe7.4 or 6.6. The buffering capacity
was determined to calculate the proton production rate (PPR). Cells were glucose starved before
a glycolysis stress test, where cells are exposed to glucose to determine the glycolytic rate from
ECAR. Cells were exposed to D or L lactate, and ECAR change was measured to determine the
effect of lactate on glycolytic rate.

YSI metabolite quantification
Activated Pmel-1 or OT-1 T cells were incubated in pHe from 7.4-6.6 for 24hrs. Glucose
consumption and lactate production were quantified in the media by YSI 2900 Biochemistry
Analyzer.

IFN- γ production
Activated B6, OT-I, Pmel-1, and OT-II were incubated at pHe of 7.4-6.6 for 24hrs, and then the
supernatant was collected. IFN- γ was measured using a Mouse IFNg Quantikine ELISA Kit
(R&D Systems, MIF00).
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Western blot
Cell lysates from B6 T cells that were incubated at pHe of 7.4 or 6.6 and equal amounts
of proteins (20–35μg) were electrophoresed through a 4–15% TGX Gel. The gel was
electrophoretically transferred to a nitrocellulose membrane (Bio-Rad Laboratories). Membranes
were incubated with MCT1 or MCT4 antibodies(SCBT) diluted according to the manufacturer's
instructions. Membranes were also incubated with actin as a loading control. Immunoreactive
proteins were visualized with an appropriate peroxidase-conjugated secondary antibody using
chemiluminescence.

Superfusion.
Superfusion experiments were performed in a plastic chamber (Pecon, TempController
2000-2) supplied by a solution line with a switcher that changed between one of two lines (the
other being diverted to the waste bottle). The plastic chamber was mounted on a confocal
microscope and heated to 37°C by a small scale temperature incubator (The Cube Life Imaging
Services). Solution exchange was attained with a time constant of 2.6 s. Solution flows were 2-4
ml/min.

Solutions and media.
Solutions for pH measurements under superfusion: For pH 7.4, 133 mM NaCl, 5.3 mM
KCl, 10 mM Glucose, 1 mM CaCl2, 1 mM MgCl2, 22 mM NaHCO3. For lower pH, NaHCO3
was reduced (compensated by NaCl) to attain a target pH, according to the Henderson
Hasselbalch equation (pH = 6.4 + log([HCO3-]/[CO2]), where [CO2] is 1.2 mM for 5%. All
solutions were bubbled in 5% CO2.
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Confocal imaging.
Imaging was performed on an SP5 system (Leica Microsystems). Cellular measurements
were performed with an oil-immersion x63 objective. Fluorescence imaging of cells was under
superfusion with CO2/HCO3- buffer. Cells were co-loaded with cSNARF1 (red) to report pH and
Hoechst-33342 (blue) to exclude nuclear areas from the analysis.

Image analysis.
Cytoplasmic pH was measured by gating pixels according to a threshold level of Hoechst
signal within cSNARF1-positive pixels. Fluorescence at 580 and 640 nm was averaged,
background offset and ratioed for each particle representing a cell. Buffering capacity was
measured from the change in weak acid/base concentration, assuming passive equilibration, and
the pH change. Transmembrane acid-base fluxes were therefore calculated as the product of pH
change and buffering capacity. Cell surface area/volume ratio assumed spherical symmetry, i.e.,
3/radius.

Efflux measurements
Measuring total MCT activity from the rate of pHi-change driven by transmembrane
lactate efflux. T-cells under superfusion were equilibrated with one of the three conditions, 30
mM lactate at pHe 7.4, 15 mM lactate at pHe 6.9 or 7.5 mM lactate at pHe 6.6. Rapid switching
to a lactate-free solution at the same pHe evoked net lactate efflux. Apparent permeability to
lactic acid can be calculated from the rate of pHi change, buffering capacity, and transmembrane
gradient. To confirm that the ensuing pHi response was not rate-limited by the speed of solution
exchange, one solution was labeled with fluorescein sulphonic acid (FS), and the rate of
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fluorescence-change indicated an exchange time constant of 2.6 s. Membrane permeability for
NH3 (added as 15 mM NH4Cl) acetic acid (Ac; 30 mM NaAcetate) and lactic acid (7.5-30 mM
NaLactate) were measured. Efflux of lactic acid was also probed in the presence of MCT
inhibitors AR-C (AR-C155858; 10 µM) and SR (SR13800; 10 µM).

Phosphofructokinase activity measurements
Enzymatic activity of phosphofructokinase was measured from pH 7.4 to 6.6 using a PFK
Activity Colorimetric Assay Kit (Sigma- MAK093).

Treatment model
C57BL/6 mice received 200mM of sodium bicarbonate water (bicarb) three days before
tumor injection and continued to receive bicarb water until the end of the experiment. Control
mice received regular tap water. A total of 1x105 B16 tumor cells were injected subcutaneously
in the left flank of C57BL/6 mice. Mice received intraperitoneal injections of 20 mg/kg of anti–
PD1 or on day three and continued to receive antibodies every three to four days until the end of
the experiment. Mice were humanely euthanized when tumors exceeded 1.5 cm in diameter,
appeared necrotic, or interfered with locomotion. Tumors were collected and weighed.

Adoptive T cell therapy
C57BL/6 mice received 200 mM of sodium bicarbonate water (bicarb) three days before
tumor injection and continued to receive bicarb water until the end of the experiment. Control
mice received regular tap water. A total of 1x105 B16 tumor cells were injected subcutaneously
in the left flank of C57BL/6 mice. Three days later, mice received a sublethal dose (600 cGy) of
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total body irradiation (TBI) administered by an X-ray irradiator. For adoptive transfer
experiments, T cells were isolated from the spleens of Pmel-1 mice and cultured in media
containing 10 IU/ml of IL-2 and 5ug/ml of gp10025-33 in vitro for five days. On day four
following tumor injections, 5x106 T cells were i.v. injected. IL-2 (2.5e5 IU) was given
intraperitoneally following T cell injection, continuing every 12 hours for three days, for a total
of six injections. Following this treatment, tumor size was measured and recorded every two
days.

Intratumoral pH measurements
pHe levels were measured using a microelectrode in B16 tumors treated with or without
200 mmol/L sodium bicarbonate therapy. Four separate animals were investigated under each
condition, and a minimum of four measurements were made in each tumor along a single needle
track.

Statistical analyses
As indicated, unpaired Mann–Whitney or two-sided Student t-tests were used to compare
between two treatment groups. All statistical evaluations of data were performed using the
GraphPad Prism Software. Statistical significance was achieved at P < 0.05.

Results
Activated effector T cells utilize glycolytic metabolism.
Metabolic pathways change, depending on T cell state and type396,402. It is known from
the literature that T cells switch to a glycolytic phenotype when they are activated to become
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effector T cells (Fig. 2A)403. This switch to glycolysis enables rapid expansion of the specific T
cell population by generating sufficient macromolecules and energy to sustain rapid
proliferation. In vitro, we can measure this switch to glycolytic metabolism using a Seahorse
Extracellular Flux Analyzer. We activated T cells isolated from WT C57 black-6 (BL/6) mice
with anti-CD3 and anti-CD28 for 48hrs and compared their metabolism to naïve (unactivated) T
cells. Comparatively, the activated T cells were much more metabolically active and exhibited
high levels of glycolysis when stimulated with glucose (Fig. 2B). This metabolic switch is likely
vital for effector function, and we, therefore, wanted to identify the role acid plays in effector
function and metabolism.

Acidic pH inhibits T cell effector function and metabolism.
Since solid tumors are unequivocally acidic and T cells are found in that acidic tumor
microenvironment, we measured T cell responses to activation in normal versus acidic pH. We
isolated T cells from BL/6, OT-I, OT-II, or Pmel-1 mice and cultured them with their specific
peptide activators (see Methods) for 48hrs under standard culture conditions in order to activate
the T cells. After activation, T cells were incubated in media at a range of pH from 7.4-6.6 for an
additional 24-48 hours, after which metabolites, cytokines, and live-cell metabolism were
measured. We measured glucose in the T cell media to quantify glucose consumption, and
glucose consumption decreased with decreasing pH (Fig. 3A), suggesting impairment of
glucose-dependent metabolism. The end product of glycolysis, lactate, was also measured and
irrespective of T cell type, lactate production always decreased with decreasing pH (Fig. 3B).
We corroborated the change in glycolytic metabolism with the Seahorse Flux analyzer, which
measures the extracellular acidification rate (ECAR) a proxy for glycolytic metabolism. ECAR
216

can be converted into proton production rate (PPR) when the buffering capacity of the media is
known. At pH 7.4, the PPR of BL/6 and OT-II T cells were 240 and 530 pmol H+/min (ca, 5-15
mmol/L cell), respectively, and PPR was significantly attenuated at pH 6.6 (Fig. 3C).
Oxidative phosphorylation as measured by basal oxygen consumption rate was slightly,
but significantly, increased at low pH (Fig. 3D) suggesting T cells compensate for the inhibition
of glycolysis by raising oxidative phosphorylation. However, this upregulation of oxidative
phosphorylation is not sufficient to maintain effector function. T cell effector function is
commonly quantified by IFN-γ production, as measured by ELISA. When T cells are exposed to
acidic pH, IFN-γ production is reduced, linking dependence of T cells on glycolytic metabolism
to their effector function. When glycolysis is low, IFN-γ is not transcribed, possibly due to
GAPDH binding to IFN-γ mRNA397. Further work (data not shown) confirmed that the decrease
in IFN-γ production was not due to acid inhibiting exocytosis of cytokines as the release of some
cytokines is increased with acidic pH. Therefore the lower the glycolytic rate, the less effector
function T cells have and as pH decreases the inhibition only increases.

Acid inhibits lactate transporters in T cells
Although we identified that acidic pH inhibits T cell metabolism and effector function,
the mechanism was unknown. We first hypothesized that acid-sensing proteins expressed by T
cells might be activated and inhibit the metabolic switch. However, our efforts in this area
proved fruitless. For example, KO mouse models of acid-sensing proteins such as G proteincoupled receptors TDAG-8 or OGR-1 exhibited the same inhibition of glycolysis and IFN- γ
when exposed to acidic pH. Other proteins which may play a role include those involved in acidbase flux across the cell membrane. This flux is critical for maintaining homeostasis and cellular
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function. Changes in flux can alter both extracellular pH (pHe) and intracellular pH (pHi).
Transporters are most commonly involved in acid-base flux and include the monocarboxylate
transporter family, MCT's which transport lactic acid out of cells. As T cells rely on glycolysis
for effector function, we confirmed by western blot that they express lactate transporters, MCT1
and MCT4, and this expression was not altered when exposed to acidic pH (Fig. 4A). Therefore,
inhibition of glycolysis in acid pH is not due to a lack of receptor expression necessary to
maintain a high glycolytic rate. We proceeded to measure if lactate efflux was altered in acidic
pH. To measure flux, we used a superfusion system to rapidly switch between lactate-containing
and lactate-free media at pHe 6.6, 6.9, or 7.4, while imaging T cells loaded with cSNARF-1 to
measure pHi. The rate of pHi change upon lactate removal can be used to calculate the
permeability coefficient of the cell membrane to lactate. We probed permeability at three
different pH conditions and saw lactate permeability at normal pH was 180μm/s in BL/6 T cells
compared to 40um/s at pH 6.6, with pH 6.9 being intermediate (Fig. 4B); therefore, acidic pH
reduces the permeability of lactate across T cell membrane.
Compared to cancer cells, the permeability of lactate was much slower in T cells, which
made us question whether lactate efflux was transporter mediated. However, after measuring
molecules which are freely permeable to cross the membrane; i.e. acetic acid and ammonia, we
observed that their permeabilities were even slower than that of lactate, ~110 and ~30 μm/s,
respectively. These data suggested that lactate efflux was an active process, likely utilizing
MCT’s. We tested the permeability of lactate in the presence of MCT1 inhibitors AR-C155858
and SR13800 (10 μM) and observed that lactic acid permeability was significantly reduced to 20
μm/s. The reduction in lactate permeability suggests acidic pH inhibits the ability of MCT
transporters to efflux lactic acid out of cells (Fig. 4C). MCT transporters bind lactate and a
218

proton intracellularly and then change conformation to release the lactate and a proton on the
extracellular side of the membrane. In an acidic environment, the proton gradient may be too
high to allow the proton to be released and the MCT cannot return to its starting conformation
and cannot efflux more lactate. Therefore, we can consider MCT-1 to be rate-limiting for T cell
effector function due to reduced transport kinetics. Alternatively, there may be an exofacial
histidine in murine MCT-1 that will inactivate activity when protonated, as is the case for His382
in human MCT-4404. Additionally, the buildup of intracellular lactate reduced glycolysis, through
thermodynamic inhibition of glycolytic enzymes. Exposing T cells to either D or L lactate
reduced their glycolytic rate, as measured by ECAR (Fig. 4D), L lactate more so due to
stereospecificity of lactate dehydrogenase (LDH) with ECAR inhibition at 21% of control
compared to 58% inhibition of control with D-Lactate. Thus, an acidic extracellular pH causes
lactate to build up intracellularly, contributing to inhibition of glycolysis.
Further, (data not shown) we have observed that incubating activated T cells at a pHe of
6.6 causes a decrease in the pHi of ~0.2pH. The drop in pHi would also contribute to a decreased
glycolytic rate as most glycolytic enzymes show a strong pH dependency405 e.g. Fig. 4E for
phosphofructokinase. The decrease in intracellular pH, from increased intracellular protons,
negatively affects glycolysis independent of intracellular lactate buildup. These protons can bind
to numerous protonatable targets in the cytoplasm, including glycolytic enzymes which can
result in reduced glycolytic rate (Fig. 4F).

Equation 1: Glycolytic rate (Jglyco) modelled as a function of pHi and intracellular [lactate].
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We can model the glycolytic rate as a function of pHi and intracellular lactate. Where K
and Q are the apparent binding constants for H+ and lactate ions, respectively, and n is the Hill
coefficient for the binding of H+ ions. It was possible to estimate cytoplasmic [lactate] at steadystate by knowing the transmembrane pH gradient, metabolic rate, and lactic acid permeability.
By best-fitting these data to Eq. 1, we described the relationship between pHi and glycolytic flux
in the absence of intracellular lactate, i.e., extract its pHi-dependence (Fig. 4F). This relationship
was found to be highly cooperative (n=4.39) and with half-maximal activation near resting pHi
(−log(K)=7.095), i.e., consistent with being an essential and robust modulatory influence. A Q of
2.1 mM best described the ensemble effect of end-product inhibition by lactate, i.e.,
accumulation of lactate to 2.1 mM would reduce glycolytic flux by half at a constant pHi.
Therefore, an acidic pHe affects both lactate transport and intracellular pH resulting in a
reduction in the glycolytic rate and function of effector T cells.

Reducing intratumoral acidity enhances immunotherapy efficacy
Although we have identified acidic pH as being inhibitory for T cell metabolism and
effector function, it is unclear whether altering pH would improve immunotherapy response. One
way to change intratumoral pH is through buffer therapy178,406,407. Using an in vivo mouse model
of melanoma, B16, mice were given tap or 200mM sodium bicarbonate water (buffer therapy).
The intratumoral pH of mice on buffer therapy, compared to control, was increased from ~ pH
6.75 to pH 7 (Fig. 5A) as measured by microelectrode. In previous studies, this buffering effect
was shown to be contained within the tumor and does not cause altered pH in other organs or the
vasculature. With an observable change in tumor pH using buffer therapy, we measured tumor
growth of B16 melanoma tumors in mice in the presence of both buffer therapy and checkpoint
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blockade, anti-PD-1. Checkpoint receptors, such as PD-1, are expressed on T cells, and
checkpoint therapy has shown response in some melanoma trials.

408

. The melanoma tumors in

mice did not respond to immunotherapy or buffer therapy alone. However, the combination of
buffer therapy and immunotherapy significantly reduced tumor volume and weight at endpoint
(Fig. 5B, C). The data suggest altered pH can improve T cell activity in tumors in combination
with checkpoint blockade. Similar results were observed in the anti-CTLA4 checkpoint blockade
(data not shown). T cells treated with checkpoint blockade had increased effector function as
measured by IFN-γ production. Production was not altered by buffer therapy suggesting the
improved tumor response was not due solely to increased IFN-γ production. Additionally, studies
using adoptive T cell transfer in syngeneic recipient mice bearing B16 melanomas showed
adoptive transfer alone caused significant reductions in the tumor growth rates, and an improved
anti-tumor response was evident, albeit not significant, in combination with bicarbonate (data not
shown). However, long-term follow up showed that the combination of bicarbonate + ACT led to
a long-term (censored at 120d) survival rate of 40%, compared to 10% for ACT alone (Fig. 5E),
which was significant (p=0.002). Importantly, the benefits of combined buffer therapy were
associated with significant increases in T cell persistence (Fig. 5F), a sensitive biomarker for
response to adoptive T cell therapy 409.

Discussion
Multiple factors regulate the response of cancers to checkpoint blockade or adoptive cell
transfer immune therapies. In this study, our findings illuminate a mechanism by which tumors
can inhibit immune surveillance by inhibiting T cells directly. We have shown that T cells have
impaired glycolytic metabolism and effector function in an acidic pH, such as is found in the
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tumor microenvironment. pH in the tumor microenvironment can be altered using buffers, and
we have observed this improves responses to both checkpoint blockade and adoptive cell
transfer. We showed low pH blocks IFN-γ production and this is associated with a
downregulation of glycolysis, which is achieved in multiple ways. The acidic tumors generate a
high proton concentration on the extracellular side of the T cell membrane, which reduces
activity of MCT transporters. MCT’s need to release a proton when exporting lactate out of the
cell; otherwise, the transporters cannot return to their starting confirmation to enable transport of
more lactate. This transporter inhibition by low pH causes a build-up intracellularly of both
lactate and protons. We measured a reduced pHi in T cells when placed in an acidic pHe, even in
the absence of lactate. The reduced pHi allosterically inhibits multiple glycolytic enzymes
resulting in a reduction of glycolytic rate. The lactate build-up results in thermodynamic
inhibition of the final step, lactate dehydrogenase, which also reduces glycolytic rate in the T
cells. We have demonstrated the reduction in glycolysis and effector function in T cells is
directly due to the effect of acidosis on lactate export. Subsequently, we tested if altering pH in
the tumor enhances T cell effector function.
We utilized buffer therapy as it had been shown previously to work in vivo in mouse
models, in both raising intratumoral pH but also reducing metastasis and primary tumor volume.
Despite this promise, it has yet to be successful in patients. The lack of success is due to the
inability of patients to tolerate the proposed amount of sodium bicarbonate needed to alter the
tumor pH. In our B16 melanoma model, we saw increased intratumoral pH with buffer therapy,
which synergized with both checkpoint blockade and adoptive cell therapy. Therefore, because
this combination works, we need alternative therapies which can raise intratumoral pH and be
combined with immunotherapy. New combination strategies could include approaches to target
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carbonic anhydrases, such as CA-IX which is often expressed by cancer to hydrate CO2 into H+
and HCO3- resulting in acidification of the tumor milieu

170

. Alternatively, targeting glycolytic

enzymes and transporters such as LDH or MCT may enable reduction of acidosis in the tumor.
However, targeting these will likely also target the glycolytic enzymes that T cells require for
their effector function.
Although acidosis commonly occurs in tumors, tumors are not the normal state of the
body, and this made us ponder why T cells would have such a profound and robust impingement
when in acidic environments. Physicians and researchers have stated that wounds can be acidic
and pH changes as wounds heal. Potentially, T cells are recruited to wounds but not activated
until the wound is at a particular state410 as determined by the pH. Additionally, pH may be
involved in adaptive immunity. Further studies on this are being undertaken by Estrella,
Swietach, and Wu et al. who have observed that lymph nodes in mice harbor acidic
microenvironments in the T-cell zone. T cells are often activated in the lymph node by antigenpresenting cells, and low pH could be utilized by the lymph node to prevent cytotoxic activation
before the T cells migrate out to their needed site. Human studies on lymph node pH have yet to
be pursued, but this would provide an answer as to the physiological reason behind T cell
inhibition by acid. Overall, we need to consider acidity as an important tumor-associated
phenotype when trying to treat cancer, as it both benefits and inhibits multiple cell types
resulting in tumor growth and treatment resistance.
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Figure 1: Current status of immunotherapy in breast cancer. Adapted from 2017 AACR – CCR Focus
Breast Cancer Paper411
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Figure 2: Activated T cells switch to glycolytic metabolism. A: Schematic of metabolic profile as T cell
state changes once activated. Naïve T cells switch from metabolically quiescent, predominantly OXPHOS
driven, to glycolysis once activated as effector T cells. As T cells become memory phenotype metabolism
switches back to more quiescent with reliance on fatty acid oxidation or glutaminolysis, unclear as of yet.
(Adapted from Pearce, E. et al. 2013. Science. "Fueling Immunity: Insights into Metabolism and Lymphocyte
Function"396.) Created with biorender.com. B: Glycolytic stress test of activated vs. non-activated BL/6 murine
T cells. Activated T cells are more metabolically active and have a substantial reliance on glycolytic
metabolism as seen by an increase in extracellular acidification with stimulation by glucose. N=5 per group.
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Figure 3: Extracellular pH influences activation and metabolism of T cells A: Glucose consumption of
Pmel-1 and OT-1 T cells at different pHe B: Lactate production of Pmel-1 and OT-1 T cells at different pHe C:
Seahorse analysis of proton production rate, linked to glycolytic rate, in B6 and OT-II T cells at neutral and
acidic pH D: Seahorse analysis of basal oxygen consumption rate, a measurement of reliance on OXPHOS, in
B6 and OT-II T cells at neutral and acidic pH E: IFN-γ production as measured by ELISA of 4 different types
of activated T cells at different pHe.
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Figure 4: Mechanism of T cell glycolysis inhibition by low pH. A: Western blot of B6 T cell lysate of
lactate transporters, MCT1 and MCT4, at neutral and acidic pH. pH B: Lactate efflux, as measured by a
change in pHi using superfusion system, decreases with increasing extracellular acidity. Mean± SEM of 10
cells per condition. C: T cell membrane permeability of freely permeable ammonia and acetic acid, and
transporter driven lactate at different pHe. Permeability reduced with MCT inhibitor AR-C (AR-C155858; 10
µM) and SR (SR13800; 10 µM) to levels similar to acidic pH. Mean± SEM of 7-15 cells per condition. D.
Glycolysis, as measured by extracellular acidification of T cells in Seahorse Flux Analyzer, reduces in the
presence of lactate, more significant reduction by L-lactate due to stereospecificity of LDH. E:
Phosphofructokinase, a glycolytic enzyme, has reduced activity as pH decreases. F: Relationship between
intracellular pH and rate of glycolysis, in lactate free conditions.
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Figure 5: Effect of buffer therapy on the efficacy of immunotherapy. A: Sodium bicarbonate buffer
therapy in drinking water increases pHe of B16 melanoma tumors. N=4 per group, n=4 measurements per
tumor p<0.001. B. Bicarbonate coupled with anti-PD1 improved immunotherapy efficacy by reducing tumor
size of B16 tumors. N=10 per group, p<0.01. C. Bicarbonate combined with anti-PD1 therapy in B16
melanoma tumors significantly reduced tumor weight. N=10 per group, p<0.05. D. IFN- γ production by T
cells, measured by ELISA, is unaffected by bicarbonate therapy but increases with anti-PD1 treatment. E.
Adoptive T cell transfer with bicarbonate treatment has a significant survival advantage compared to adoptive
T cell transfer alone. N=10 per group, log-rank P=0.002. F: T cell persistence increases with buffer therapy in
adoptive T cell transfer (p<0.05).
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Abstract
Significant prior work has shown a strong correlation between tumor acidity and
increased invasion and metastasis, and that neutralization of tumor acidity can prevent formation
of metastases in many systems. However, correlation is not causation. In this study, we test the
hypothesis that acidosis can systemically cause metastasis by induction of acid production
though expression of plasma membrane proton exporters. We designed two “gain-of-function”
systems to generate acid production independent of metabolic acid production. We engineered
acid-exporting cells by overexpressing a yeast proton pump, H-ATPase (PMA1), or a proton
exporting exofacial human carbonic anhydrase 9 (CA-IX). In vitro studies showed expression of
either transporter into non-metastatic human cancer cell lines enhanced aerobic glycolysis,
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migration, and invasion in vitro. In vivo, the acid-producing cells formed higher grade tumors
with higher rates of spontaneous and experimental metastases. Neutralizing the acidity of these
tumors with oral buffers reduced the incidence of metastases. Therefore, increased rates of H+
export can drive increased aerobic glycolysis (the Warburg Effect) and convert non-metastatic
cells into those that form extensive metastasis. Thus, we propose that variables associated with
metastasis may act via increased acid production, which can be systemic causal of metastasis.

Introduction
One of the major issues faced in cancer research is an inability to treat and prevent
metastatic disease412. Determining what is systemically causal of cancer metastasis could,
therefore, be targeted to help patient outcome413. Once patients are diagnosed with metastasis, no
matter the type of cancer, it is often fatal. For example, while the five-year survival rate for
localized breast cancer is over 85%, that for metastatic breast cancer is only 27%414. We do not
know if or when cancer will metastasize, but specific phenotypes are associated with an
increased incidence of metastases. Mechanistic studies of these associated phenotypes can
identify their causes and consequences and thus aid in generating preventative or curative
metastasis treatments.
Metastasis occurs via discrete steps, viz. disassociation from the primary tumor and
migration into the heme- or lymph- vasculature (intravasation), followed by localization into a
host organ (extravasation), and successful colonization 415. Phenotypes associated with increased
metastasis can differ between cancer types, but include an epithelial-mesenchymal transition
(EMT)416-418, resistance to anoikis

419,420

, enhanced motility421 hypoxia422,423, and elevated

aerobic glycolysis 424,425. Cells who have undergone an EMT have increased rates of all 3 steps:
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intravasation, extravasation, and colonization. Markers of EMT include increased expression of
vimentin, N-cadherin426, and Sox2

427

. Metastatic cells resist anoikis, a type of apoptosis that

occurs after detachment from basement membrane, to resist cell death. In melanoma and breast
cancers, adapting cells to growth under acidic conditions has been shown to render them resistant
to anoikis

196,428

. Resistance to anoikis is associated with stem cell-like properties and these can

be measured in vitro by an increased ability to form spheroids

429,430

. Another phenotype

associated with metastasis is enhanced motility, which can be measured in vitro using both
migration and invasion assays. Numerous studies have shown a positive association between in
vitro motility, and in vivo metastasis

431-433

. Tumors that maintain an acidic extracellular pH,

pHe, have an enhanced ability to invade and colonize 60,199,201, which has been formulated into an
“acid-mediated invasion” hypothesis 156.
Aerobic glycolysis is both a hallmark of cancer, and of metastasis 1. Increased glycolytic
rates in patient tumors correlate with tumor aggressiveness and poor prognosis17. There are
many hypotheses as to why cancer cells prefer aerobic glycolysis, which is energetically
inefficient. Relevant to the current work, we have proposed that there is a strong Darwinian
selection for cells that produce acid which allows them to outcompete their neighbors61.
The benefits of acid production to the fitness of cancer are numerous. For example,
acidity enhances degradation of the extracellular matrix via release of cathepsins or activation of
MMP-14114.

Also, tumor acidity inhibits immune surveillance434. Most studies have equated

low pH with increased glycolysis and the production and export of lactic acid, but there are other
causes of acidosis in the tumor microenvironment. As tumors grow, the vasculature does not
form at the same rate causing a build-up of waste in the tumor microenvironment, reducing
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extracellular pH, pHe. Even when vasculature forms, it is often leaky due to an inability of
tumors to stimulate growth of functioning blood vessels435. Alternatively, extracellular acid can
be generated by exacerbating the intra- to extracellular pH gradient via expression of proton
exporting exporters; e.g. sodium hydrogen antiporter436 and carbonic anhydrases437. Carbonic
anhydrases hydrate CO2 into protons and bicarbonate. The CA-IX isoform is commonly
upregulated in cancer, for example, in astrocytoma and breast where expression is correlated
with worse patient prognosis and outcome. CA-IX has a slightly different structure to other
carbonic anhydrases enabling it to maintain enzyme activity at lower pH171 and act as pH stat to
maintain an acidic tumor pHe170.

Additionally, CA-IX has clearly been associated with

increased invasion and metastasis in a number of systems115,438 . Neutralizing acidity in the
tumor, by using buffer therapy, can reduce metastasis in multiple mouse models30,178. Despite
the pre-clinical promise, buffer therapy has proven intolerable in human patients in clinical trials,
NCT01350583, NCT01198821, and NCT01846429. Hence, the above evidence has shown an
acidic tumor pHe is associated with increased metastasis, that neutralization of tumor acidity can
prevent metastases, and acidic pHe may be related to the expression of CA-IX. However, to
date, no study has addressed if there is a causal relationship between acidity and metastasis.

In this study, we present evidence that acid production can induce cancer metastasis.
Specifically, we demonstrate by engineering cancer cells to export acid through the expression of
membrane acid exporters leads to upregulation of proximal causes of metastasis. These include
increased glycolysis, resistance to anoikis, increased migration and invasion in vitro, and
increased experimental and spontaneous metastasis in vivo. Neutralizing acidity with buffer
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therapy reduced metastasis. Hence, we have identified acid production as an independent
variable that is systemically causal of metastasis.

Materials and Methods
Construction of stable cell lines
Plasmids. Yeast plasma membrane ATPase 1 (PMA1) cDNA construct was designed based on
the sequence (Accession Number: NM_001180873; Saccharomyces cerevisiae S288c PMA1).
The codons were optimized for the suitable expression in mammalian cells and restriction
enzyme sequences Hind III and Xho I were inserted at the 5’ and 3’ ends of the full-length
sequence, respectively. The fully designed DNA sequence was commercially synthesized (Blue
Heron Biotechnology, Bothell, WA, 98021). This was cloned into pcDNA3.1/Zeo (+) vector in
which PMA1 gene expression was driven under the CMV promoter. The sequence of the
pcDNA/PMA1 construct and the identity of the parental cell line were confirmed by the
molecular genomics core facility (Moffitt Research Institute, Tampa, FL). Carbonic anhydrase 9
(CA9)

construct

was

designed

by

Origene

based

on

the

sequence(Accession

Number:NM_001216 ; Homo sapiens) and cloned into a pCMV6 vector (PS10001, Origene,
MD) to form pCMV6/CAIX vectors (CQ10630, RC204839 subclone, Origene, MD)in which
CA9 gene expression was driven under the CMV promoter.
Cell lines. The MCF-7 cells and HEK 293 cells as transfection host cell lines were acquired
from American Type Culture Collection (ATCC HTB-22, Manassas, VA) and maintained in
RPMI media 1640 (Life Technologies Gibco®, 11875-093) supplemented with 10% FBS
(Hyclone Laboratories, UT) under standard cell culture conditions. The U2-OS cell line was a
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gift from Jillaina Menth, Moffitt Cancer Centre Translational Research Core, and maintained in
RPMI media 1640 (Life Technologies Gibco®, 11875-093) supplemented with 10% FBS
(Hyclone Laboratories, UT) under standard cell culture conditions. The MCF-7 cells were
transfected with empty pcDNA, pcDNA/PMA1, pCMV6 (PS10001, Origene, MD) and
pCMV6/CAIX vectors (CQ10630, RC204839 subclone, Origene, MD) respectively, resulted in
MCF-7/MOCK-1 cells, MCF-7/PMA1, MCF-7/MOCK-2 and MCF-7/CAIX cell lines by
standard clonogenic stable cell construction procedures using Fugene HD (Promega, E 2311).
The U2-OS and HEK-293 cells transfected with empty pCMV6 (PS10001, Origene, MD) and
pCMV6/CAIX vectors (CQ10630, RC204839 subclone, Origene, MD) respectively, resulted in
U2-OS/MOCK-2, HEK/MOCK-2 and U2-OS/CA-IX and HEK/CAIX clones. Briefly, a number
of individual single clones were selected in the media containing 300 µg/ml zeocin (Invitrogen,
450430, Carlsbad, CA), or 300 µg/ml G418 and stable expression in individual clones were
verified using western blotting. Cell lines were tested for mycoplasma using MycoAlert assay
(Lonza).

Spheroid formation
Spheroids were formed as previously described

439

. Briefly, cells were suspended in

Perfecta 3D hanging drop plates (HDP1096, 3D Biomatrix, MI) at 25K cells/40ul droplet.
Spheroids were allowed to form for 5 days and then centrifuged at 450rpm, with no brake, into
media-containing Costar Ultra low attachment U-bottom 96-well plates (CLS3474, Corning,
NY). Spheroids were imaged in the Celigo Imaging Cytometer (Nexcelom Bioscience, MA)
using bright field imaging single colony verification analysis.
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Western blotting
Chemiluminescence. The cell membrane protein samples were collected using Mem-PER
eukaryotic membrane protein extraction reagent kit (Thermo Scientific, 89826, MA) according
to the protocol instruction, and the protein samples were further purified and concentrated by
Pierce SDS-PAGE sample prep kit (Thermo Scientific, 89888). Thirty micrograms of protein
per sample was separated on polyacrylamide-SDS gels and electrophoretically transferred to
nitrocellulose membranes. Membranes were incubated with primary antibody against PMA1
(1:1000, Abcam, ab4645), and GAPDH (1:1000, Santa Cruz Biotechnology, TX, se-25778). For
visualization, horseradish peroxidase (HRP)-conjugated secondary antibodies: Goat anti-rabbit
IgG HRP and goat anti-mouse IgG HRP, followed by ECL kit (Thermo Scientific, 32209) were
used.
Fluorescence. Fifteen µg of protein per sample was separated on a BioRad Mini-protein 4-15%
precast 12 well 20 µl gels (4561085, Bio-Rad, CA) and electrophoretically transferred to
Odyssey

Nitrocellulose membrane (P/N 926-31092, LI-COR, NE). Membranes were blocked

with Odyssey TBS Blocking Buffer ( P/N 927-50000, LI-COR, NE) and incubated with primary
antibody against CA-IX(1:1000, M75 mouse monoclonal CA-IX, Bioscience Slovakia), ER
alpha ( 1:2000, Rabbit polyclonal ab 75635, Abcam), rabbit Anti-CA12 antibody [EPR14861] C-terminal (ab195233), rabbit Anti-Carbonic Anhydrase II antibody [EPR5195] (ab124687), βActin(1:2000, (8H10D10) Mouse mAb #3700- Cell Signaling), GAPDH (1:4000, rabbit
monoclonal ab 181602, Abcam). For visualization, IRDye Fluorescent secondary antibodies (LICOR) were used: IRDye 680RD Goat Anti-mouse IgG (H+L), IRDye 680RD Donkey anti-rabbit
IgG (H+L), IRDye 800CW goat anti- mouse IgG(H+L) and IRDye 800CW donkey anti-rabbit
IgG(H+L). Membranes were imaged on LI-COR Odyssey Blot Imager and quantified using
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Image Studio Version 2.1(LI-COR). Uncropped versions of western blots are available in
Supplemental.

Immunocytochemistry
Cells were grown on glass coverslips and fixed in 4% paraformaldehyde (Sigma-Aldrich)
for 10 min at room temperature. Cells were blocked in 5% BSA for 1hr at room temperature.
Cells were stained with the PMA1 antibody (1:100; SC-33735, Santa Cruz Biotechnology) or
CA-IX antibody for 2 hours (1:500, ab184630, Abcam) and washed in PBS. Cells were further
incubated for 1 h with secondary anti-rabbit-Alexa Fluor 594 antibody (1:2000; A11072,
Invitrogen) or anti-mouse-Alexa Fluor 594(1:2000; A11005, Invitrogen) and additionally
incubated in WGA, cell membrane marker (W6748, Invitrogen) for 10 min on ice. The cells
were mounted for fluorescence with DAPI (H-1200, Vector). The slides were viewed by Leica
inverted SP5 AOBS confocal microscope, and micrographs were taken and images were
subsequently acquired in the Moffitt Analytic Microscopy Core Facility by using dual
photomultiplier tube detectors and LAS AF software (Leica Microsystems). For detection of
intracellular PMA1, cells were fixed and permeabilized with 1:1 mixture of methanol and
acetone, and immunostained with PMA1 antibody for 1h, followed by 1 hour of incubation with
the secondary anti-rabbit Alexa488 antibody (Molecular Probes, Invitrogen). The cells were
mounted and viewed by fluorescence microscopy.

Proliferation rate assay
Cells were cultured in a 24-well plate under normal cell culture conditions for 24, 48, 72,
96 hours and the cell number and viability were determined with a trypan blue dye by using the
Countess automated cell counter (Invitrogen).
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Oxygen consumption and proton production rate measurements (OCR and PPR)
Real-time oxygen consumption (OCR) and proton production rate (PPR) were measured
by using the Seahorse Extracellular Flux (XFe-96) Analyzer (Seahorse Bioscience, Chicopee,
MA). The cells were seeded in an XFe-96 microplate (Seahorse, V3-PET, 101104-004) in
normal growth media overnight. The growth media were replaced with DMEM powder base
media ( Sigma D5030) supplemented with 1.85g/L sodium chloride and 1mM glutamine, and the
cells were incubated in the media in the absence of glucose, when testing glycolysis, in a nonCO2 incubator for one hour prior to the measurement. PPR and OCR were measured in the
absence of glucose associated with the non-glycolytic activity, followed two sequential injections
of D-glucose (6mM) and oligomycin (1µM) in real time, which are associated with glycolytic
activity and glycolytic capacity (reserve). The mitochondrial stress test was also used where cells
were incubated in glucose (5.5mM) and glutamine (1mM) containing media and basal OCR and
PPR measured, prior to sequential injection of Oligomycin (1 µM), associated with ATP linked
OCR, FCCP(1µM) associated with mitochondrial reserve capacity and Rotenone/Antimycin A
(1µM). Following the measurements, protein concentrations were determined in situ for each
well using a standard BCA protein assay (Thermo Scientific Pierce). The OCR and PPR values
were normalized to µg protein. Results were also normalized using Celigo High Throughput
Micro-Well Imaging Cytometer (Nexcelom Bioscience) by bright field direct cell counting and
normalized per 10K cells prior to assay.

Glucose consumption and lactate production assay
Figure 1: Cells were seeded in a 6-well plate in growth media containing 10% FBS. Once cells
reached 90% confluence, the growth media were removed, and the cells were washed twice in
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PBS and incubated in serum-free and phenol-red free media for 24 h. The media were collected
from 24 h incubation for both glucose consumption and lactate production assays. The cells were
trypsinized and the cell densities were determined. Glucose quantification was conducted using
glucose colorimetric/fluorometric assay kit (BioVision, K606-100) as described per
manufacturer instruction. The lactate assay kit II (BioVision, K627-100) was used to measure L
(+)-Lactate in the culture media according to the manufacturer’s instructions. Data were
normalized by cell density per well and were reported as lactate production and glucose
consumption as a percentage of control (MCF-7 or Mock).
Figure 3: Cells were seeded in a 96-well plate in the growth media containing 10% FBS. Once
cells reached 90% confluence, the growth media were removed, and the cells were washed twice
in PBS and media was replaced for 24 h. The media were collected from 24 h incubation for both
glucose consumption and lactate production assays. The cells were then trypsinized and the cell
densities were determined. Glucose quantification was conducted using glucose bioluminescent
assay kit (Glucose Glo Assay, Promega) as described per manufacturer instruction. The lactate
assay kit (Lactate Assay kit, Sigma Aldrich) was used to measure L (+)-Lactate in the culture
media according to the manufacturer’s instructions. Data were normalized by cell density per
well and were reported as lactate production and glucose consumption per ug protein.

Glucose uptake radioactive Aassay
Cells were seeded in 24 well plates to 80% confluence. Cells were incubated for 1hr with
1 µCi of Deoxy-D-glucose, 2-[1,2-3H(N)] (NET549250UC, Perkin Elmer, MA) at 37◦. Cells
were washed 2 x DPBS and lysed with 300ul of NaOH, cell extract was added to a vial with 6ml
of Eoscint XR scintillation liquid (LS-272, National Diagnostics, GA). Uptake was quantified by
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measuring 3H in a Perkin Elmer TriCarb scintillation counter and normalizing to protein
concentration.

YSI 2950D biochemical analysis of lactate
Cells were seeded in a 96-well plate in the growth media containing 10% FBS. Once cells
reached 90% confluence, the growth media were removed, and the cells were washed twice in
PBS and media was replaced for 24 h or 48hr. The media were collected from 24 h & 48hr
incubation for lactate production measurement. The cell densities per well were determined by
Celligo imaging cytometer brightfield cell count application. Lactate quantification was
measured by the YSI. Data were normalized by relative cell number and were reported as lactate
production in g/L/per cell.

Untargeted metabolomics
Samples were prepared according to Beth Israel Deaconess Medical Centre Mass
Spectrometry Core and run on a Thermo QExactive Plus/HF Orbitrap LC-MS/MS. Briefly, cells
were grown to 80% confluence in 10cm2 dishes. Cells were changed into fresh media two hours
prior to collection, media was aspirated, cells were washed in ice cold PBS, and 1ml of 80%
methanol (-80°C) added to plate on dry ice, then transferred to -80°C freezer for 15 minutes. The
cell plate was scraped on dry ice and contents collected. Sample was spun in cold centrifuge at
max speed for 20min and supernatant removed. Supernatant was dried in speed vac for 5hrs then
stored at -80°C. Before Mass spec analysis, samples were resuspended in HPLC grade water
relative to protein concentration. Data were analysed using Metaboanalyst online software, there
was no data filtering, and data were normalized by sum of all metabolites per sample.
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Intracellular pHi
Solutions and media. (i) Solutions for Seahorse experiments: 2mM HEPES, 2mM MES, 5.3 mM
KCl, 5.6 mM NaPhosphate, 11 mM glucose, 133 mM NaCl, 0.4 mM MgCl2, 0.42 mM CaCl2,
titrated to given pH with NaOH. For reduced Cl- experiments, 133 mM NaCl was replaced with
133 mM NaGluconate and MgCl2 and CaCl2 were raised to 0.74 mM and 1.46 mM, respectively,
to account for gluconate-divalent binding. Calibration solutions for nigericin: 145 mM KCl, 1
mM MgCl2, 0.5 mM EGTA, 10 mM HEPES, 10 mM MES and adjusted with NaOH to required
pH. pHe media to measure pHi: Solution A: 125mM NaCl, 4.5mM KCl, 1mM CaCl2, 1mM
MgCl2, 11mM glucose base media. Split solution A into two parts- Solution B: 22mM HCO3and Solution C: 22mM NaCl. Mix B&C as follows- 40ml B & 0ml C= 22mM HCO3- (pH7.41),
20ml B & 20ml C =11mM HCO3- (pH7.11), 10ml B & 30ml C=5.5mM HCO3- (pH6.81), and
4ml B & 36ml C=2.2mM(pH6.41).
Cells were loaded with 10uM cSNARF1 and 2.7uM Hoechst 33342 for 10mins at 37º.
Cells were washed in neutral pH media and imaged in various pHe media (6.4-7.4) on Leica SP5
Confocal Microscopy x40 objective.
Image analysis. Cytoplasmic pH was measured by gating pixels according to a threshold level of
Hoechst signal within cSNARF1-positive pixels. Fluorescence at 580 and 640 nm was averaged,
background offset and ratioed for each particle representing a cell.

Cell invasion and migration assay in vitro
In vitro cell motility and invasiveness were measured by methods as previously reported
with some modifications

30.

The motility change was measured by the circular wound healing
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assay using OrisTM Cell Migration Assay Kit (Platypus, CMAU101). Cells were plated on a 96well plate at 1 x 106 cells/ml while a cell seeding stopper masker the circular area at the center of
each well. The cell seeding stoppers were removed 24 hours after the plating and cells were
cultured a further 30 hours to monitor the closing of the cell-free area (wound area). The area
covered by live cells was measured by labeling cells with Calcein-AM (Life Technology, C3099)
and analyzing microscopic images (2.5x) by Image J (NIH). The smaller wound size represents
the higher motility.
Wound healing scratch assay was used to measure motility into CA-IX clones. 96-well
plates were seeded with 1 x 106 cells/ml per well in 10% FBS, 1% PenStrep RPMI-1640 and
incubated overnight. The plate was uniformly scratched with Essen Bioscience 96 Woundmaker,
media was removed, and the plate washed with DPBS and then 200ul of media was added to
each well. The wound was imaged on Celigo Imaging Cytometer and the number of cells that
migrated into the wound was quantified by direct bright field cell counting at 0, 24, 48hr.
Cell invasiveness was measured by monitoring cells escaping from Matrigel (Becton
Dickenson, 356231). Cells were suspended in 50% Matrigel in serum-free RPMI-1640 at 1 x 107
cells/ml. A Matrigel droplet (volume = 5 µl) was placed on each well of a 24-well plate. The
Matrigel was solidified by incubating at 37°C overnight and then FBS-containing normal growth
media was added. The cells escaped from the Matrigel droplet were monitored in real-time by
using the IncuCyte ZOOM system (Essen BioScience) or Celigo Imaging Cytometer (Nexcelom
Bioscience, MA). After 7 days of culture, the cell expansion from the droplets was quantified by
Celigo single colony verification algorithm or Image J after fixing cells in 3.7 % formaldehyde
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and staining in crystal violet solution. The larger area occupied by cells represents the higher
invasion potential.
Normalization of invasion and migration assays.
The results of invasion and migration assays were normalized by the proliferation rates of
the cells. Proliferation rates were calculated by a linear fit of cell growth, 48 hours after seeding
the cells (See Figure S3) and weighted by the standards error. The normalization was carried out
in order to eliminate inherent differences between clones making it possible to compare them. In
the case of the invasion assay, final growth was divided by the proliferation rate of each of the
cells. For the migration assay (i.e. wound healing assay), the relative healed area was divided by
its corresponding growth rate and then multiplied by the growth rate of the mock cells. This
allowed comparison between the normalized healed areas of each clone, to one of the mock cells.
We used the Matlab R2012a curve fitting toolbox (The MathWorks, MA). Matlab code is
available in the Supplemental materials.

SCID mice
Six-week-old female SCID Beige mice were purchased from Charles River Laboratories.
Mice were given a week to acclimate to the animal facility before they were studied. To
minimize the risk of any exogenous infection, the SCID mice were maintained and cared for in a
sterile, static micro-isolation cage. Mice received irradiated food (Harlan Laboratories) and
sterile water ad libitum. All animal experiments were performed under a protocol approved by
the University of South Florida Institutional Animal Care and Use Committee.
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Metastasis assays in vivo
Since MCF-7 cells are estrogen-dependent for tumor formation, estrogen pellets, 17 β
estradiol, 0.72 mg/pellet, 60-day release (Innovative Research of America, SE-121) were
subcutaneously implanted in the shoulder region of the mice two days prior to tumor inoculation.
For the spontaneous metastasis study with MCF-7/MOCK-2 or MCF-7/ CA-IX M6 cells, mice
were given 200nM 17 β estradiol in drinking water to try and prevent adverse side effects of
pellet use, including balder stones and urinary tract infections.
For the experimental metastasis, SCID mice were injected through tail veins with 1 ×
106 cells in 200 µl of PBS solution (either MCF-7/MOCK-1 , MCF-7/PMA1-C1, MCF7/MOCK-2, MCF-7/CAIX M1 or MCF-7/CAIX M6 cells). Three months after injection of the
cancer cells, the mice were euthanized, and the lung tissues were surgically excised, fixed, and
stained with hematoxylin and eosin (HE). Lung sections (at least three histologic sections for
each lung specimen) were examined for metastatic nodules under a light microscope by a breast
cancer pathologist (A.L or M.M.B) who was blinded to identifiers.
For the spontaneous metastasis studies, approximately 10×106 cells (either MCF7/MOCK-1 and MCF-7/PMA1-C1, or MCF-7/MOCK-2 and MCF-7/CAIX M6 cells) in 100 µl
of PBS +100 µl of Matrigel were injected into the mammary fat pads of mice. Once tumors
reached approximately 400 mm3, the tumors were resected, fixed, and stained with H&E, PMA1
or CA-IX antibody. Three months after resection, the mice were sacrificed, and lung sections
were examined for lung metastases. The tumors were measured twice every week throughout the
study with a digital caliper and volume values were calculated with the formula V=
(Length×Width2)/2. The body weights were monitored twice a week throughout the study.
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Treatment model
Female SCID Beige mice received 200mmol/L of sodium bicarbonate water 2 days prior
to tail vein injection for experimental metastasis study. Mice continued receiving bicarbonate
water until the end of the experiment. Control mice received regular tap water. Since MCF-7
cells are estrogen-dependent for tumor formation, estrogen pellets, 17 β-estradiol, 0.36
mg/pellet, 90-day release (Innovative Research of America, SE-121) were subcutaneously
implanted in the shoulder region of the mice two days prior to tumor inoculation. For the
experimental metastasis, SCID mice were injected through tail veins with 1 × 106 cells in 200
µl of PBS solution (MCF-7/MOCK-2 and MCF-7/CAIX M6 cells). Once MCF-7/CAIX M6
control group had observable lung metastasis by T2 MRI (~74 days), mice were humanely
euthanized and lungs and kidney collected.

Histology
The tissues were harvested, fixed in 10% neutral buffered formalin (Thermo Scientific),
processed, and embedded in paraffin. Tissue sections (4 µm) were prepared and stained with
H&E in the Moffitt Cancer Center Tissue Core. The histological slides of resected primary breast
tumor xenografts from MCF-7/MOCK-1 or MCF-7/PMA1-C1 groups, and MCF-7/MOCK-2,
MCF-7/CAIX M1 and MCF-7/CAIX M6 groups. were blindly examined under a light
microscope by a pathologist (A.L or M.M.B) for tumor grades using the most common grading
system: G1: well differentiated (low grade); G2: moderately differentiated (intermediate grade)
G3: poorly differentiated (high grade); G4: undifferentiated (very high grade), as assessed
according to histological features of stromal hypercellularity, atypia, stromal mitotic activity,
presence of stromal over-growth and mitosis, necrosis, spindle cells differential and chromatin
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activity. Tumor burden in the lung was measured by Aperio ImageScope (Leica Biosystems, IL)
and calculated as % of total lung tissue and compared between groups. Tumors were drawn
around by hand using the Aperio software and confirmed by a pathologist (M.M.B), % area of
tumor in lungs was then calculated by comparing the area of total lung tissue to the area of the
tumor within lungs.

Immunohistochemical (IHC) staining
The cross-sections were stained with various antibodies as per normal laboratory protocol
in the Moffitt Tissue Core Histology Facility. Positive and negative controls were used for each
antibody staining and staining condition was optimized for each antibody. The antibodies were
utilized in this study as follows: rabbit anti-Saccharomyces cerevisiae PMA1 (sc-33735, Santa
Cruz Biotechnology); rabbit anti-human CA-IX (ab15086, Abcam, Cambridge, MA); rabbit antihuman MCT1 (sc-50324, Santa Cruz, CA); rabbit anti-human GLUT1 (ab15309, Abcam,
Cambridge, MA); rabbit anti-human NHE1 (sc-28758, Santa Cruz, CA); rabbit anti-human ER(
#RM9101,ThermoFisher Scientific, MA). Histological stained slides were scanned using the
Aperio ScanScope XT digital slide scanner and positivity analysis for each target gene staining
was carried out using Aperio ImageScope V 10.2.1.2314 software. Positive cell percentage was
calculated for PMA1, CA9, MCT1, GLUT1, and NHE1 expression on the entire tissue crosssection using algorithm membrane 9 in which positive cells include the cells with (3+) strong;
(2+) medium; (1+) weak membrane intensity staining.
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RNA analyses in formalin-fixed, paraffin-embedded (FFPE) tissue
FFPE tissue samples were cut in 10µm- thick sections on a microtome, and
deparaffinized by deparaffinization solution (Qiagen, 19093). Total RNA was extracted from
deparaffinized FFPE sections with the miRNeasy FFPE kit (Qiagen, 217504) following the
manufacturer’s protocol. Real-time qRT-PCR analyses for PMA1 mRNA were described above
in the qRT-PCR section. Experimental Ct values from PMA1 amplification were normalized with
GAPDH Ct values and were expressed relative to MCF-7/MOCK-1 control Ct values.

Statistical analyses
A two-tailed unpaired student T-test or Welch’s T-test was employed to determine
statistical significance. Ordinary one-way ANOVA with Geisser Greenhouse correction and
Tukey’s Multiple Comparison test, with a single pooled variance. A p-value of less than 0.05
was considered statistically significant or otherwise indicated. Kaplan Meier Curve was used to
analyze overall survival in mouse models with Log-Rank Test curve comparison.

Data and code availability
The authors declare that the data supporting the findings of this study are available within
the paper and its Supplemental information files. The code is available in the Supplemental data.
Figures with raw data associated include Fig. 1G and 1H, associated raw data are found in
Supplemental figures S4 and S5.
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Results
Over-expression of yeast proton pump PMA1 in cancer cells
To test our hypothesis that acid is systemically causal of cancer metastasis, we
engineered lowly-glycolytic, non-invasive, and non-metastatic MCF-7 cells to ectopically
express the yeast H-ATPase, PMA1. PMA1 is one of the most abundant proteins in nature. It is a
P-type H+-ATPase that electrogenically pumps H+ out of the cell enabling maintenance of
electrochemical gradients across the plasma membrane while maintaining intracellular pH
homeostasis 440. Prior work has shown ectopic expression of PMA1 in murine 3T3 fibroblasts led
to tumorigenesis441 and, unexpectedly, to increased aerobic glycolysis with elevated intracellular
pH442,443. In the current study, we selected two clones following zeocin selection (PMA1-C1 and
PMA1-C5) and confirmed, by western blot, that compared to empty vector (MOCK-1)
transfectants, the PMA1 transfectants had elevated PMA1 protein expression (Fig.1A).
Moreover, using immunocytochemistry of permeabilized (Fig.1B) or non-permeabilized
(Supplemental Fig.1) cells, we verified PMA1 protein expression on the plasma membrane and
in the cytoplasm of both PMA1 clones.

PMA1 expression enhances proton production rate
To characterize the activity of PMA1, we used a Seahorse real-time extracellular flux
(XF) analyzer to measure proton production rates (PPR) in living cells, using glycolysis and
mitochondrial stress tests (GST and MST, respectively). These showed that the glucose-induced
PPR (Fig.1C), and the glycolytic reserve (Supplemental Fig. 2) were significantly higher in the
PMA1 clones, compared to empty vector MOCK-1 or parental clones, suggesting functional
247

activities of the transfected pump. There were no significant differences in oxygen consumption
rates (OCR) between PMA1 clones and controls (Fig. 1D), suggesting that glycolysis was the
primary source of protons and energy for PMA1 activity, rather than oxidative metabolism. We
further confirmed these metabolic alterations by measuring glycolytic fluxes. PMA1 clones had
significantly higher glucose consumption rates (Fig. 1E) and lactate production rates (Fig. 1F)
compared to MOCK-1 or parental MCF-7 clones. These data indicate that expression of a proton
pump, PMA1, in MCF-7 cells promotes aerobic glycolysis, or a Warburg phenotype. Therefore,
acid export can directly lead to increased glucose fermentation.

PMA1 expression increases cell motility.
Another hallmark of metastasis is enhanced cell motility. In vitro studies of migration and
invasion have been shown to clearly correlate to metastatic potential. As an acidic extracellular
pH (pHe) is known to promote cellular invasion and migration60, we investigated these behaviors
in our acid-producing PMA1 clones. To measure invasion and migration, we used gel escape and
circular wound healing assays, respectively. In the gel escape assay, expansion out of the gel is
due to a combination of proliferation, invasion, and migration. Compared to the MOCK-1cells,
both PMA1 clones expanded significantly more out of the gel drop (Fig. 1G & Fig. S4). In the
circular “wound-healing” assay, we monitored the migration of cells into a cell-free area
(Supplemental Fig. 5). Again, compared to MOCK-1, the PMA1 clones had increased migration
rates (Fig. 1H). Together, these results indicate cellular invasion and migration are significantly
enhanced by PMA1 expression and acid production.

248

PMA1 induces a metastatic phenotype in vivo
To investigate if acid production led to in vivo effects, we measured the metastatic ability
of these cells in vivo in both spontaneous (from the mammary fat pad) and experimental (tail
vein injected) metastasis models. In our in vitro studies, the proliferation rates of PMA1-C1 and
the empty vector MOCK-1 clones were similar, whereas the growth rate of PMA-C5 was much
slower (Supplemental Fig. 3). Hence, we did not include PMA-C5 in our in vivo studies to
reduce the possibility of proliferation being a confounding variable. In experimental metastasis
study, only 1 of 10 MOCK-1 mice developed lung metastases, whereas 7 of 12 PMA-C1 mice
developed lung metastases (Fig. 2A).

Lung metastases of PMA1 cells, visualized by H&E

staining (Fig. 2B), were further validated by immunohistochemistry (IHC) of PMA1 (Fig. 2B)
and RNA analysis of FFPE lung tissue for PMA1 gene expression (Supplemental Fig. 6). In the
spontaneous metastasis model (see Methods), similar to our experimental metastasis model, we
observed that only 1 of 10 MOCK-1mice developed distant metastases, compared to 4 of 9
PMA-C1 tumor bearing mice developed lung metastases (Fig.2A). Maintenance of PMA1
expression in vivo was confirmed with quantitative IHC of the resected primary tumors,
demonstrating a significant difference in PMA1 protein expression between the MOCK-1 (19%±
3.0, n = 10) and PMA-C1 (90%± 2.5, n = 9) tumors (Fig. 2G & 2H, Supplemental Fig. 6).
Notably, primary tumors revealed no significant differences in growth between PMA1 and
MOCK-1 tumors (Fig. 2C), or final tumor volume (Fig. 2D). However, blind grading (1 to 4) of
H&E stained tumor sections by a board-certified pathologist (A.L.) graded MOCK-1 primary
tumors as 2.7 ± 0.52 compared with 3.4 ±0.67 for the PMA1 primary tumors (Fig. 2E and 2F).
The average grade was significantly higher in the PMA1 tumors (p=0.016).
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Metabolic markers
With increased glycolytic metabolism in vitro and subsequent increased metastasis in
vivo, we were interested in determining if the primary tumor displayed changes in protein
expression to accommodate increased glycolysis. We compared the expression of metabolic and
pH relevant proteins by IHC within the MOCK-1 and PMA1 primary tumors. Previous studies
have shown an association of a monocarboxylate (lactate) transporter, MCT1, with malignancy
of breast cancer444. In our studies, the PMA1 group, compared to MOCK-1, had higher MCT1
expression (Fig. 2I &2J), potentially to sustain the higher glycolytic rate induced by PMA1
expression. Other proteins such as glucose transporter 1 (GLUT1), the sodium hydrogen
exchanger 1 (NHE1), and MCT4 showed no differences between the PMA1 and MOCK-1
groups (Supplemental Figs. 7 & 8). These data suggest that the increased glycolytic flux, which
requires glucose uptake by GLUT1, can be accommodated by native protein levels of GLUT1
(i.e., it is not rate-limiting). Finally, the pH regulatory protein carbonic anhydrase 9 (CA-IX) was
analyzed as it is a component of a proton exporting complex that has been associated with breast
cancer aggressiveness445. We observed that the PMA-C1-expressing tumors had significantly
lower CA-IX expression, compared to MOCK-1 (Fig. 2K &2L). CA-IX plays a vital role in
regulating tumor pH170,444,446 and, we postulate, its activity may have been made redundant by
PMA1.
Thus, a combination of in vitro and in vivo data indicate that the PMA1-expressing cells
are more aggressive and malignant compared to empty vector MOCK-1 transfectants. Even
though these observations are consistent with prior work from us and others showing a
relationship between acidity and metastasis, it must be cautioned that this is only one cell line
and one proton exporter, so the increased metastasis may be an epiphenomenon unrelated to
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PMA1 activity (e.g. insertional mutagenesis). Consequently, we investigated another proton
exporting system, CA-IX.

Overexpression of CA-IX in cancer cells
To investigate whether the PMA1 results were epiphenomena, we initiated studies with
CA-IX, which is a mammalian counterpart that also participates in H+ export. Both PMA1 and
CA-IX use energy to drive H+ export. In the case of PMA1 it is direct chemical energy of ATP
hydrolysis. In the case of CA-IX, it is indirectly electrochemical energy, as it is dependent on
the Na+-gradient driven uptake of HCO3- 223. As CA-IX expression was reduced in the PMA1
system, we used this model to investigate whether CA-IX expression recapitulated the previous
PMA1 results. Numerous studies in e.g. breast (Fig. 3A), ovarian
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and astrocytoma447 cancers

have shown that CA-IX expression correlates with poor prognosis and reduced survival.
Therefore, CA-IX is a clinically significant target and was of interest to understand why this
proton exporter is expressed by so many different cancer types. We confirmed by western blot
that parental MCF-7 cells express other carbonic anhydrase family members, CA-II and CA-XII,
but do not express CA-IX under normoxic conditions (Fig. 3B). Thus, we transfected MCF-7
cells with a CA-IX vector, and isolated two individual clones (M1 and M6) and confirmed CAIX protein expression (Fig. 3B). We also transfected MCF-7 cells with an empty pcmv6 vector
hereafter referred to as MOCK-2, As CA-IX is an exofacial membrane-bound protein, we
confirmed by ICC that CA-IX was expressed on the plasma membrane of both CA-IX clones
(Fig. 3C).
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CA-IX reduces OXPHOS and increases aerobic glycolysis
In order to determine if CA-IX expression altered glycolytic metabolism, we measured
the PPR of these clones using the Seahorse XFe96 Extracellular Flux (XF) Analyzer. Both
clones exhibited higher PPR upon glucose stimulation, compared to MOCK-2 or parental clones
(Fig. 3D). The proton source was identified as being the result of glucose fermentation to lactic
acid by metabolite analysis. Using glucose uptake assays (Fig. 3E), radioactive 2-deoxyglucose,
2DG, uptake assays (Supplemental Fig. S9) and lactate production rate assays (Fig. 3F &
Supplemental Fig. S10), we confirmed CA-IX expression increased aerobic glycolysis. In
contrast to the PMA1 transfectants, the CA-IX clones also reduced their reliance on oxidative
phosphorylation. This was measured by Seahorse MST showing decreased basal oxygen
consumption rate, OCR (Fig. 3G) and reduced ATP-linked oxygen consumption rate
(Supplemental Fig. 11. Further testing showed CA-IX expressing clones had hyperpolarized
mitochondria (Supplemental Fig. 12), suggesting CA-IX expression could be both limiting
reliance on oxidative phosphorylation and upregulating glycolysis, and not just globally
upregulating all ATP turnover.
It is possible that the observed metabolic responses were specific to the MCF-7 cell line.
To test this, we further extended these findings by over-expressing CA-IX in a U2-OS
osteosarcoma human cell line and a HEK 293 human embryonic kidney cell line. In both cell
lines, we observed CA-IX expressing clones with upregulated glycolysis as seen by increased
aerobic lactate production (Supplemental Figs. 13 & 14). Even in HEK 293 cells, which have
higher basal glycolysis compared to the other cell lines, over-expression of the proton exporting
CA-IX still enhanced their glycolytic rate. These additional cell lines corroborate our findings
that expression of proton exporters increased aerobic glycolysis.
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Metabolomics of CA-IX expressing cells
To investigate which components of the glycolytic pathway were activated with CA-IX
expression, we analyzed the influence of CA-IX expression on intracellular metabolites using
untargeted metabolomics (see methods). Statistical analyses showed clear separation of MOCK2 and parental MCF-7 from the CA-IX clones in the majority of glycolytic intermediates.
Specifically, principal component analysis was able to discriminate the Mock and Parental MCF7 cells from the two CA-IX expressing clones (Fig. 4A). Heatmap visualization of the top 50
most significantly altered metabolites showed clear differences between the MOCK-2 and
parental clones, yet that both are clearly different from the two CA-IX clones, which exhibited
the same metabolic profiles (Fig. 4B). MOCK-2 up-regulated significantly different metabolites
compared to parental. This may be a consequence of the MOCK-2 cells growing more rapidly in
vitro compared to either the parental MCF-7 or the CA-IX clones (Supplemental Fig. 15).
However, this difference in growth rate was not evident when MOCK-2 cells were grown as
tumors in the mammary fat pad of mice (Supplemental Fig. 16). Within the most significantly
changed metabolites in the heatmap, the CA-IX clones exhibited increased levels of all
glycolytic intermediates upstream of pyruvate kinase (Fig. 4C-J).

Pyruvate kinase (PK)

catalyzes the conversion of phosphoenolpyruvate (PEP) + ADP à pyruvate +ATP. It appears
that that PK has become rate limiting in the CA-IX expressing cells (Fig. 4J). As the CA-IX cells
have higher glycolytic flux, the simplest interpretation is that CA-IX expression de-repressed all
of the enzymatic steps upstream of PK.

Overall, CA-IX expression enhances the flux of

glycolytic intermediates globally resulting in enhanced lactate and acid production.
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Role of CA-IX in pHi
In our metabolomics studies, we observed global up-regulation of glycolytic
intermediates. Therefore, we hypothesized CA-IX expression may raise the intracellular pH of
cells which could increase glycolytic enzyme rates. Most glycolytic enzymes have protonatable
residues which can alter their enzyme activity. Recently, these residues have been characterized
for all glycolytic enzymes through homology modelling, which predicted glycolytic enzyme
activities generally increase with pHi above neutral405. We tested the PPR in MCF-7 parental
cells after altering pHi in a range of pHe media 6.6-7.4, expecting that the PPR rate would
increase when pHi is increased. Cells were incubated with either a chloride containing solution
or an iso-osmotic replacement solution containing gluconate. The gluconate will change the
chloride driving force at the cell membrane causing chloride and protons to flux out of the cell,
resulting in an elevated pHi at the same pHe448. Irrespective of pHe (from 6.6-7.2), cells in
gluconate media exhibited significantly (p<0.001) higher glycolytic rates measured by PPR
compared to those in chloride containing media (Supplemental Figs. 17 & 18). Given that
changes in pHi can increase glycolytic rate, we measured pHi in our CA-IX expressing cells.
CA-IX is capable of forming a transport metabolon with bicarbonate exporters449. When CA-IX
hydrates CO2 it produces H+ and HCO3-, the protons can acidify the tumor milieu but, through
coupling with bicarbonate exporters, bicarbonate can be taken up intracellularly to maintain pH
homeostasis and potentially increase pHi. To measure effects on intracellular pH (pHi), we
loaded MCF7 parental or the CA-IX expressing clones with cSNARF1, a pH-reporter dye. A
cSNARF1 calibration curve was generated using nigericin (Supplemental Fig. 19). We
equilibrated the cells in media at pHe 6.6, 6.8, 7.1, and 7.4 and co-loaded them with cSNARF1
and nuclear dye Hoechst 33342. This allowed post-processing masking the nucleus, ensuring
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that only cytoplasmic pH would be measured. At an acidic pHe 6.4, MCF7 cells had a higher
intracellular pH (Fig. 4K & O). However, at pHe 6.8 and 7.1, the CA-IX expressing clones had
significantly higher pHi (Fig. 4L,M,O), this is likely due to optimal CA-IX enzyme activity at
pH6.8171, . Below pHe 6.8, the CO2 forming reverse reaction is favored.

There was no

significant difference in pHi at pHe7.4 (Fig. 4N & O). Overall, our CA-IX expressing cells can
alter the pHe and pHi to favor glycolytic metabolism.
CA-IX expression increases cell motility in vitro
After corroborating our previous PMA1 metabolism findings in our CA-IX clones, we
ventured to see if the motility results were also recapitulated in the CA-IX model. We utilized
scratch assays and gel escape to measure migration and invasion in the CA-IX clones. Scratch
assays showed that M1 had increased migratory ability (Fig. 5A), closing the wound
significantly more rapidly than controls. However, this was not observed in the M6 CA-IX
clones.

In the gel escape assay, the M6 CA-IX clone invaded significantly more rapidly,

compared to the MOCK-2 and parental clones (Fig. 5B). Enhanced invasion was not observed in
the M1 CA-IX clones. Together, these studies suggest that CA-IX expression can enhance
motility in cells by increased migration and local invasion. Furthermore, aggressive cancers often
resist anoikis, which can be measured in vitro by the ability of cells to form spheroids
independent of attachment to a basement membrane. Utilizing the hanging droplet technique, we
observed that CA- IX expression enabled spheroid formation, compared to the MOCK-2 and
parental MCF-7 clones, which could not (Fig. 5C). This spheroid forming ability suggests CAIX not only enhances cell:cell adhesion, but suggests that increased proton export can contribute
to anoikis resistance when detached from the basement membrane necessary for metastasis.
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CA-IX expression increases metastasis in vivo
As observed in the PMA1 model, our CA-IX expressing clones demonstrated higher
invasive and migratory behavior without effects on cell proliferation in vitro, so we investigated
the metastatic ability of both of these clones in vivo using an experimental metastasis model. We
observed and had confirmed by a board-certified pathologist (M.B.) who was blinded to sample
identities, that neither the parent nor MOCK-2 cells resulted in metastases, but that both CA-IX
clones had significant macrometastases in the lung (Fig. 6A). The CA-IX clones exhibited gross
metastasis (Fig. 6B) and this was confirmed histologically (Fig. 6C).

The resultant

macrometastases significantly reduced overall survival in mice harboring either of the CA- IX
clones (Fig. 6D) and the lung metastasis stained positive for human estrogen receptor, a marker
of MCF7 cells, as well as CA-IX (Fig. 6E). Prior studies have shown neutralization of acidity
using oral buffers inhibits metastasis178,407. As our CA-IX clones produced an abundance of
fermented acid, we asked whether buffer therapy would reduce metastatic burden. Using the
experimental tail vein metastasis model, we compared untreated to buffer-treated M6 or MOCK2 mice. The tumor burden in the lungs of the M6 mice was significantly reduced with buffer
therapy (Fig. 6F & G).

Only two out of ten MOCK-2 mice had micrometastasis and no

metastases were found in the buffer therapy MOCK-2 group. These data show an induced acid
model behaves similarly to experimental cancer models treated with buffer therapy and that
increasing pH is beneficial for cancer outcome by reducing metastasis.

Discussion
Systemic causality describes an independent cause that activates a network of dependent,
proximal causes resulting in a systemic, or global, outcome450,451.An example of systemic
256

causation is global warming being systemically causal of increased natural disasters452. For
example, by temperatures increasing, water evaporation increases resulting in reduced moisture
content in the soil and increasing the likelihood of wildfires. Systemic causality philosophy
applies to many systems, including biological conditions such as cancer.
In this study, we aimed to identify the systemic cause of metastasis. In order to determine
cause, according to Aristotle and Kant, three conditions must be met: 1). The variables are
associated with the outcome, 2). The independent variable precedes the dependent variable 3).
All possible variables have been accounted for.
We believe acid production being causal of metastases meets all 3 of these conditions.
Through the use of two models PMA1 and CA-IX, we provide evidence that acid production
increases the hallmarks of metastasis i.e. increased motility, inhibition of anoikis, aerobic
glycolysis, and increased metastasis in vivo. These hallmarks have all been associated with acid
production and can be inhibited by acid neutralization. We show here that inducing acid
production occurs prior to the activation of these hallmarks of metastasis. Finally, from the
literature and our studies, it does not appear there is an alternative variable that could be
systemically causal in these systems, only acid production meets all systemic causality
conditions and induces metastasis.
The significance of our study is three-fold. First, our data have shown that expression of
proton exporting proteins, which generate an acidic tumor pHe, in lowly metabolically active and
non-metastatic cancer cells can induce a more glycolytic and aggressive phenotype. This is
contradictory to common belief, which states acid production is a consequence of elevated
glycolysis. There were substantial changes in metabolism emanating from the expression of
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these exporters. In particular, cells expressing CA-IX showed increased abundance of all
glycolytic metabolites upstream of pyruvate kinase, along with significantly increased glycolytic
flux. CA-IX can physically couple to lactate exporters453 to maintain transporter function by
wicking protons to the PG domain of CA-IX to maintain a favorable proton gradient and support
increased lactate production. Due to global changes in glycolytic metabolism, we further
expanded these studies and identified changes in pHi as driven by CA-IX expression, which
could account for the global upregulation of glycolytic metabolism. CA-IX can also couple to
NBC exporters, so when CA-IX produces bicarbonate it can be taken up intracellularly by NBC
to raise intracellular pH enhancing glycolytic enzyme activity as, notably HK, GAPDH, and
PFK-1, have alkaline pH optima405 and thus increased pHi can increase glycolytic rate.
Second, the expression of proton exporters enhanced motility, as measured by migration
and invasion in vitro, which is another direct cause of cancer metastasis. Third, not only do we
see increased metastatic phenotypes in vitro through the increased spheroid formation,
suggesting inhibition of anoikis resistance, but in vivo, we see increased primary tumor growth,
spontaneous metastasis, and experimental metastasis. Consistent with the “acid-mediated
invasion” hypothesis, we observe directly that cancer cells that export protons have a selective
advantage to metastasize compared to non-acid producing tumors. Altering the described
independent variable, acidosis, had a positive impact on metastasis, reducing tumor burden in
organs further solidifying our hypothesis that acidosis, from proton exporting proteins, is
systemically causal of cancer metastasis.
These metastatic hallmarks have been unsuccessfully targeted in the clinic. Aerobic
glycolysis is arguably one of the most challenging hallmarks to target, as normal cells (including
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cells of the immune system) utilize glycolytic metabolism and therefore targeting any of the
enzymes will most likely have toxic side effects. However, a sequela of glycolytic metabolism is
acid production, which may be targetable as it occurs rarely in normal tissues. Although
numerous studies have shown correlations between acid production and tumor formation, acid
has not been commonly considered a driver of cancer. Reducing acidosis inhibits tumor growth
and metastasis178,194, but few studies have tried to understand why cancer cells favour acid
production. In this study, we have shown that inducing acid production per se can be
systemically causal of cancer metastasis.
Cancers commonly express proteins which can acidify the tumor microenvironment.
These proton exporting proteins include carbonic anhydrases, e.g. CA-IX, but their expression is
often concurrent with aerobic glycolysis. We have shown that expression of proton exporting
proteins, can precede changes in cancer metabolism. This finding is very significant as it enables
us to kill two birds with one stone. i.e. targeting acid exporting proteins may reduce acidosis in
the tumor microenvironment and have a knock-on effect at reducing other hallmarks of
metastasis such as aerobic glycolysis. Ultimately, this could enable targeting and reduction of
cancer metastasis.
Neutralizing acid with buffers is not trivial and has failed in clinical trials due to
intolerable side effects. Targeted approaches, such as proton pump inhibitors454 or targeted
urease228 are currently in trials. Alternatively, this acidic axis can be targeted by inhibiting the
proton exporters (e.g. CA-IX), shown here to be responsible for aerobic glycolytic metabolism
and proton production.

As CA-IX is not robustly expressed in the normal tissues455, CA-IX

inhibitors may be successful, especially in combination with other therapies. However, due to the
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similarity of the active site in all carbonic anhydrases, these inhibitors need improved specificity
and selectivity. Notably, more studies are showing acidosis inhibits immune surveillance of
tumors30, and immune cells are a prominent feature in the tumor microenvironment . Therefore,
improving immune cell functionality and reducing the immune suppressive phenotype generated
by acid production in the tumor could improve patient outcome.
In conclusion, acid production appears vital for cancers to survive, progress, and
metastasize. It can no longer be considered an epiphenomenon of increased metabolism but as a
driving force in metastasis. We have identified acidosis as the systemic cause of metastasis.

260

Figure 1.1: Over-expression of yeast ATPase proton pump, PMA1, in MCF-7 breast cancer cells
increases glycolytic metabolism, migration, and invasion in vitro A: Immunoblotting of protein lysates
from MCF-7 cells transfected with empty vector (MOCK-1) or PMA1 vector (C1 and C5). Proteins from total
cell extracts were immunoblotted for PMA1 and GAPDH (loading control). B: Representative
immunocytochemistry images of PMA1 expression in mock, PMA-C1 and PMA1-C5 permeabilized MCF-7
cells. PMA1 clones exhibit PMA1 staining, whereas MOCK-1cells do not. DAPI nuclear stain (blue) and
PMA1 stain (red). C: Seahorse extracellular flux analysis of glycolysis associated proton production rate,
measured after glucose is added, in MCF-7 parental, MOCK-1, PMA-C1, and PMA1-C5 MCF-7 cells. Data
shown as mean ± SD n=9 biological replicates. Statistical analysis using ordinary one-way ANOVA.
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Figure 1.2: Over-expression of yeast ATPase proton pump, PMA1, in MCF-7 breast cancer cells
increases glycolytic metabolism, migration, and invasion in vitro D: Seahorse extracellular flux analysis of
basal oxygen consumption in the presence of glucose for MCF-7 parental, MOCK-1, PMA-C1, and PMA1-C5
MCF-7 cells. Data shown as mean ± SD n=20 biological replicates. Statistical analysis using ordinary one-way
ANOVA. E: Glucose concentration in tumor-conditioned media collected after culturing at confluence from
MCF-7 parental, MOCK-1, PMA-C1 and PMA1-C5 MCF-7 cells for 24hrs, measured using hexokinase
activity assay. Data shown as mean ± SD n=9 biological replicates. Statistical analysis using ordinary one-way
ANOVA. F: Lactate concentration in tumor-conditioned media collected after culturing at confluence from
MCF-7 parental, MOCK-1, PMA-C1 and PMA1-C5 MCF-7 cells for 24hrs, measured using fluorescent lactate
assay. Data shown as mean ± SD n=9 biological replicates. Statistical analysis using ordinary one-way
ANOVA. G: Gel escape assay to measure migration and invasion in MOCK-1, PMA-C1 and PMA1-C5 MCF7 cells. Cells are embedded in a Matrigel droplet without serum and they are surrounded by media containing
serum. Droplets are monitored over 1 week for cell invasion out of the droplet and the area measured is
normalized to cellular proliferation rates. N=4 biological replicates. Statistical analysis using ordinary one-way
ANOVA. H. Circular wound healing assay of MOCK-1, PMA-C1 and PMA1-C5 MCF-7 cells. A circular
wound is created with a rubber stopper and then cells are monitored migrating into the area to close the wound.
Area healed is quantified in % relative to starting area and normalized to cellular proliferation rate.

N=4
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biological replicates. Statistical analysis using ordinary one-way ANOVA. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001

Figure 2.1: In vivo studies of PMA1 expressing cells and the effect on tumor growth, metastasis, and
expression of metabolic markers. A: Table quantifying both the spontaneous and experimental metastasis
studies comparing the PMA1 C1, or MOCK-1 cells and the resultant number of mice with metastasis.
Statistical analysis using Fishers exact t-test. B: Representative lung images (5mm and 100um) from the
experimental metastasis study in SCID beige mice, whereby MOCK-1 or PMA-C1 cells were injected via the
tail vein and allowed to grow for 3 months. At endpoint, lungs were resected and sections were stained with H
& E to look for metastases and PMA1 to confirm expression in the PMA C1 metastases. C: Primary tumor
growth rate in SCID beige mice of MOCK-1 or PMA1-C1 cell lines, injected subcutaneously. Data are shown
as mean ± SD over time, N=7(Mock) N=6 (PMA1). D: Quantification of primary tumor volume, MOCK-1 or
PMA1-C1, resected after 33 days of growth in SCID beige mice. Tumors were resected to allow for
spontaneous metastasis studies to continue. Data are shown as mean ± SD, N=9 (Mock) and N=9 (PMA1),
statistical analysis using Unpaired t test with Welch’s correction. E: Histological grade of MOCK-1 and
PMA1 tumors. Data are shown as mean ± SD, N=10 (Mock) and N=9 (PMA1), statistical analysis using
Unpaired t test with Welch’s correction.
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Figure 2.2: In vivo studies of PMA1 expressing cells and the effect on tumor growth, metastasis, and
expression of metabolic markers. F: Representative images of H & E staining in MOCK-1 and PMA1
primary tumors used to score histological grade. G: Immunohistochemistry representative images of PMA1
and

MOCK-1

primary

tumors

stained

for

PMA1

protein

expression.

H.

Quantification

of

immunohistochemistry staining for PMA1 protein in FFPE sections of resected primary tumors, MOCK-1 and
PMA1-C1. Data are shown as mean ± SD, N=10 (Mock) and N=9 (PMA1), statistical analysis using Unpaired
t-test. I: Quantification of immunohistochemistry staining for MCT1 protein in FFPE sections of resected
primary tumors, MOCK-1a nd PMA1-C1. Data are shown as mean ± SD, N=10 (Mock) and N=9 (PMA1),
statistical analysis using Unpaired t test with Welch’s correction. J: Representative immunohistochemistry
images of FFPE sections of resected primary tumors, MOCK-1 and PMA1-C1 stained with antibody for
MCT1. K: Quantification of immunohistochemistry staining for CA- IX protein in FFPE sections of resected
primary tumors, MOCK-1 and PMA1-C1. Data are shown as mean ± SD, N=10 (Mock) and N=9 (PMA1),
statistical analysis using Unpaired t-test. L: Representative immunohistochemistry images of FFPE sections of
resected primary tumors, MOCK-1 and PMA1-C1, stained with antibody for CA-IX. *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001
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Figure 3: Over-expression of CA-IX in MCF-7 breast cancer cells increases glycolytic metabolism,
invasion and spheroid formation in vitro A: Relapse-free survival Kaplan-Meier Curve comparing low and
high CA9 gene expression in basal breast cancer n=879(kmplot.com). Statistical analysis using LogrankP test
p=0.0024. B: Immunoblotting of protein lysates from MCF-7 cells transfected with empty vector (MOCK-2)
or CAIX vector (M1 and M6). Proteins from total cell extracts were immunoblotted for CAIX, CAII, CAXII,
and B-actin (loading control). C: Representative immunocytochemistry images of CA-IX protein expression in
MCF-7, MOCK-2, and CA-IX clones M1 and M6. CA-IX clones (M1 & M6) exhibit CAIX membrane
staining, whereas MOCK-2 and parental MCF-7 cells do not. DAPI nuclear stain (blue), Wheat germ
agglutinin membrane stain (green) and CA-IX stain (red). D: Glycolysis associated proton production rate
(PPR) using the seahorse extracellular flux analyzer, measured post glucose injection. Data are shown as mean
± SD, N=8 biological replicates per group, statistical analysis using ordinary one-way ANOVA. E: Glucose
uptake of cells in each group over 24hr, measured as luminescence generated using Glucose Uptake-Glo assay
(Promega). N=3, statistical analysis using ordinary one-way ANOVA. F: Lactate measured in extracellular
media after 24hr using Sigma kit. N=3 biological replicated per group, statistical analysis using ordinary oneway ANOVA. G: Basal oxygen consumption rate (OCR) measured using the Seahorse extracellular flux
analyzer in 5.8mM glucose concentration. Data are shown as mean ± SD, N=8 biological replicates per group,
statistical analysis using ordinary one-way ANOVA. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
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Figure 4.1: Unlabeled metabolic profiling of CA-IX expressing MCF-7 cells intracellular metabolites
and analysis of the glycolytic metabolites A: Principal component analysis of intracellular metabolites in
CA-IX expressing, MOCK-2 and Parental MCF-7 cells. B: Heatmap (hierarchical clustering) of the fifty most
significant fold changes of intracellular metabolites between CA-IX expressing clones, MOCK-2, and Parental
cells. Numerous glycolytic intermediates were significantly higher in CA-IX expressing cells compared to
MOCK-2 and Parental. C-F: Average peak intensity of each glycolytic intermediate in CA-IX expressing,
MOCK-2 and Parental MCF-7 Cells. N=5-6 biological replicates per group, statistical analysis using ordinary
one-way ANOVA.
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Figure 4.2: Unlabeled metabolic profiling of CA-IX expressing MCF-7 cells intracellular metabolites
and analysis of the glycolytic metabolites G-J: Average peak intensity of each glycolytic intermediate in
CA-IX expressing, MOCK-2 and Parental MCF-7 Cells. N=5-6 biological replicates per group, statistical
analysis using ordinary one-way ANOVA. K-N: Intracellular pH as measured using cSNARF1 in varying
extracellular pH n=158-438 cells analyzed per group, statistical analysis using Kruskal-Wallis test. O: Table
showing calculated intracellular pHi mean in MCF7 and CA-IX expressing cells. *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001
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Figure 5: Over-expression of CA-IX in MCF-7 breast cancer cells increases migration, invasion, and
inhibits anoikis in vitro A: Migration assay comparing the ability of cells to close an artificially generated
wound in a 96- well plate, number of cells migrated into the wound area is measured using Celigo imaging
cytometer. N=8 biological replicates, statistical analysis using ordinary one-way ANOVA. B: Gel escape assay
to measure migration and invasion in MCF-7, MOCK-2, CA-IX clones M1 and M6. Cells are embedded in a
Matrigel droplet without serum and they are surrounded by media containing serum. Droplets are monitored
over 1 week for cell invasion out of the droplet and the area measured is normalized to cellular proliferation
rates. N=12 biological replicates per group. Statistical analysis using ordinary one-way ANOVA. C: 3D
spheroid representative images, generated 7 days post seeding in hanging droplet assay comparing MCF-7,
MOCK-2, and CAIX clones (M1 and M6) ability to form 3D spheroids. N=12 per group. *p<0.05, **p<0.01,
***p<0.001, ****p<0.0001
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Figure 6: In vivo studies of CA-IX expressing cells and the effect on tumor growth, metastasis, and
buffer therapy A: Table of experimental metastasis study results. Quantification of the number of mice in
each group, MCF-7 parental, MOCK-2, and CA-IX clones M1 and M6 with lung metastases, as identified by a
pathologist. Statistical analysis using Fisher’s exact t-test p-value. B: Kaplan-Meier Survival curve of
experimental metastasis study in SCID beige mice, 90-day endpoint after tail vein injection of cells. Log-rank
test performed p=0.0062, df=3. N=5(MCF-7), 6(MOCK-2), 7(M1), 7(M6) mice. C: Representative whole lung
images from MOCK-2 and M6 experimental metastasis model showing the extent of metastasis visible. D:
Representative immunohistochemistry of H&E staining in the lungs of the experimental metastasis groups,
showing gross metastasis of the lungs. E: Representative immunohistochemistry of M6 lungs with antibodies
towards CA-IX and ER, to confirm the generated M6 clone were the cells forming tumors in the lungs. MCF-7
cells are ER-positive. F: Effect of buffer therapy on experimental metastasis of CA-IX clone M6 and MOCK-2
cells in SCID beige mice and the % of tumor burden in the lungs, 77days after IV injection of cells. Data are
shown as average % ± SD, N=6(M6), 9(M6 Bicarb), 9(MOCK-2), 7(MOCK-2 Bicarb) mice, statistical
analysis using ordinary one-way ANOVA. G: Immunohistochemistry of H&E staining in the lungs of the M6
control and bicarb treated experimental metastasis study groups, showing gross metastasis of the lungs.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
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Figure S1: Characterization of PMA1-expressing cells by ICC staining (non-permeabilized). [Primary
Ab: DAPI (blue), WGA (green), PMA1; Secondary Ab: Alexa Fluor 594 (red)]
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Figure S2: Glycolytic Reserve
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Figure S3: Growth rates of control and PMA-1 cells over 96hrs.
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Figure S4: Gel escape raw data and images
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Figure S7: Quantitation of GLUT1 protein staining.
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Figure S8: Quantitation of NHE1 protein staining
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Figure S9: Radioactive glucose uptake using tritiated 2-DG.
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Figure S10: YSI analysis of lactate production
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Figure S13: YSI lactate production of U2-OS CA-IX transfected clones
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Figure S17: The effect of altered pHi on glycolytic rate (ECAR)
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Figure S18: Graph of the effect of altered pHi on glycolytic rate (ECAR) in varying pHe media
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Figure S19: cSNARF1 calibration curve
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Chapter 8: Implications and future directions
Implications
Chapter 2- Metabolic profiling of healthy and cancerous tissues in 2D and 3D
Over the next few decades, as our population grows and continues to age, the incidence
of cancer will increase. Treatment will become more "personalized" in that patients' cancers will
be extensively profiled to identify optimal treatment strategies.

In order to personalize

medicine, we need methods and tools which are informative and fast. Our 3D metabolism studies
can profile metabolic heterogeneity and may be useful to screen potential drug treatments of
individual biopsy samples. This advance in technology could prevent patients from undergoing
non-efficacious treatment. It may be commonplace that multiple modalities are used concurrently
to treat patients best. Tumors could be imaged, metabolically tested, genomically profiled, and
histologically analyzed before deciding which treatment avenue to follow. Currently, this
workflow is used in mouse models combining MRI imaging and coregistered histology to
determine different habitats which may provide insight into how to proceed with treatment456.
This method can be enhanced by the addition of metabolic profiling in order to understand how
imaging parameters and protein expression correlate with metabolic phenotype.
Although our study mainly focused on the implications in cancer, any organ or tissue
from which we can derive microtissues from has the potential to be metabolically profiled.
Toxicity to essential organs, such as heart, liver, and kidneys, are severe adverse events that can
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occur in clinical trials. Organ toxicity must be investigated in at least two animal models to
generate an Investigational New Drug (IND) application. Even so, this often does not predict
adverse events that occur in human clinical trials. Metabolism is exquisitely sensitive and
responds rapidly to toxic drug exposure. Drug screening before animal models and clinical trials,
using organ derived microtissues, possibly from human donors, may enable prior modification of
drugs to prevent such severe organ toxicity. Additionally, in the case of minimal metabolic
response by the organ to the drug, clinician investigators can be forewarned to monitor specific
metabolic perturbations even more closely for such side effects.
Additionally, techniques to maintain biological function and integrity may be analyzed by
this method to determine the impact of such techniques. Organ transplants are vitally important,
and methods to prolong the time between transplant are essential to help the most people
possible457. This semi-high throughput method could also be used to determine if techniques to
maintain transplant organs sustain normal biological function and increase longevity for organs
between transplants. For example, one issue facing the corneal transplant community is infection
after transplantation which occurs in up to 30% of patients458. Both bacterial and fungal
infections have been observed, resulting in transplant failure, and clinicians are trying to find a
way to pre-treat corneal transplants without damaging the physiology of the cornea. This 3D
metabolism method could be used to generate microtissues from the cornea to compare
treatments for their ability to prevent infection and functional deterioration. If there is an impact
on metabolism, it can be monitored over time using the Seahorse to determine if corneal
metabolism reverts to normal. Treatments to prevent infection can be injected acutely during
metabolic monitoring and may identify therapies which would improve the success rate of
corneal transplant.
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3D metabolism studies may apply to other research avenues such as the optimization of
in vitro fertilization (IVF) and embryo implantation. One issue facing the IVF community is egg
quality which is usually calculated by the number of eggs a woman has remaining and her age.
Therefore, there is a substantial area for improvement in egg choice if there is a metric to
measure egg quality. There has recently been a push for non-invasive methods to screen and
optimize egg quality before fertilization, and embryo quality before transfer. Metabolic studies
have been suggested as a non-invasive method.

Our 3D metabolic method is semi high

throughput and non-invasive. Monitoring metabolism of eggs in response to various hormones
and supplements may enable more successful embryo formation and implantation459. After
fertilization, the embryo must move down the oviduct to implant in the uterus, and this requires a
switch to increased glucose consumption460,461. This metabolic switch could be monitored in the
embryos to optimize implantation timing. By optimizing both egg choice and implantation, odds
for successful pregnancy could be improved, resulting in fewer rounds of IVF for prospective
parents.
Alzheimer's is another disease in which any advances we can make to treat it will be
welcome. Unfortunately, this is a disease which is increasing and is the sixth leading cause of
death in the US462. The brain consumes high levels of glucose, but this is depressed in
Alzheimer's disease. There is also higher oxidative stress resulting in oxidative damage in the
brain. Both of these aspects could be monitored using the 3D microtissue and spheroid metabolic
profiling in the Seahorse. Monitoring glycolysis and OXPHOS in brain microtissues in the
presence of potential Alzheimer's drugs may identify which drugs return metabolism to
normal463.
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Similarly, global obesity rates are increasing, and nonalcoholic fatty liver disease is a
growing concern. During the progression of this disease altered lipid metabolism occurs.
Seahorse technology can measure both the oxidation of exogenous and endogenous lipids and
may be used to improve therapy response for those with NAFLD and to retard its progression to
nonalcoholic steatohepatitis464,465. Hence, the 3D metabolism studies pioneered here have the
potential to be applicable in numerous disease states, monitor normal tissue function, and
improve drug screening methods.

Chapter 3, 4, 5- Cancer cell phenotype drives aggressiveness and influences surrounding stroma
We have observed that cancer-induced bone pain (CIBP) can be alleviated, in part, by
using V-ATPase inhibitors. This is a promising avenue and needs to be further clinically
evaluated. There has been a substantial effort to utilize buffer therapy in clinical trials. In mouse
models, buffer therapy has been well-tolerated and reduced metastasis195. There have been three
clinical trials so far NCT01350583, NCT01198821, and NCT01846429, each utilizing sodium
bicarbonate as the buffer. Both NCT01350583 and NCT01846429 were trialing buffer therapy as
a pain reduction treatment. In NCT01350583 and NCT0119882, poor patient accrual and
compliance, due to the taste of sodium bicarbonate, led to a reformulation of the buffer into
940mg capsules. Although 4 out of 9 patients on trial NCT01846429 had reduced pain scores
after three weeks on therapy, all patients experienced grade 1-2 GI disorders throughout the
study, including vomitus. The other clinical trial NCT01198821 was to try and improve response
to gemcitabine in pancreatic cancer. Gemcitabine, in combination with sodium bicarbonate,
showed no improvement in overall survival, and patients complained of the taste, leading to poor
compliance and sometimes patients took too large a dose resulting in GI problems. In all trials,
292

few patients were accrued, there was poor compliance in taking buffer therapy, and there were
widespread complaints of GI discomfort. Additionally, if people are eating an acid-producing
diet, this may be sufficient to inhibit the benefits of buffer therapy; therefore, dietary
management to an alkalinizing diet may be necessary to see benefits.
Although these buffer therapy trials were not very successful, minimizing acidosis in the
primary and metastatic tumor environment has benefits. Our studies on lactic acid as a fuel
source for osteoclasts and acidification of the metastatic bone environment resulting in cancerinduced bone pain show that inhibiting the source of acid production, rather than low pH alone
using buffer therapy, may have more significant results. Further studies on V-ATPase inhibitors
alone, MCT inhibitors alone, CA-IX inhibitors alone, and combinations of these inhibitors will
be vital to improve pain reduction as well as reduce metastatic burden. Our studies highlight the
inter-cooperativity within bone metastasis and highlight the need to disrupt this co-operation to
reduce bone pain caused by metastasis or prevent the formation of metastasis.
Another feature of the bone microenvironment is that it is hypoxic342. Hypoxia and
acidosis are associated with more aggressive cancers. Hypoxia activated pro-drugs may enable
higher concentrations of e.g., V-ATPase inhibitors to be used, minimizing off-target effects
resulting from higher doses. In turn, this targeted approach may improve reduction in bone pain.
There is an ever-increasing portion of the global population dealing with chronic pain and
hyperalgesia. The direct cause of why these patients experience such high levels of pain is
unclear, but acid production is an underexplored as a cause. Acidosis, as a potential cause of
chronic pain, warrants further exploration. There are a few known acid sensitive proteins such as
V-ATPase, capsaicin receptor (TRPV1), transient receptor potential cation channel 1 (TRPA1),
293

and acid sensing ion channels (ASIC’s). The use of inhibitors against these proteins , as well as
the use of alkalinizing diets227 may reduce pain in this population. V-ATPase inhibitors are well
tolerated in cancer patients so may be a viable treatment option for chronic pain patients with
minimized risk. TRPV1, under low pH, is more sensitive to capsaicin and is activated by acid
pHe. Some studies have shown no effect on pain when using TRPV1 agonists466, however others
in a cancer bone pain model did show pain attenuation using TRPV1 agonists467. ASIC’s are
another option as they are sensitive to decreased pH. ASIC’s are expressed in the bone, and
inhibitors may reduce cancer induced bone pain. ASIC’s are also expressed throughout the body,
including in muscle468, and targeting these may improve chronic pain. In a rat model to measure
pain, inhibitors against ASIC 3, resveratrol, reduced ASIC3 expression and had an
antinociceptive effect469. Current treatment options for chronic pain include anti-depressants,
NSAID’s, and opioids which have varying success and a high risk for addiction. Therefore, any
improvement or alternative treatments for chronic pain are welcome.

Chapter 6 – Acidosis in the tumor microenvironment inhibits T cell function and efficacy of
immunotherapy
Through our studies on the impact of acidity on effector T cells, it is appreciated that
many components of the immune system could be negatively impacted by low pH. Within
cancer research alone, the surge in immunotherapies means this work is both relevant and vital
for clinical success. We have shown acid can not only inhibit effector T cell function but
reducing acid load can improve response to checkpoint blockade and adoptive cell transfer
(ACT) therapies.
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ACT therapy relies on utilizing a patient's tumor-infiltrating lymphocytes, TILs. T cells
isolated from, and that react to, the patient's tumor are expanded and reinfused back into the
patient. Unfortunately, this therapy is not without its challenges. One issue with TIL therapy is
preventing activation of effector T cells without impacting their proliferation rate. Clinicians
want to infuse the highest number of T cells to enable maximal tumor cell killing and the best
chance of success. In a melanoma study, a higher number of T cells correlated with tumor
regression470. However, increased proliferation during the expansion phase of TIL therapy can
be coupled with activation of T cells rendering them anergic or exhausted by the time they are
infused in the patient. Our studies have shown that an acidic tumor microenvironment reversibly
inhibits T cell effector functions by inhibiting their glycolytic metabolism. Low pH could be
used ex vivo as an advantage in TIL therapy, by placing the activated cells in low pH media so
they can be prevented from premature or excessive activation before infusion into the patient.
Pre-treatment of TIL’s with acidic pH ex vivo to prevent excessive activation does not
prevent the inhibition of effector T cells in vivo in an acidic tumor microenvironment.
Neutralizing intratumoral pH may benefit TIL infusion patients as well as those undergoing
checkpoint blockade. In mouse models, we have observed improved response and outcome when
combining checkpoint blockade and buffer therapy to increase intratumoral pH, but this has not
been as successful in patients. Thus, it is imperative to identify the source of acid production
within the tumor to tailor combination treatments to improve clinical outcome and
immunotherapy response. If acid production is due to aberrant vasculature, drugs that can
improve perfusion may enable removal of acidic waste.

Bevacizumab an anti-angiogenic

treatment, which targets VEGF471,472, may improve vasculature function and enable waste
removal, which could increase intratumoral pH. Similarly, if low pH is generated through proton
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exporting proteins such as CA-IX or V-ATPase, specific drugs or neutralizing antibodies could
be given before immunotherapy to reduce acidosis. In patients, a change in pH can be measured
using CEST MRI394,473. Imaging patients post acid-reducing treatment can determine the optimal
timing for TIL therapy infusion or checkpoint blockade. Finally, metabolic acidosis, as generated
by glycolytic metabolism, is commonly observed in tumors by FDG PET scanning and MCT
inhibitors are currently being trialed to reduce lactate efflux473. MCT's are essential for T cell
effector function via their up regulation of glycolytic metabolism, and the use of MCT inhibitors
will inhibit their effector function. Thus, optimization of the treatment schedule would be
needed. Overall, identifying and targeting acid production before or during immunotherapy
could improve patient outcome.
Another area in immunotherapy looking to enhance patient response is CAR-T cell
therapy. CAR-T therapy is in a similar vein to TIL therapy, except that patient T cells are
engineered to express receptors that target specific proteins on tumors. Although it is not yet
tested, CAR-T therapy may benefit from a reduction in intratumoral acidosis. Alternatively,
engineering CAR-T cells to rely on oxidative metabolism for their effector function could
overcome a reliance on glycolysis and inhibition by acidity. As low pH inhibits T cell glycolysis
in part through inhibiting MCT transport kinetics, engineering CAR-T's to express proteins
which could alter their surface pH may help to maintain the glycolytic rate necessary for effector
function. CA-IX is not expressed in T cells, but many CA-IX expressing cancers are highly
glycolytic and appear unaffected by acidosis. We hypothesize that CA-IX maintains a slightly
higher surface pH to minimize inhibition of MCT transporters by acidic pHe, enabling a higher
lactate efflux rate. Both altering metabolism of T cells and alleviating the inhibition of glycolysis
by acidic pH are potential avenues to improve CAR-T therapy.
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As mentioned previously, buffer therapy has been investigated as a treatment strategy to
reduce pH; however, it has not been well tolerated by patients in clinical trials. Sometimes the
ability of buffer therapy and T cells reach solid tumors is impaired, making intratumoral
injections an attractive alternative. Before or in combination with intratumoral T cell injection,
drugs such as TRC101 which is a micron-sized buffer particle could be injected into the tumor to
try and increase intratumoral pH. Usually, this is a drug given orally for chronic kidney disease
but could be re-purposed for use in cancer treatment.
Organ transplant is another area plagued by failure with resultant organ rejections, and it
is argued that much of this is due to high levels of effector T cell infiltration474. Could organs be
flushed with low pH media to prevent activation of T cells by inhibiting their glycolytic
metabolism? Would buffer therapy in this instance be detrimental to patients receiving organ
transplants or could it, in fact, prevent organ rejection? These are areas which warrant further
investigation.
Other diseases, such as rheumatoid arthritis are immune-mediated. Over 1% of the global
population displays rheumatoid arthritis symptoms, an autoimmune disorder characterized by
swollen joints, fatigue, severe pain, and mobility issues. The immune system attacks the lining of
the joints, and a significant component of that immune response is thought to be mediated by
CD8+ effector T cells. Although their role seems to both protective and deleterious, owing to
conflicting results obtained from studies, pH manipulations could provide a potential avenue for
treatment475. As we know that acid inhibits their effector function, we can either increase or
reduce pH accordingly depending on the role of CD8's.
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Chapter 7 – Acid production in the tumor microenvironment systemically causes cancer
metastasis
Cancer treatment has improved, especially in the treatment of primary tumors, but one
area where we still struggle is in treating metastasis. There are currently very few specific
treatments to prevent or treat metastasis, as most therapies are palliative. Although palliative
treatments can improve a patient’s quality of life476 it does not improve overall survival. Our
discovery of acidosis as a systemic cause of metastasis provides insight into how metastasis
should be treated. This understanding could widely impact the treatment of both primary tumors
and metastases. Low pH could be measured in patients and treated acutely and chronically to try
and prevent the release of cells from the primary tumor as well as preventing the formation and
growth of metastasis. Subsequently, in metastatic patients (Chapter 4), treating acidosis could
reduce chronic bone pain in bone metastasis patients.
Our CA-IX expressing cells maintained a high glycolytic rate even in the presence of low
pH. In our Chapter 6 T cell studies, we observed inhibition of T cell glycolytic rate with low
pH. Therefore CA-IX expression in T cells could be used as an alternative immunotherapy
strategy. CA-IX may increase pH at the cell surface to maintain a higher glycolytic rate than
would typically occur at low pHe. A significant issue in immunotherapy is maintaining effector
T cell function in the tumor, and CA-IX expression may alleviate one of the inhibitory stressors
found in the microenvironment.
We have challenged the dogma that glycolytic metabolism is the driver of acid
production, and we have shown the converse can occur, that acid production can increase
glycolytic metabolism. This understanding emphasizes the importance of pH in cancer
etiopathology. Furthermore, realizing the far-reaching consequences of CA-IX expression and its
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role in metastasis, CA-IX inhibitors could be used in combination with chemo-, or immunetherapies to improve patient response.
Future directions

3D metabolism studies
Our metabolism studies proved very fruitful as we observed how vital it is to maintain
intratumoral heterogeneity to recapitulate the metabolism of in vivo models. We envision that
these studies could be expanded into three areas: 1. Increased variety of metabolic tests available.
2. Altering the composition of spheroids. 3. Further insights into organ toxicity.
1. Increased variety of metabolic tests available.

Our studies focused heavily on only a single metabolic test, the mitochondrial stress test,
but this provides only a limited view of ATP producing metabolism. In order to increase the use
of this methodology, we propose to optimize more metabolic tests to probe different parts of
metabolism. These tests include mitochondrial stress test, mitochondrial fuel test, glycolytic rate
assay, glycolysis stress test, ATP rate assay, exogenous and endogenous fatty acid oxidation
assay, and cell energy phenotype assay. It would be imperative to optimize the timing and
concentration of the drugs in each assay in order to ensure we can accurately measure the
capacity and dependency of these metabolic fuels.
One commonly used test is the glycolytic stress test or glycolytic rate assay, which
measures glycolytic rate and capacity by measuring extracellular acidification rate. In the
glycolytic stress test, cells are starved of glucose. In 2D cultures, this is achieved by washing
and incubating cells in glucose-free media, however, in 3D cultures, glucose can be sequestered
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inside the spheroid for much longer; therefore, longer depletion times would be required. It
would be important to measure the concentration of glucose in the 3D cultures during incubation
in glucose-free media to ensure complete glucose depletion. The YSI Biochemistry analyzer can
measure glucose in media. Subsequently, the response of spheroids to glucose may require more
extended incubation periods in the Seahorse Analyzer to measure glycolysis accurately.
Additionally, in our studies, we saw in the mitochondrial stress test, the spheroids had a
delayed reaction to oligomycin, and this is a component of the glycolytic stress test. We have
previously shown penetrance of oligomycin into the spheroid was not an issue in the
mitochondrial stress test by using a lower molecular weight Complex 5 ATP synthase inhibitor.
However, this will still need to be tested in the glycolytic stress test setting to optimize the time
necessary to see a complete response by the spheroids to oligomycin.
Since penetrance was not the reason for the delayed oligomycin response, we
hypothesized that the cell: cell contact changed the surface expression of proteins in the
spheroids. Changes in protein expression have been observed in 3D colorectal cancer studies477.
Our study was mainly method-based rather than identifying biological mechanisms for altered
metabolism. It would be interesting to determine the changes in protein expression in different
cancer cells models and correlate this with their metabolic phenotype.
2. Altering composition of spheroids.

Our studies to date have only looked at spheroids composed of 100% cancer cells.
Although 3D spheroid models better recapitulate in vivo conditions, they do not contain other
cell types found in the tumor microenvironment. These include fibroblasts and various immune
cells, for example, T cells and macrophages, which have been shown to influence the metabolic
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phenotype of cancer cells. It would be interesting to analyze how changing the composition of
the spheroids alters their overall metabolism, as an intermediate to understanding the metabolic
profiles of tumor slices. These measurements can then be further used to test the protective role
these other cells play in resistance to therapy.
Although fibroblasts can be mixed into cell cultures prior to seeding spheroids, immune
cells naturally migrate into the tumor. To recapitulate this in our model, we would surround
spheroids with T cells to allow infiltration into the spheroid. Comparisons between activated
versus non-activated T cells may shed light on which is most inhibited by tumor cell metabolism.
Our work has shown that both tumor cells, and T cells, favor glycolytic metabolism, and it would
be interesting to see how the interaction of both cells types together changes the overall
metabolism of the spheroid. Subsequently, we can compare the therapy response of models
composed of 100% tumor cells, fibroblast mix, immune cell mix, or immune-fibroblast-tumor
mix. Correlating the histology of combination spheroids with their metabolism may identify
optimal treatment strategies. We can further expand these studies with more in vivo models by
generating microtissues from tumors as we have shown previously.
3. Organ microtissue studies

One of the most significant issues with approved and new therapies are the organ
toxicities that sometimes are unobserved until undertaking clinical trials. Our method enabled the
metabolic profiling of both heart and kidney. We chose heart and kidney as they commonly
exhibit organ toxicity with drug treatments. This organ metabolic screening has the potential to
be applied to multiple organ types if they can be sectioned with minimal variation. Expanding
these studies into other organ types could minimize off-target organ toxicity. We would like to
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further delineate the metabolism of these organs by looking at specific regions such as the atria
and ventricles int the heart and, the cortex and medulla in the kidney. Each of these sections may
be affected differently by therapy, which could only be delineated by testing the regions
independent of one another. As this method is semi-high throughput, we could screen new drug
libraries to test both the efficacy of drugs against the tumor and the impact on organs. Although
toxicity is sometimes unavoidable, if there is awareness, either the drug can be modified, or we
can monitor patients more closely for signs of toxicity. Although we have only looked at this
method from a cancer perspective, it could be useful for other disease types and drug testing. For
example, chronic kidney disease, fatty acid liver disease, and obesity are all likely to alter organ
metabolism and returning these tissues to their normal metabolic state may aid in their function,
response to other drugs and overcoming the disease.

Stromal studies
In bone, we identified co-operation between cancer cells and osteoclasts increases bone
metastasis. The metabolism of cancer cells generates lactate which is consumed as the preferred
fuel source by the osteoclasts. As we have seen, "pioneer" cells that are more invasive and
glycolytic, dominate the invasive edge of the tumor. We have further shown that, by steering the
tumor environment into a less acidic phenotype, we can favor the "engineer" species of cancer
cells that are less invasive and aggressive. Therefore, targeting glycolytic metabolism can benefit
both the primary tumor and the metastatic niche. Targeting the glycolytic production of lactate,
lactate uptake, and acid production can prevent cell invasion from the primary tumor, metastatic
lesion formation, and cancer-induced bone pain in patients. Further inhibitor studies are needed
to determine the optimal acidosis inhibitor to reduce bone pain in cancer patients. Alternatively,
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could dietary intervention prevent lactate production by cancer cells and thus minimize the
activity of osteoclasts in enhancing bone metastasis?

T cell studies
Our T cell studies warrant further investigation, as a more in-depth understanding may
identify improved treatment strategies. The response of T cells to low pH is likely an
evolutionarily conserved trait that has been co-opted by cancer cells. It would be imperative to
determine the effect of low pH in normal sites of T cell localization, activation, and function. T
cells are commonly found in sites of wound healing. We will generate wound models and look at
the two stages of wound repair in which T cells are most vital: the inflammatory phase and reepithelialization phase410. At both stages, we would measure wound healing, infiltration, and
function of the T cells in a neutral and acidic pH. Normal activity of T cells could be measured
by IFN-g production.
Immune privileged sites, previously thought to be devoid of immune cells, are now
appreciated to have immune cells that maintain non-responsiveness to self. These sites include
the eye and the brain, as well as the pregnant uterus, testes, and several others478,479. Immune
privileged organs were historically and operationally defined as sites in the body where foreign
tissue grafts can survive for extended, often indefinite periods, whereas similar grafts placed at
regular sites in the body were acutely rejected480. Immune cell entry was thought to be forbidden
in immune-privileged organs; leukocytes were believed to be excluded from these vital organs
by the presence of specialized physical barriers, the blood–tissue barriers. Such immune
privilege is thought to be an evolutionary adaptation to protect indispensable tissues, yet have
limited regeneration capacity, like the brain and the eye. The body must protect them from the
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potentially damaging effects of an uncontrolled inflammatory immune response. In contrast to
the previous view that immune privilege is maintained by immune cell exclusion, it is now
increasingly accepted that the privileged status is preserved by local active mechanisms that
suppress responses to antigens within the privileged tissues481. We want to determine if acidic
pH is one of those suppressive mechanisms and if this could be utilized to combat autoimmune
disease.
One site which we are in the midst of determining if low pH occurs is in the lymph nodes
of the lymphatic system. We have observed in functional and healthy lymph nodes, there appear
to be specific regions of low pH. These studies on the pH of lymph nodes have only been
undertaken in mouse models so far and would require confirmation in patients to see if there is
relevance in human research. Often, during primary tumor resection, lymph nodes are removed
to ensure accurate staging of cancer. Before removal, the pH of the lymph nodes could be
measured with a microelectrode. Although this comes with the caveat that if tumor cells are
present within the chosen lymph node, this may affect the measured pH. Pre-clinical data suggest
that lymph node pH is not affected by cancer positivity, but this would need corroboration in
patients. Additionally, invasive procedures to measure pH may promote metastatic
dissemination. CEST MRI is a potential option but will be challenging, as lymph nodes are so
small, the resolution may not be high enough to generate accurate pH maps in humans.
We predominantly showed the effect of low pH on activated effector T cells. As more
studies are using CAR- T cells, we should also determine if engineering these T cells affects
their response to low pH. It will be necessary to complete more studies on the effect of low pH
on generating CAR-T and activity of CAR-T cells as well as changing the pH of chemotherapy
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to determine if it improves therapeutic response. As discussed, we would like to understand
further if CA-IX over-expression can alleviate the inhibition of T cell function by acidic pH by
over-expressing CA-IX in CAR-T cells.

Acidosis is a systemic cause of cancer metastasis studies
CA-IX role in glycolytic metabolism

In this project, it would be interesting to understand the role of CA-IX as a pH-stat170.
Our studies have shown that CA-IX expression enhances glycolytic metabolism and enables
maintenance of an acidic pHe. Studies have shown that optimal activity of CA-IX is at ~pH
6.8171. Our metabolomic studies only looked at metabolite concentrations in neutral pH;
measuring metabolic flux in acidic pH could elucidate how important CA-IX activity is for upregulating glycolytic metabolism. Our studies have yet to complete CA-IX activity studies with
sufficient replicates to calculate significance. These activity studies would be imperative, going
forward. In order to understand the effect of activity on glycolytic metabolism, we must know if
and how the CA-IX inhibitors and CA-IX neutralizing antibodies we are using are inhibiting
activity. We have developed a superfusion system on our confocal microscope, which can be
used for activity assays446. Currently, we are still optimizing this, but, to date, we have only had
success in measuring lactate efflux rates in T cells using this superfusion system (see Chapter
6). Therefore, we would also like to measure lactate efflux of our CA-IX expressing cell lines
and correlate efflux with CA-IX activity at different pHe’s and in response to inhibitors.
Targeting glycolytic metabolism in aggressive tumors is challenging due to the expression of
glycolytic enzymes in normal tissues. Identifying optimal CA-IX inhibitors and their effect on
glycolysis may provide an alternative treatment strategy for tumors with a Warburg phenotype.
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Surface pH studies

One of our hypotheses that we have not managed to explore fully is the role of CA-IX in
modulating the pH at the exofacial cell membrane. CA-IX is expressed in many cancer types and
is almost always poorly prognostic. We elucidated a likely evolutionary benefit as to why so
many tumors express CA-IX, by showing its influence on glycolytic metabolism and its role in
systemic causation of metastasis. However, in our immune cell studies, we have seen that low
pH inhibits the transport kinetics of lactate from cells and thus can inhibit glycolytic rate, but in
CA-IX cells we do not see this inhibition. We question whether there is a fitness advantage
provided by CA-IX expression. We would like to measure the surface pH of CA-IX expressing
cells. The CA-IX protein has a PG domain which can act as a proton antenna to wick away
protons from the cells surface482. This wicking of protons could increase the surface pH, slightly
alleviating the inhibition on MCT transport kinetics. We propose to use both mathematical
modeling and biological models to test this. We would propose to utilize WGA-fluorescein to
measure pH at the exofacial surface of CA-IX expressing cells in a range of pHe conditions. We
hypothesize that the exofacial membrane pH is slightly higher at the cell surface, even at lower
pHe. Our math model predicts the pH would be slightly increased at the cell surface, enabling a
higher glycolytic flux to be maintained and reducing the acid load on the cell requiring less
energy expenditure to maintain acid-base balance.
Intracellular pH studies

The observation that CA-IX expression can change intracellular pH, which enhances
glycolytic rate warrants further investigation. It has been untested if using CA-IX inhibitors or
neutralizing antibodies will revert intracellular pH to pH of non-expressing cells. If we do not
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observe this change, it is likely to be mediated mainly by the ability of CA-IX to wick away
protons due to its structure rather than its enzyme activity. The multiple carboxyl groups, 18
glutamate, and 8 aspartate residues can bind protons which can increase the removal of
intracellular CO2 and thus play a role in increasing intracellular pH. We would propose to
substitute residues in the PG domain which acts as a proton antenna. To our knowledge, studies
which have mutated these sites individually, or all sites have not been undertaken. Modification
of these residues could identify which are most important for wicking away protons, or if it is
simply a sufficient number of residues are required to maintain sufficient wicking. CA-IX
inhibitors could be dual-targeted to these residues and the active site to minimize the effect of
CA-IX on pH and glycolysis.
Mitochondrial further studies.

One unusual and unexpected result we did not see in our proof of concept model, PMA1,
is the negative effect on the mitochondria of our CA-IX expressing cells. We tried to measure the
polarity of the mitochondrial membrane and look at number and morphology of mitochondria
which was surprisingly challenging. However, we still have not looked at changes in ROS level
nor the effect of cytoplasmic pH on mitochondrial function. As we showed, CA-IX increased
pHi and it would thus be interesting to see if this affects ATP production and morphology of
mitochondria. We could follow up with isolated mitochondrial studies in varying pHe to measure
the effects on mitochondrial oxidative phosphorylation.
Conclusion
Understanding the role of acidosis in cancer highlights how pleiotropic are the effects of low pH.
Not only are the effects tremendous, but low pH can be both positive and negative, depending on
307

the situation. By taking an overview of numerous components in the tumor microenvironment,
we have highlighted the importance of considering pH as a driver of tumor aggressiveness and
metastasis. We have shown that tumor aggressiveness is driven by both acid generated by
metabolism and acid generated independent of metabolism, by proteins such as carbonic
anhydrase IX. Glycolytic metabolism can enhance metastasis, and we have shown the lactate
generated can be taken up as a fuel for osteoclasts in the bone environment, enhancing bone
metastasis. We have also produced a methodology to measure metabolism in 3D cancer cell
models to better recapitulate the in vivo conditions of a tumor.
Additionally, acid production from proton exporting proteins can enhance glycolytic
metabolism, and we have deemed acidosis a systemic cause of metastasis. Irrespective of the
method of acid production, it can hamper the invading immune cells. Our studies have shown
that acid production inhibits the glycolytic metabolism of T cells, necessary for their effector
function and can subsequently influence response to immunotherapy. Clinically, we have seen
acid production enhances cancer-induced bone pain by stimulating bone stromal cells such as
fibroblasts to produce cytokines and chemokines, which sensitize nociceptors, causing increased
patient bone pain. Overall, understanding and targeting the pathways and proteins necessary for
acid production and response can enhance therapeutic effectiveness and improve clinical
outcomes.
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